

**Senate Committee on Finance Questions for the Record**  
**Drug Pricing in America: A Prescription for Change, Part II**  
**February 26, 2019**

**Questions for:**

**Pascal Soriot**

**Executive Director and Chief Executive Officer**

**AstraZeneca**

**I. Senator Grassley**

1. At the hearing, you testified that AstraZeneca does not withhold samples from generic manufacturers in order to block generic versions of your drug from entering the market. You also expressed your support for the “Creating and Restoring Equal Access to Equivalent Samples Act,” also known as the CREATES Act. However, the FDA has a list on its website which identifies reference listed drug (RLD) access inquiries where brand manufacturers may have prevented generic companies from obtaining samples of products necessary to support FDA approval. AstraZeneca is on this FDA list. This would appear to contradict your testimony at the hearing that AstraZeneca has not withheld samples of their products to delay generic competition.

- a. **Could you please explain in detail why AstraZeneca is on the FDA list?**

AstraZeneca appreciates the opportunity to address the question of one of our medicines, BRILINTA® (ticagrelor) appearing on the Reference Listed Drug Access Inquiries list (RLD List). We would first like to state that AstraZeneca supports allowing generic manufacturers access to samples. Withholding or otherwise blocking such access is inconsistent with that position. Our internal review has not identified any unanswered, delayed, or outstanding requests for samples of BRILINTA by any generic manufacturers.

It is our understanding that BRILINTA was included on the RLD List based on a single inquiry received by the FDA. Unfortunately, the RLD List does not identify the company that reportedly requested information (or samples) from AstraZeneca, the date the information was requested, or any other information that would allow AstraZeneca to better understand or further investigate the circumstances of this inquiry. On its website, the FDA does advise that it has “not independently investigated or confirmed the access limitations described in the inquiries received.”<sup>1</sup> Given this limitation, the listing of an inquiry on the RLD List does not mean that the FDA has in fact determined that access to samples by generic

---

<sup>1</sup> *Reference Listed Drug (RLD) Access Inquiries*, U.S. Food and Drug Administration, <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm607738.htm> (last updated Feb. 07, 2019).

manufacturers was limited or withheld for the medicines identified. Indeed, based on our internal review, we have not identified any circumstances that substantiate the inquiry received by the FDA relating to BRILINTA.

b. **Could you please explain in detail the discrepancy between your testimony and the FDA list?**

AstraZeneca is not aware of any instances where the company has withheld or otherwise blocked access to samples by generic manufacturers. Based on our internal review, AstraZeneca is not aware of any unanswered, delayed, or outstanding requests for samples of BRILINTA by any generic manufacturers.

In addition, BRILINTA is and has always been available via normal commercial distribution channels (i.e., wholesalers) since its U.S. launch. It has never had a restricted distribution program.

Finally, more than 15 generic manufacturers have applied for regulatory approval from the FDA for the manufacture of generic ticagrelor and some, like Watson/Teva, have received tentative approvals from the FDA. Because conducting bioequivalence studies with the branded medicine is an FDA pre-approval requirement, it is clear that these generic manufacturers are not having difficulty accessing branded ticagrelor for their studies.

In light of the context provided above, it is unclear why any generic manufacturer would be unable to obtain a sample of BRILINTA for their purposes or why an inquiry was lodged with the FDA related to this medicine.

c. **Has AstraZeneca ever blocked access to samples?**

AstraZeneca is not aware of instances where the company has refused to sell samples or has otherwise blocked access to samples by generic manufacturers.

2. The Department of Health and Human Services' proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees", envisions that drug manufacturers will offer upfront discounts rather than the back-end rebates that are now commonly provided. Some observers argue that a 1996 court case called into question whether manufacturers could offer upfront discounts, resulting in today's rebate-based system. I've heard differing opinions as to whether the issues related to the initial court case are still relevant.

**If the HHS proposed rule is finalized, can you assure the Committee that your company will offer upfront discounts? If not, why?**

If the HHS proposed rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts.

3. **Please describe how you expect your company to respond to the HHS proposed rule to eliminate safe harbor protection for back-end rebates in Medicare Part D that is referenced above if it is finalized. Assuming you are confident that antitrust laws do not prevent your company from offering upfront discounts, specifically, do you envision that your company lowers the list price of a drug to the current after-rebate net price, offer discounts equal to the current rebate amount, or a combination of both?**

Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector, and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

4. **To what extent are the back-end rebates your company currently offers contingent on the amount of market share realized for your drugs as a result of Part D plan formulary placement and other techniques?**

Our arrangements in Part D do not include a market share component.

5. **Please provide a breakdown of percentage of sales that go to each payer (including Medicare, Medicaid, private pay, other) and a similar percentage by volume of the total number of each drug compared to total volume. Please provide this data for the most recent year available.**

Below you will find our estimated relative payer split of Gross Product Sales in the U.S., for the year ending December 31, 2018.

<b>Total Products</b>		
<b>Payer</b>	<b>Sales \$ Millions</b>	<b>Proportion of Total Business</b>
Medicaid	1,826,337	11.0%
Fed Gov't (VA, DOD, CDC, PHS)	2,986,585	18.1%
GPO/LTC	1,362,663	8.2%
Commercial	5,019,907	30.4%
Medicare Part D	3,514,858	21.3%
Tricare	70,799	0.4%
Non-Contracted Sales/Other	1,756,851	10.6%
<b>Total</b>	<b>16,538,000</b>	<b>100.0%</b>

6. **Do your companies hire consultants or lobbyists to promote products at state Medicaid Pharmacy & Therapeutics Committees? To whom do you disclose advocacy activities surrounding state Medicaid programs, if at all?**

AstraZeneca does not utilize consultants or lobbyists to promote medicines at state Pharmacy & Therapeutics (P&T) Committees. However, AstraZeneca Medical Affairs personnel may engage in peer-to-peer medical discussions with members of the medical community including Medicaid P&T committee members.

AstraZeneca has comprehensive internal policies that oversee interactions between AstraZeneca employees and government officials. Federal and state laws and regulations also govern lobbying activities, and AstraZeneca complies with the attendant disclosure requirements.

7. **Please describe how the costs of patient assistance programs are accounted for within your company's financial statements. Please also describe the types of market information, such as prescribing and use patterns, that your company collects from different types of patient assistance programs and patient hub services.**

AZ&Me™ Prescription Savings Program (Patient Assistance Program):

In furtherance of its objective of ensuring patient access, AstraZeneca was one of the first manufacturers in the industry to establish a patient assistance program to facilitate access to certain medicines for uninsured and underinsured low-income patients. This program, known as AZ&Me, provides eligible patients with medicines at no cost.

We account for the costs of medicines provided through the AZ&Me program as a component of our Operating Expenses.

In connection with the AZ&Me program, AstraZeneca collects general program enrollment data such as number of patients in the program and medicine provided.

Access 360™ (Patient Hub):

AstraZeneca's patient hub, Access 360, is a reimbursement support program that provides patients and their healthcare providers with limited access and reimbursement support for AstraZeneca specialty care medicines. Access 360 collects patient, provider and payer coverage data in conjunction with appropriate patient opt-ins to administer the limited reimbursement services offered by the program.

8. **Please provide a list of all contributions since January 1, 2014, that your company has made to any tax exempt organizations working on issues related to drugs within your product lines, including but not limited to patient groups, disease awareness groups, medical or professional societies, universities or hospitals, industry associations or leagues. For each contribution, please provide the name of the organization that received the donation, the date the donation was made, the amount of the donation, and a description of the purpose of the contribution (i.e., was the contribution for the general fund, a specific purpose to a specific program, or continuing medical education). Please also note whether the contribution was unrestricted or restricted; if it was restricted, please explain all restrictions. Finally, if your company maintains a foundation or other separate charitable arm, please provide the name of all such entities, and list all donations made from that entity or entities.**

Our commitment to improving the lives of patients goes beyond our innovative medicines. We place significant value on collaboration and partnerships, including work done by non-profits, patient advocates, medical professionals, and researchers. To that end, we provide support for eligible programs through corporate contributions, research support, fellowships, and medical education grants. We also support conferences and initiatives for healthcare professionals and scientists.

AstraZeneca believes in providing information to the public about our company, our medicines and about how we do business. In 2008, we began publishing biannual reports of our contributions to nonprofit organizations. We use contributions as our umbrella term for financial support to nonprofit organizations contributing to the public good (e.g. donations, sponsorships and partnerships).

The below data reflects the total value of contributions made by AstraZeneca to nonprofit organizations in the U.S. in the years 2014-2018. A full list of contributions, including the recipient organization, associated program name, and amount of each contribution, can be found here:

<https://www.astrazeneca-us.com/sustainability/Corporate-transparency/grants-and-contributions-disclosure.html>

- **2018:** \$18.3 million
- **2017:** \$5.5 million
- **2016:** \$10.9 million

- **2015:** \$19.8 million
- **2014:** \$15.5 million

In addition, in 1993, AstraZeneca founded the AstraZeneca HealthCare Foundation, a 501(c)(3) entity. The AstraZeneca HealthCare Foundation aims to promote public awareness surrounding healthcare issues, further public education and medical knowledge, and support charitable and qualified exempt organizations whose work aligns with the Foundation's charitable goals.

In furtherance of AstraZeneca's commitment to improving health, in 2010 the AstraZeneca HealthCare Foundation launched the Connections for Cardiovascular Health<sup>SM</sup> (CCH) program. With the mission of improving cardiovascular health in the U.S., CCH awards grants to U.S.-based nonprofit organizations whose work supports CCH's mission. Since its launch, CCH has awarded nearly \$23 million to 52 organizations working to prevent cardiovascular disease.

The below data reflects the approximate total value of grants made by CCH per year between 2014 and 2018. A full list of grants, including the recipient organization, associated program name, and amount of each contribution, can be found here: <https://www.astrazeneca-us.com/sustainability/healthcare-foundation/connections-for-cardiovascular-health.html#past-grant-awardees--0>

- **2018:** \$1.2 million
- **2017:** \$993,880
- **2016:** \$1.8 million
- **2015:** \$1.9 million
- **2014:** \$2.6 million

AstraZeneca also awards medical education grants and scientific sponsorships. These grants are offered to support independent medical education, scientific sponsorships, and fellowship or healthcare professional-in-training. Grants are offered for conduct of programs, are awarded on the basis of individual applications through our medical education grants process, and are not conditioned on services. This process and all grant decisions are managed independently within our Medical Affairs group and have no connection to our sales and marketing departments.

The below data reflects the approximate total value of medical education grants made by AstraZeneca per year, since 2014. A full list of medical education grants offered to non-profit organizations, including the recipient organization, associated program name, date, and amount of each contribution, can be found in [Appendix A](#).

- **2018:** \$28.9 million
- **2017:** \$17.5 million
- **2016:** \$11.6 million
- **2015:** \$24.9 million
- **2014:** \$14.8 million

9. Pay for delay agreements cost consumers and taxpayers billions in higher drug costs every year. The FTC has gone after drug companies that enter into these settlements where the brand pays the generic company to keep its lower cost alternative off the market. I'm the lead republican sponsor of S. 64, the "Preserve Access to Affordable Generics and Biosimilars Act," which would help put an end to these deals.

a. **Do you agree that these pay-off agreements keep drug costs high for patients because they delay competition?**

AstraZeneca has confidence in patents that protect our medicines and, where appropriate, we file lawsuits to protect our intellectual property.

AstraZeneca does not enter into "pay-off agreements," if those are understood to include settlements that pay generic competitors to delay entry into the market. AstraZeneca engages in patent settlements but we do not believe these resolutions contribute to increased prices. In the absence of a settlement, a generic would not necessarily prevail in the patent litigation and therefore would not be able to enter the market. Indeed, AstraZeneca has entered into many early-entry patent settlements that allow generic manufacturers to license innovator patents and thereby permit generic competition before expiration of AstraZeneca's patent rights.

Settlement agreements that permit entry of generic drugs before expiration of relevant patent rights do not stifle competition but instead permit early entry by resolving patent disputes that would otherwise prevent generic alternatives to branded medication.

All of AstraZeneca's patent settlements fully comply with the law. These settlements provide increased clarity and stability to both parties, allowing innovators like AstraZeneca to continue investing substantially in new medicines for patients and frequently allowing generic competitors to enter the market before expiration of AstraZeneca's patent rights.

b. **Has your company ever entered into these kinds of settlements with a generic company?**

AstraZeneca does not enter into settlements that pay generic competitors to delay entry into the market.

c. **Do you support the pay for delay bill?**

While AstraZeneca supports efforts to curb patent settlement abuses, we have concerns about the “Preserve Access to Affordable Generics and Biosimilars Act” in its current form. For example, the proposed legislation would be retroactive to 2013 and would unfairly subject to potential scrutiny lawful settlements entered into based on the then existing legal construct. As a general matter, AstraZeneca believes that patent settlement agreements are pro-competitive because they can permit entry of generic drugs before expiration of relevant patent rights.

10. Rebate Traps/Walls. I’m increasingly concerned about the effect of so-called “rebate traps” or “rebate walls” on patients’ access to quality, lower cost medicine. I understand there is ongoing litigation challenging these practices as anti-competitive.

a. **Does your company engage in the bundling of rebates over multiple products? If so, why? And what benefit does the consumer gain from that?**

AstraZeneca offers portfolio discount arrangements to improve patient access and affordability across multiple medicines, thus ensuring the right medicine can be prescribed for the right patient. Portfolio discounting allows manufacturers and plans another mechanism to negotiate for formulary access for the patient, in addition to single-medicine discounts and rebates. Irrespective of the approach to discounting, AstraZeneca also ensures discounts are appropriately reported in government price reporting metrics (e.g., Best Price, Average Manufacturer Price, and Average Sales Price).

b. **Does your company view these practices as anticompetitive or harmful to patients’ access to quality, lower cost medicine?**

AstraZeneca does not view these practices as anticompetitive or harmful to patients’ access. In fact, AstraZeneca offers portfolio discount arrangements to improve patient access and affordability.

c. **If a policy were adopted to eliminate rebates, or to require that rebate savings be passed on to the consumer, would that in and of itself solve the issue of rebate “traps” and “walls”? And would consumers benefit from such a policy?**

AstraZeneca believes that evolving the current system of paying for and delivering drug therapies to one in which patients more directly benefit from the discounts and rebates that AstraZeneca provides is an important step towards improving affordability and supporting innovation. This can best be accomplished by eliminating rebates in Medicare Part D and the commercial sector, which would create competition between manufacturers on net price instead of rebate amounts, thereby helping to eliminate rebate “traps” and “walls.”



AstraZeneca also believes that patient cost-sharing should be more aligned to a medicine's net price, and that eliminating rebates and moving to a point-of-sale discount model should help accomplish this goal. Additionally, it is important to note that lowering list prices in the U.S. without addressing broader challenges, including benefit design, will not improve affordability for many patients. While eliminating rebates is an important step, benefit designs must also be evaluated.

11. Drug Pricing.

- a. **When setting the list price of a drug, does your company consider regulatory costs or compliance? If so, how specifically do those factors affect the list price of a drug? Please provide at least one specific example, if applicable, from your current product portfolio.**

AstraZeneca does not directly consider regulatory or compliance costs when setting the list price of a drug. AstraZeneca's approach to pricing across all medicines is driven by a number of factors, including clinical value, patient access and affordability, patient population, government and payer coverage requirements, R&D expenditures, manufacturing costs, and competitive dynamics. AstraZeneca is mindful of healthcare costs and is continuously exploring innovative opportunities and solutions to deliver medicines while considering cost and value. In setting drug prices, AstraZeneca takes into account both the budget impact to payers (including Medicare and pharmacy benefit managers (PBMs)) as well as patient out-of-pocket costs to maintain patient access to needed medication. AstraZeneca has also been a leading innovator in developing alternate payment structures for its medicines. In particular, AstraZeneca has emphasized value-based agreements, which, broadly speaking, seek to link access, reimbursement or price, to a demonstrated clinical benefit or outcome.

- b. **When setting the list price of a drug, does your company consider the risk of liability or litigation? If so, how specifically do those factors affect the list price of a drug? Please provide at least one specific example, if applicable, from your current product portfolio.**

AstraZeneca does not consider the risk of liability or litigation when setting the list price for a particular drug.

II. Senator Roberts

1. **What role do you see Value Based Arrangements (VBAs) playing in the effort to reduce prescription drug costs? What potential do these arrangements have to find the "sweet spot" between controlling costs to patients and encouraging innovation of new drugs?**

We believe medicines are part of the solution to controlling healthcare costs. They not only improve patient outcomes and increase quality of life, but also reduce downstream costs. Value-based agreements allow us to reimburse

the healthcare system if our medicines do not deliver as intended. This solution demonstrates our willingness to stand behind the value of our medicines.

AstraZeneca is working closely with payers and health systems to explore innovative solutions to improve access and affordability that demonstrate the value our medicines bring to patients and the healthcare system. Our value-based agreements aim to manage the totality of treatment costs and keep people healthy and out of the hospital. For several years, AstraZeneca has been exploring these types of solutions through value-based agreements where we are willing to work with healthcare stakeholders to tie payment to patient outcomes.

To date, we have entered into approximately 40 value-based agreements across our therapeutic areas with a variety of payers, making AstraZeneca a leader in the field of value-based agreements.

As an example, and as noted in the written testimony submitted to the Senate Committee on Finance, AstraZeneca agreed with Express Scripts that for IRESSA, an oral treatment for certain types of lung cancer, we will fully reimburse Express Scripts for discontinued use before the third fill, including if discontinuation occurs because patients did not respond to treatment.

## 2. **How can VBAs help lower what patients pay out-of-pocket?**

While most of these agreements have been focused on securing patient access to our medicines and delivering better patient outcomes, where payers are willing, we are also looking to more directly address patient out-of-pocket affordability through these innovative arrangements.

Our ambition is that these agreements will evolve to enable reimbursement back to a payer to be shared with the patient when medicines do not perform as expected.

As an example where a value-based agreement directly reduced out-of-pocket costs for patients, we recently announced the initiation of a value-based agreement for University of Pittsburgh Medical Center (UPMC) Medicare patients who are prescribed BRILINTA. This value-based contract, which was effective as of January 1, 2019, is groundbreaking in two ways. First, the contract lowers the out-of-pocket costs for a UPMC Medicare Part D patient to approximately \$10 for a 30-day supply. Second, what UPMC pays for BRILINTA will vary based on patient outcomes, tying the cost of the medicine to its real-world clinical performance.

We are currently exploring another value-based agreement in Medicare Part D. In addition to having a significant outcomes-based component, this arrangement would reduce patient out-of-pocket costs. This type of agreement allows patients to access their medicines at a lower out-of-pocket

cost and payers to control their overall healthcare costs through paying for outcomes.

3. **Can Congress do more to allow for and encourage the use of VBAs?**

We believe that there are steps the government can take to address challenges and help encourage the timely adoption of value-based agreements, including in public sector programs like Medicare.

For example, at this time, the current Anti-Kickback Safe Harbor (AKS) regulations do not expressly address value-based agreements. Accordingly, manufacturers must seek to structure value-based agreements to meet the requirements of existing safe harbors from the AKS, such as the discount safe harbor and personal services safe harbor, that were created for purposes other than value-based agreements. Although we believe that value-based agreements can strongly benefit patients and the healthcare system overall, the lack of clarity in application of the safe harbors to value-based agreements creates regulatory uncertainty that discourages broader implementation of value-based agreements in public-sector programs.

In addition to the risk of AKS liability, value-based agreements present other regulatory challenges that manufacturers must navigate. For example, manufacturers must manage complex government price reporting calculations that may not account for price fluctuations over time that may be associated with a value-based agreement.

In a future system, the default approach should be that pricing and reimbursement for drug therapies are tied to patient outcomes and the value the particular therapy provides. As such, it is imperative that manufacturers and payers—including Medicare plans—engage in value-based agreements similar to the IRESSA and BRILINTA examples referenced previously.

Policies to encourage these arrangements and to reduce or eliminate existing challenges will be essential to their long-term success. To that end, AstraZeneca appreciates the support of Senators Warner and Cassidy for value-based agreements, as demonstrated by their requests for input on the Patient Affordability Value and Efficiency (PAVE) Act. This draft legislation would promote the development of value-based agreements by offering increased flexibility for manufacturers to enter into such arrangements, including with Medicare Part D plans by addressing AKS and government pricing concerns.

This legislation is particularly important given the Administration's proposal to eliminate PBM rebates under the discount safe harbor. Currently, many value-based agreements are structured using a rebate agreement, under which the terms of a discount are based on clinical or cost outcomes measures. Therefore, the elimination of discount safe harbor protection for rebates without an exception for value-based agreements could inadvertently reduce incentives for value-based agreements, which we do not believe is the Administration's intent. We have therefore recommended to HHS that value-based agreements are exempt from the proposed changes to the discount safe harbor and we encourage members of Congress to support this exemption.

Through the partnership of payers and policymakers, we look forward to a future where implementation of value-based agreements across public and private payers is widespread.

**III. Senator Cornyn**

1. We continue to hear that rebates negotiated off of the list price of a drug are both good and bad. Pharmacy benefit managers and plans have argued that rebates are used to lower premiums across the board and that it is the best way to seek a price concession on otherwise expensive drugs. Your industry argues that these payers are insisting on higher rebates that can only be achieved by raising list prices. But patients often lose under this system, with out of pocket costs being tied to list price. Insulin patients appear to be routinely impacted by this perversity in the system.

a. **Please explain to the committee how your company would reduce list prices if rebates were no longer a part of the equation?**

Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector, and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

b. **What assurance can you provide that you would in fact lower your prices?**

Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the

commercial sector and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

c. **What actions should be taken to ensure that patients are actually seeing the benefits of lower out of pocket costs?**

In the absence of rebates, the market incentives for the differential between list and net price should be reduced because manufacturers will be competing on the basis of net price instead of rebate amounts. Because Part D patient cost-sharing is currently based on list price and not net price, this change may also result in lower cost-sharing for patients. Additionally, it is important to note that lowering list prices in the U.S. without addressing broader challenges, including benefit design, will not improve affordability for many patients. While eliminating rebates is an important step, benefit designs must also be evaluated.

AstraZeneca also supports monthly and annual out-of-pocket caps in Medicare Part D to further ensure that patients see the benefits of lower out-of-pocket costs.

2. **If rebates are driving high list prices for drugs as drug manufacturers' claim, why do you think that Part B drugs, which have no PBM rebates, are also seeing significant price increases? Whose fault is that?**

For our Part B products, price increases are modest and generally in line with inflation. We are supportive of competition, including policies that support more widespread use of biosimilars.

**IV. Senator Daines**

1. As an advocate for improving Montanans' access to low-cost medications, I've been a champion of the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which would combat anticompetitive practices used by some brand-name pharmaceutical companies to block or delay competing generic drugs from entering the market. During the hearing when I asked if your company had ever withheld samples from generic manufacturers, you answered emphatically no. Yet, according to the Food and Drug Administration (FDA), generic drug makers have made inquiries with the agency claiming they were unable to access samples provided by Pfizer and AstraZeneca that are needed to conduct studies to produce low-cost generic drugs.

a. **Do you agree that denying generic drug manufacturers access to samples keeps drug costs high for patients due to lack of competition?**

AstraZeneca is supportive of allowing generic manufacturers to have access to samples.

b. **Has your company refused to sell samples or placed any barriers in the way of generic drug makers acquiring samples?**

AstraZeneca is not aware of instances where the company has refused to sell samples or has otherwise blocked access to samples by generic manufacturers.

c. **Are you aware of any outstanding requests for samples?**

AstraZeneca is not aware of any unanswered, delayed, or outstanding requests for samples of our medicines by generic manufacturers.

It is our understanding that one of our medicines, BRILINTA, was included on the Reference Listed Drug Access Inquiries List (RLD List) based on a single inquiry received by the FDA. However, BRILINTA has always been available via normal commercial distribution channels (i.e., wholesalers) and has never had a restricted distribution program.

Unfortunately, the RLD List does not identify the company that reportedly requested information (or samples) from AstraZeneca, the date the information was requested, or any other information that would allow AstraZeneca to better understand or further investigate the circumstances of this inquiry. On its website, the FDA does advise that it has “not independently investigated or confirmed the access limitations described in the inquiries received.” Given this limitation, the listing of an inquiry on the RLD List does not mean that the FDA has in fact determined that access to samples by generic manufacturers was limited or withheld for the medicines identified. Indeed, based on our internal review, we have not identified any circumstances that substantiate the inquiry received by the FDA relating to BRILINTA.

d. **How does your company work to prevent abuses in the sample system?**

AstraZeneca is supportive of allowing generic manufacturers to have access to samples and is not aware of instances that would be considered abuse of the samples system.

V. **Senator Young**

1. **Re-evaluating Business Strategies in Foreign Countries.** Since taking office, President Trump has made reducing drug prices one of his highest priorities – and has repeatedly spoken about his frustration with the U.S. subsidizing the costs of pharmaceuticals for the rest of the world. He has gone so far as to issue proposals, like the International Pricing Index (IPI) Model, in an attempt to bring down prescription drug prices. With the increased scrutiny of the industry and of the drug supply chain as a whole in the United States ....

a. **Have any of your companies re-evaluated your business strategy in foreign countries?**

We continuously evaluate our business approaches in all markets and adjust our strategies accordingly based on many factors, including the overall environment.

b. **If not, then why?**

See response above.

c. **If a proposal, like IPI, were implemented, would it force your companies to potentially “walk away from the negotiating table when other countries demand low prices subsidized by America’s seniors,” as HHS Senior Advisor for Drug Pricing Reform John O’Brien has said?**

If the IPI model were put into effect as proposed, where an identified average international price would be derived from 16 countries, this would impact our ability to sell our medicines in some of the identified markets.

The IPI model was issued as an Advanced Notice of Proposed Rulemaking (ANPRM). Important details such as the medicines that would be included in the model, the final list of nations included as reference countries, and the timing of reimbursement changes are still unknown. We look forward to engaging with policymakers on this proposal.

d. **What are some of your ideas on how we can ensure Americans aren’t shouldering the full cost of pharmaceuticals?**

We agree that out-of-pocket costs are unsustainable in the U.S., but the answer is not to move to a system found in other countries or to link pricing in the U.S. to the International Pricing Index.

It is critical to recognize that while price controls are the default in many other countries, these price controls result in reduced access to important medicines. In the 16 countries referenced in the International Pricing Index model proposal, only 55% of new cancer medicines are available, compared to 96% in the U.S. In those countries, it also takes more than a year longer for the medicines to become available and this can have significant impacts on patients. For example, in 2018, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved a new indication for LYNPARZA for ovarian cancer. However, the U.K.’s National Institute for Health and Care Excellence (NICE) has not recommended that the U.K.’s National Health System (NHS) reimburse for LYNPARZA in this indication, resulting in limited access for patients in the U.K.

Instead of international reference pricing, we should focus on market-based solutions. We believe that there are several steps that lawmakers can take to ensure that drug prices are affordable for Americans, while ensuring that innovation in the biopharmaceutical

sector can continue to flourish in the U.S. Our suggestions fall in five main categories, described in more detail below:

- **Rebate Reform:** The current pharmacy benefit manager (PBM) rebate system does not fully benefit patients and has resulted in a lack of transparency across the supply chain. We support the current proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care. We also support efforts to eliminate rebates in the commercial sector as well, which will likely require legislation. We therefore recommend that Congress explore legislation that would eliminate rebates in the commercial market.
- **Value-Based Agreements:** As described in detail in our written testimony to the Senate Committee on Finance hearing, we are also working closely with payers and health systems to explore innovative solutions to improve access and affordability that demonstrate the value our medicines bring to patients and the healthcare system. For several years, AstraZeneca has been exploring these types of solutions through value-based agreements where we are willing to work with healthcare stakeholders to tie payment to patient outcomes. To date, we have entered into approximately 40 value-based agreements across our therapeutic areas with a variety of payers, making AstraZeneca a leader in the field of value-based agreements.

We believe that there are steps the government can take to address certain regulatory challenges to the broader implementation of value-based agreements and help encourage the timely adoption of value-based agreements, including in public sector programs like Medicare. To that end, AstraZeneca appreciates the support of Senators Warner and Cassidy for value-based agreements, as demonstrated by their requests for input on the Patient Affordability Value and Efficiency (PAVE) Act. This draft legislation would promote the development of value-based agreements by offering increased flexibility for manufacturers to enter into such arrangements, including with Medicare Part D plans.

- **Biosimilars:** We also encourage Congress to consider policies to encourage greater use of biosimilars in the U.S. We believe that competition is a key component to reducing costs, and that is why we support expanded use of biosimilars in the U.S. As a global company, we operate in countries, particularly those in the European Union, where biosimilar competition is particularly robust. We support a similarly vigorous biosimilars market in the U.S.

We therefore appreciate the efforts of the FDA to increase the availability of biosimilars in the U.S., including the FDA's development of a Biosimilars Action Plan. We support efforts



to streamline and improve the efficiency of the biosimilars approval pathway for the benefit of patients. Such efforts could include increased transparency into the patents applicable to biologic medicines.

We also support cost-sharing and reimbursement policies that facilitate the uptake of biosimilars. Such policies include Medicare reimbursement rates that ensure that biosimilars can compete on equal footing with innovator medicines, and reductions to cost-sharing amounts for biosimilars.

- **Out-of-pocket Caps for Medicare Patients:** In the commercial market, it is common for patients to have a cap on total out-of-pocket amounts. However, such a construct does not exist in the Medicare program. Because of the way the Part D benefit is designed, for example, cost-sharing can be particularly high in the first months of the plan year and/or in the first months of therapy. A recent study found that rates of prescription abandonment and delayed initiation of oral cancer therapies increase as cost-sharing amounts rise. Such a result reflects the need for a restructuring of the current benefit design, which could be accomplished by establishing a monthly or annual out-of-pocket cap. This would give patients greater certainty in the total amount of out-of-pocket costs they could face.
- **Transparency:** We support greater transparency across the biopharmaceutical supply chain, which includes greater transparency into drug pricing. To that end, we generally support the policies included in the current versions of the SPIKE and C-THRU Acts. There are a variety of state-level drug pricing transparency laws and regulations. We believe that having a consistent, federal standard for drug pricing transparency requirements, like those included in the SPIKE Act, should pre-empt state transparency laws to reduce confusion and compliance burden.

We also support transparency efforts to ensure that patients and prescribers have meaningful information on out-of-pocket costs at the point of prescribing, so that they can make informed decisions about the most appropriate and affordable therapy.

2. Foreign Countries' Pricing and Reimbursement. President Trump and Secretary Azar have both repeatedly described their frustrations with "foreign freeloading" of U.S. drugs in the last year. "When foreign governments extort unreasonably low prices from U.S. drug makers, Americans have to pay more to subsidize the enormous cost of research and development. . . . It's unfair and it's ridiculous, and it's not going to happen any longer."

- a. **Do you agree that because of foreign countries' pricing and reimbursement systems, U.S. patients and innovators are shouldering the burden for financing medical advances?**

We agree that many foreign countries' pricing and reimbursement systems do not adequately recognize innovation in the biopharmaceutical sector. In many other countries, the government utilizes price controls for drug therapies, and in many cases these price controls result in reduced or delayed access to therapy for patients in those countries. The U.S. benefits from an open-market system that supports competition and innovation and accordingly Americans place high value on both choice and access to the latest medicines. For patients in the U.S., it is not a question of *when* an important treatment will be available, but rather *how* they will access that medicine. It is in this context that AstraZeneca continues to engage with other stakeholders regarding possible solutions and specific actions that can be taken to address pricing concerns, which we describe in greater detail in our written testimony. These approaches must balance the need to improve access and affordability while fostering innovation. Pricing controls as well as access and reimbursement practices in other countries are a challenge.

b. **How do foreign countries' pricing and reimbursement systems affect our prescription drug costs?**

We do not take into account foreign market pricing in setting U.S. prices.

c. **Are foreign governments taking note of the concerns being raised by the Trump Administration and have they responded in any way?**

While these matters have been widely reported on globally, we do not have insights into actions being taken by other health authorities directly in response to the Trump Administration's efforts in this area.

d. **Has there been any noticeable change in any of our trade agreements since these concerns have been raised by the Trump Administration?**

AstraZeneca and the biopharmaceutical industry have consistently advocated for trade agreements that support strong intellectual property rights and protect market access. We believe our trade partners should be fair and transparent so that patients around the world can benefit from U.S. innovation.

3. Medicaid Closed Formulary Proposals. In an attempt to bring down drug costs, various states have been exploring whether to exclude certain drugs from its Medicaid program. For example, the state of Massachusetts recently asked CMS for permission to create a closed formulary where the state Medicaid program would pick at least one drug per therapeutic class. CMS denied their waiver request citing violation of federal law, but this proposal does bring up important questions on how to contain drug prices in state Medicaid programs.

- a. **If the principles of the Medicare Part D program – including the necessary patient protections – were applied to state Medicaid programs, do you think it [would] lower drugs costs while ensuring access to patients?**

Under the current construct in Medicaid, manufacturers provide mandatory rebates and in turn, states are required to cover all of the manufacturer's drugs. This ensures that Medicaid patients have access to the full range of available therapies. We support increased flexibility for state Medicaid agencies in managing their Medicaid programs, but only so long as there are robust protections that ensure that Medicaid patients can continue to access the medicines they need.

4. **Medicaid "Best Price".** In the Trump Administration's Blueprint, they suggested that because drug manufactures have to give Medicaid the "best price" on drugs, there is no incentive to offer deeper discounts to other payers - both government and commercial - than what is already offered under the Medicaid Drug Rebate Program.

- a. **Does the Medicaid "best price" requirement encourage manufacturers to increase initial prices?**

We do not believe that the Medicaid Best Price requirement encourages manufacturers to increase their initial list price. However, the requirement does impact decisions regarding the size of rebates and discounts offered in the commercial sector because setting a new Best Price can result in significantly increased Medicaid rebate and 340B liability. Additionally, manufacturers may be hesitant to offer very aggressive value-based agreements due to the risk of setting a new Best Price.

- b. **What, if any, changes would you suggest we make to the program?**

We recommend an exemption from Best Price for value-based agreements, which is a policy included in Senator Grassley's and Senator Warner's draft version of the PAVE Act.

5. **Outcomes-Based Contracts.** In almost all of your testimonies, you highlight your support of outcomes-based contracts and how we need to be shifting our system toward that approach.

- a. **How will these contracts lower drug costs for patients in both the near-term and long-term?**

While most value-based agreements have been focused on securing patient access to our medicines and delivering better patient outcomes, where payers are willing, AstraZeneca is also looking to more directly address patient out-of-pocket affordability through these innovative arrangements.

As an example, we recently announced the initiation of a value-based agreement for University of Pittsburgh Medical Center (UPMC) Medicare patients who are prescribed BRILINTA. This value-based contract, which was effective as of January 1, 2019, is groundbreaking in two ways. First, the contract lowers the out-of-pocket costs for a UPMC Medicare Part D patient to approximately \$10 for a 30-day supply. Second, what UPMC pays for BRILINTA will vary based on patient outcomes, tying the cost of the medicine to its real-world clinical performance.

We are currently exploring another value-based agreement in Medicare Part D. In addition to having a significant outcomes-based component, this arrangement would reduce patient out-of-pocket costs. This type of agreement allows patients to access their medicines at a lower out-of-pocket cost and payers to control their overall healthcare costs through paying for outcomes.

b. **How will they lower overall healthcare costs for our federal programs?**

We believe medicines are part of the solution to controlling healthcare costs. They not only improve patient outcomes and increase quality of life, but also reduce downstream costs. Value-based agreements have the potential to increase efficiencies in the healthcare system, including government programs, by ensuring that payment is based on value rather than reimbursement based on volume. These agreements support patients receiving the most appropriate treatment, ensure appropriate patient behaviors and, most importantly, tie reimbursement to improved patient outcomes.

In many cases value-based agreements encourage a focus on important patient behaviors such as adherence and persistence as well as improved emphasis on patient education to promote healthier lifestyles and choices. These agreements broaden payer focus to the total cost of care and quality outcomes. It is important that we look at all aspects related to the cost of care to find efficiencies that drive greater value in the healthcare system. These opportunities exist in both the commercial and government sectors.

We support value-based agreements because they allow us to reimburse the healthcare system if our medicines do not deliver as intended. This solution demonstrates our willingness to stand behind the value of our medicines.

Through the partnership of payers and policymakers, we look forward to a future where implementation of value-based agreements across public and private payers is widespread.

c. **What have the preliminary results looked like so far?**

We are frequently asked if we have ever had to “pay out” on a value-based agreement, and the answer is yes. For example, we have entered into an agreement for one of our oncology medicines with a large payer. We have reimbursed the payer for more than 20% of patients on that medicine. Of course, we also have examples where we have seen the medicine perform as well or better than our clinical data. This is good for patients and good for the payer and health system overall in that, by providing access to that medicine, they have seen improved patient outcomes.

6. Transparency/Point of Sale. In almost all of your testimonies, you express your support for the Trump Administration’s proposal to allow manufacturers to provide PBMs up-front discounts that are passed onto patients at the point-of-sale.

a. **Do you feel like this proposal will make the transactions within the drug supply chain more transparent?**

Yes, the Trump Administration’s rebate proposal should make transactions more transparent because cost-sharing will reflect point-of-sale discounts and, therefore, net prices. We encourage the Administration and Congress to closely assess the impact of such increased transparency on patients and the biopharmaceutical supply chain more broadly.

b. **If so, would this transparency bring down drug costs – overall and for specialty drugs?**

In general, we believe that increased transparency due to point-of-sale discounts will in turn lead to greater competition and reduced costs overall. However, the impact of transparency on the prices of specific drugs will vary based on the competitive landscape for that medicine.

7. The Relationship between Wholesalers and Manufacturers. When talking about the pharmaceutical supply chain, a lot of focus has been placed on the Pharmacy Benefit Manager. But there’s another side of the equation that I’d like to ask about -

a. **How do wholesalers negotiate pricing with manufacturers?**

In general, wholesalers do not negotiate pricing with manufacturers. Wholesalers receive service fees from manufacturers for bona fide services they provide.

b. **What impact does this have on drug costs?**

In general, wholesalers do not negotiate pricing with manufacturers.

c. **What incentives or disincentives do they have to contain price increases?**

Wholesalers receive service fees from manufacturers for bona fide services they provide. Certain fees across the supply chain—including with wholesalers—are based on a percentage of the list price. We support efforts to “de-link” such fees from the list price across the supply chain, as this would align incentives across the supply chain to lower prices.

VI. **Senator Wyden**

1. **Proposed Rebate Rule.** As has been done in many other settings, drug manufacturers said during the hearing that one reason list prices for drugs are high is that pharmaceutical benefit managers (PBMs) demand larger and larger rebates in order for the drug to receive favorable placement on a formulary. You and your colleagues who testified during the hearing stated if the Administration’s proposal on changes to the anti-kickback safe harbor for pharmaceutical rebates took effect, your company would likely lower list price. Like many Oregonians, I am skeptical drug manufacturers would voluntarily lower their prices.

**Therefore, would you support legislation that would 1) make similar changes the Administration has put forward related to Part D and Medicaid managed care, 2) change the rebate system in a similar way to the proposal for the commercial market, and 3) require drug makers to lower the list price of their drugs equal to the amount of rebates provided today?**

Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

2. **Medicaid Drug Rebate Program.** The Medicaid Drug Rebate Program (MDRP) requires manufacturers to provide a basic rebate and an additional inflationary rebate for both brand and generic drugs. The inflationary rebate is an increasingly substantial part of total rebates due in large part to large increases in drug prices that exceed inflation. Under current law, this inflationary rebate is capped at 100 percent of Average Manufacturer Price (AMP). This is the case even when manufacturers continue to raise their prices well above inflation.

- a. **Please provide a list of all of your pharmaceutical products that have reached the Medicaid AMP rebate cap in any of the 20 quarters from January 1, 2014 through December 31, 2018.**

Please see [Appendix B](#).

- b. **For each drug listed in response to question 1, please also provide a list of which quarters and years each drug hit the cap.**

Please see [Appendix B](#).

3. **Medicaid Drug Rebate Program Compliance.** I am concerned about recent reports and legal settlements surrounding drug manufacturers' failure to comply fully with the requirements of the MDRP. For example, an analysis by the U.S. Department of Health and Human Services Office of Inspector General found that between 2012 and 2016 taxpayers may have overpaid by as much as \$1.3 billion for 10 potentially misclassified drugs. That is why I introduced the Right Rebate Act with Chairman Grassley to prevent drug manufacturers from manipulating Medicaid to increase their profits. However, I continued to be concerned about oversight and manufacturer compliance with the requirements of the Medicaid Drug Rebate Program.

**Accordingly, please describe the following:**

- a. **Your company's current compliance plan and procedures used to ensure compliance with the requirements of the Medicaid Drug Rebate Program including internal audits or other checks you use to identify compliance vulnerabilities.**

All aspects of AstraZeneca's compliance with the requirements of the Medicaid Drug Rebate Program, including Statutory Pricing (average manufacturer price (AMP) and Best Price) and Medicaid Rebate payments, are covered by AstraZeneca's compliance framework. This compliance plan includes a robust review process, including Sarbanes-Oxley testing, self-auditing, and formal audits by internal and external audit.

- b. **Any past or ongoing issues of non-compliance.**

Since the implementation of AstraZeneca's compliance framework, we are not aware of any compliance issues that have been identified via this internal and external audit process.

- c. **Any corrective actions taken to address identified problems or issues of non-compliance with the MDRP and how such steps were communicated to the Centers for Medicare & Medicaid Services.**

As noted above, to date, no compliance issues have been identified via this internal and external audit process.

- d. **Any steps taken to improve compliance and ensure that all Medicaid drug rebates owed to the federal government and the states are paid in full.**

AstraZeneca has a comprehensive compliance framework that includes Sarbanes-Oxley testing, self-auditing, and formal audits by internal and external audit. Additionally, as it relates to Medicaid drug rebates owed to the federal government and states, AstraZeneca performs additional reviews of claims-level data, ensuring the completeness and accuracy of both the payments made by manufacturers as well as claims submitted to manufacturers. This process has identified duplicate pharmacy claims submitted to State Medicaid Agencies resulting in overpayment by both States and manufacturers. Clearly, these overpayments disadvantage both the States and manufacturers like AstraZeneca.

4. **Bonus Payments Tied to Specific Drugs.** I am concerned by the potential for employee financial incentives to encourage high launch prices and price increases for prescription drugs.

- a. **Is your salary, bonus or other compensation tied to sales or revenue targets of a single product your company sells? Has it ever been? If yes, please state the product or products to which your salary, bonus or other compensation was tied.**

The CEO's compensation as well as the compensation of other senior leaders is directly based on three areas of performance that are generally weighted equally: development and delivery of innovative science, our aggregate sales, and other important financial metrics.

AstraZeneca understands that executive pay is a closely scrutinized issue. As part of our compensation decisions, we are mindful of the sensitivity of this issue as we determine how best to incentivize, reward and retain executives capable of leading a global pharmaceutical company in a highly competitive market.

- b. **Is your salary, bonus or other compensation tied to either revenue or net income of the company as a whole? Has it ever been? If yes, please explain what assumptions about price increases are used when the compensation committee sets revenue or net income goals. Does the compensation committee provide any guidance to executives in regards to the amount of revenue that the company will generate from price increases versus volume growth?**

The CEO's compensation as well as the compensation of other senior leaders is directly based on three areas of performance that are generally weighted equally: development and delivery of innovative science, our aggregate sales, and other important financial metrics. AstraZeneca's Remuneration Committee does not provide any guidance on price increases.



5. Provision of Rebates in Exchange for Formulary Placement. In today's system, drug makers receive a limited time window to sell their drug without competition. After that period has expired, low-cost generics should become available. However, drug makers often prevent access to these cheaper generic drugs in Medicare. Researchers have found that 72 percent of Medicare Part D plans charged lower cost-sharing for a brand name drug compared to its generic equivalent. This means seniors were charged less out of pocket for brand name drugs compared to generics that are on average four times cheaper than the brand-named drug. This happens because drug makers pay a rebate to the Part D plans in order to give the more expensive drug better treatment than a generic. As a result, Medicare spending increases due to the current structure of the Part D benefit.

a. **Has your company ever paid a rebate to a Part D plan so that a brand name drug would get preferential treatment (i.e. lower cost-sharing or less utilization management) compared to a cheaper generic?**

In certain instances, AstraZeneca enters into arrangements under which a branded agent is discounted at or below the net cost of the generic(s) in the market, therefore benefiting the plan and the beneficiary. AstraZeneca typically enters into these types of arrangements for medicines already existing on formulary. These arrangements benefit patients by ensuring greater affordability for the branded medicine and by ensuring continuity of treatment if a patient has already been prescribed a branded medicine. These arrangements also support competition because they provide the opportunity for multiple competitors and medicine options to compete on price and other factors. We have had several such arrangements in Medicare Part D (see [Appendix C](#)).

b. **If so, please provide:**

(i) **A list of the drugs for which your company has done this since January 1, 2014.**

A list providing this information is attached as [Appendix C](#).

(ii) **The number of Part D plans in which this type of rebate was given for each drug in each year.**

A list of the relevant Part D plans is included in [Appendix C](#).

6. Net Prices. During your testimony, you stated, "the estimates for 2018 show that across our medicines, our average rebate is nearly 50 percent of our gross revenues in the U.S. Despite this, in recent years, in our primary cap portfolio, we have seen flat to declining net effective prices for most of our medicines."

**Please describe how the company's year-over-year aggregate net price is calculated.**

The analysis discussed during the hearing on February 26, 2019 was completed by brand; the change in Net Price was calculated at the brand level, and then weighted based on Net Sales for each brand as a percent of Total Net Product Sales for 2018.<sup>2</sup>

**Please also specifically address the following questions:**

- a. **How many products are included in the calculation of the average net price change? What was the median net price change?**

The analysis discussed during the hearing on February 26, 2019 included 26 brands that represent 98% of annual Net Product Sales in the United States for the period ending December 31, 2018.

The Median Price Change (prior to weighting) was a Net Price decrease of 1%.

- b. **Is net price weighted? If so, how? For example, in determining the aggregate net price does the company assign different weights to different products based on volume or other factors? Are "on patent" and "off patent" drugs weighted identically? Are other statistical weights used or are all products treated equally?**

The analysis discussed during the hearing on February 26, 2019 was completed by brand; the change in Net Price was calculated at the brand level, and then weighted based on Net Sales for each brand as a percent of Total Net Product Sales for 2018 irrespective of whether the medicines are on or off patent.

- c. **Does the figure that you provided during your testimony account for U.S. prices, international prices, or both? Generally speaking, when your company reports net price changes, does it differentiate between U.S. and international prices?**

The analysis discussed during the hearing on February 26, 2019 referred to 26 brands that represent 98% of annual Net Product Sales in the United States for the period ending December 31, 2018.

- d. **Please list the five drugs your company sold in the U.S. that had the greatest year-over-year net price increase in 2018, noting the increase for each drug by dollar figure and percentage. Please list the five drugs your company sold in the U.S. that had the**

---

<sup>2</sup> Net Product Sales reflect the invoiced amount less movements in estimated accruals for rebates and chargebacks given to managed-care and other customers. Cash discounts for prompt payment are also deducted from sales. Average Net Price per Unit excludes product returns, and the figures were arrived at using the conventional Net Price calculation, that is, before deducting cost of goods sold, royalties, and variable selling expenses.

**lowest year-over-year net price increase (and/or the greatest decrease) in 2018, noting the increase (or decrease) for each drug by dollar figure and percentage.**

In 2018, we experienced a Weighted Average Net price decline in our hyper-competitive respiratory and diabetes therapeutic areas, with declines of 2.4% and 1.9%, respectively. Our Weighted Average Net prices in oncology remained flat. Brand-specific pricing information is competitively sensitive information.

- e. **For 2018, what was the average net price change in the U.S. market for (1) drugs with no competition, (2) drugs with only branded competition, and (3) drugs with generic competition?**

For 2018, the Weighted Average Net price change in the United States market for:

- Medicines with no competition was an increase of 0.6%;
- Branded “on patent” medicines without generic equivalents was a decrease of 4.7%;
- “Off patent” medicines with generic equivalent competition was an increase of 4.6%.

With respect to the last category of medicines described above, we note by way of context that once generic options enter the market, our market share rapidly erodes, as many PBMs, insurers, and government agencies to which AstraZeneca offers rebates and discounts replace our branded medicines on their formularies with these generic competitors. Accordingly, the mix of business for medicines with generic competition shifts towards programs whereby health plans/PBMs chose to list our branded medicines on their formularies given a lower net cost versus generics, and to individual patients who chose to pay for branded agents over generic agents, resulting in a higher average net effective price across all distribution channels.

- f. **You state that “the estimates for 2018 show that across our medicines, our average rebate is nearly 50 percent of our gross revenues in the U.S.” For each product, please disclose the gross revenue and the amount of rebates paid.**

The table below reflects our Product Sales in the U.S. for the period ending December 31, 2018, including the proportion of Gross Sales allocated to estimated amounts we expect to pay to third-party managed care organizations, hospitals, long-term care facilities, group purchasing organizations and various federal or state programs. The percentage of Gross Product Sales column reflects our effective rebate rate per channel, a combination of mix of business in that channel and related rebate rate.

	USD (in millions)	% of Gross Product Sales
<b>Gross Product Sales</b>	\$ 16,538,000	
Chargebacks	\$ (2,224,000)	-13%
Regulatory – Medicaid and state programs	\$ (1,304,000)	-8%
Contractual – Managed-care and Medicare	\$ (4,600,000)	-28%
Cash and other discounts	\$ (286,000)	-2%
Customer returns	\$ (119,000)	-1%
U.S. Branded Pharmaceutical Fee	\$ (140,000)	-1%
Other	\$ (989,000)	-6%
<b>Net Product Sales</b>	\$ 6,876,000	

Brand-specific pricing information is competitively sensitive information.

## VII. Senator Menendez

1. During the hearing, when I asked whether your company engaged in tactics to delay generic production of your products, you answered “no”. However, AstraZeneca appears on the FDA’s list of companies who have access complaints against them.

**Can you explain the discrepancy between your answer and the FDA list? The FDA list can be found here:**

<https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm607738.htm>

AstraZeneca appreciates the opportunity to address the question of one of our medicines (BRILINTA®) appearing on the Reference Listed Drug Access Inquiries list (RLD List). We would first like to state that AstraZeneca supports allowing generic manufacturers access to samples. Withholding or otherwise blocking such access is inconsistent with that position. Our internal review has not identified any unanswered, delayed, or outstanding requests for samples of BRILINTA (ticagrelor) by any generic manufacturers.

It is our understanding that BRILINTA was included on the RLD List based on a single inquiry received by the FDA. Unfortunately, the RLD List does not identify the company that reportedly requested information (or samples) from AstraZeneca, the date the information was requested, or any other information that would allow AstraZeneca to better understand or further investigate the circumstances of this inquiry. On its website, the FDA does advise that it has “not independently investigated or confirmed the access limitations described in the inquiries received.” Given this limitation, the listing of an inquiry on the RLD List does not mean that the FDA has in fact

determined that access to samples by generic manufacturers was limited or withheld for the medicines identified. Indeed, based on our internal review, we have not identified any circumstances that substantiate the inquiry received by the FDA relating to BRILINTA.

BRILINTA is and has always been available via normal commercial distribution channels (i.e., wholesalers) since its U.S. launch. It has never had a restricted distribution program.

Finally, more than 15 generic manufacturers have applied for regulatory approval from the FDA for the manufacture of generic ticagrelor and some, like Watson/Teva, have received tentative approvals from the FDA. Because conducting bioequivalence studies with the branded medicine is an FDA pre-approval requirement, it is clear that these generic manufacturers are not having difficulty accessing branded ticagrelor for their studies.

In light of the context provided above, it is unclear why any generic manufacturer would be unable to obtain a sample of BRILINTA for their purposes or why an inquiry was lodged with the FDA related to this medicine.

2. **Part 1: When new products enter the market, do drug companies set high initial rebates and then provide deep rebates in order to gain access to insurance plan's formularies?**

No, this is not AstraZeneca's general practice. We negotiate rebates and discounts with payers and pharmacy benefit managers (PBMs)—including in Medicare Part D—to help ensure that patients have the most robust access possible to our therapies. Without these discounts and rebates, many life-saving medicines would not be placed on plan formularies and therefore would be largely unavailable to the patients who need them most.

The current rebate system creates misaligned incentives. This results in a growing differential between list and net prices. We support reforms of this system that include the elimination of rebates in the commercial sector and in Medicare Part D, which will result in the reduction of the differential between list and net prices and which would allow manufacturers to ensure that the initial list price of a drug reflects its net value.

3. **Part 2: If CMS finalizes the rebate rule, do you anticipate future products entering the market with significantly lower initial list prices?**

We believe that eliminating rebates across Medicare Part D and commercial will generally result in lower initial list prices than in the absence of reform, although the impact on specific medicines will vary based on the competitive dynamics for that medicine. Reform only in Part D and not commercial is unlikely to impact initial list price setting practices, as the current structure does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector).

## VIII. Senator Carper

1. **What are your recommendations for lowering prices for the 40 percent of drugs that do not offer rebates in Medicare Part D? In the health**

**insurance plans that you offer your employees, do you ask your insurers to pass through the full manufacturer rebates to the beneficiaries?**

All of our medicines are rebated under the statutory requirements of Medicaid, Federal Supply Schedule, 340B, and the Part D coverage gap discount program. For our highly innovative, targeted therapies, we do not typically provide additional rebates other than through our value-based agreements, where such discounts are based on patient outcomes.

In general, medicines with minimal rebates are the newest and most innovative on the market. Expanded use of value-based agreements is a key component to lowering costs and improving access to these medicines that are currently not in highly rebated therapeutic classes. Under such arrangements, manufacturers may contract to reimburse plans if the medicine does not work as expected, lowering risks for the payer. This also results in competition across manufacturers of medicines in these classes by facilitating competition across clinical results and outcomes.

As we stated before the Senate Committee on Finance, AstraZeneca has put forward several proposals in addition to value-based agreements to address drug pricing:

- Moving away from the current rebate system, while continuing to work with payers and PBMs to ensure robust negotiations;
- Using a portion of discounts and rebates to create out-of-pocket caps for Medicare patients;
- Encouraging biosimilars and eliminating policy and commercial barriers to their greater use.

AstraZeneca also supports increased transparency across the biopharmaceutical supply chain, including transparency with respect to drug pricing. To that end, we generally support the policies included in the current versions of the SPIKE and C-THRU Acts. There are a variety of state-level drug pricing transparency laws and regulations. We believe that having a consistent, federal standard for drug pricing transparency requirements, like those included in the SPIKE Act, should pre-empt state level laws to reduce confusion and compliance burden.

We also support transparency efforts to ensure that patients and prescribers have meaningful information on out-of-pocket costs at the point of prescribing, so that they can make informed decisions about the most appropriate and affordable therapy.

AstraZeneca wants to be a constructive partner in identifying solutions that continue to allow manufacturers to innovate while creating a more efficient and more affordable system.

AstraZeneca provides generous healthcare benefits to its employees. Today, we provide a point-of-sale discount on prescription medicines in the form of low out-of-pocket costs for our employees. We cap our employees'

out-of-pocket costs on prescription medicines at \$50 per fill to ensure they do not forgo their prescriptions due to high out-of-pocket costs.

2. The systems for pricing and distributing drugs are opaque and difficult to understand.

**What are your recommendations for increasing transparency in how your companies set the list prices for drugs, and for improving transparency in the supply chain for prescription drugs? Would you support federal standards for transparency in setting the list prices for drugs?**

We do believe that greater transparency is needed for manufacturers as well as other entities in the supply chain. We therefore would generally support transparency requirements such as those included in the SPIKE and C-THRU Acts. Any transparency requirements should consider the need to protect competitively sensitive information to ensure robust competition in the market.

There are a variety of state-level drug pricing transparency laws and regulations. We believe that having a consistent, federal standard for drug pricing transparency requirements, like those included in the SPIKE Act, should pre-empt state level laws to reduce confusion and compliance burden.

3. In nearly every sector of the health care industry, Medicare, Medicaid, employers, and insurers are moving away from fee-for-service payments to reimbursements based on value and performance. Prescription drugs and medical devices were the glaring exceptions to this trend until recently.

**How many of your drugs are included in value-based contracts and how many patients are benefiting from them? How do these value-based contracts work to lower drug prices for both patients and taxpayers?**

We believe medicines are part of the solution to controlling healthcare costs. They not only improve patient outcomes and increase quality of life, but also reduce downstream costs. Value-based agreements allow us to reimburse the healthcare system if our medicines do not deliver as intended. This solution demonstrates our willingness to stand behind the value of our medicines.

AstraZeneca is working closely with payers and health systems to explore innovative solutions to improve access and affordability that demonstrate the value our medicines bring to patients and the healthcare system. Our value-based agreements aim to manage the totality of treatment costs and keep people healthy and out of the hospital. For several years, AstraZeneca has been exploring these types of solutions through value-based agreements where we are willing to work with healthcare stakeholders to tie payment to patient outcomes.

To date, we have entered into approximately 40 value-based agreements for 15 medicines across our therapeutic areas with a variety of payers, making AstraZeneca a leader in the field of value-based agreements. Tens of

thousands of patients have benefited from improved access as part of these agreements.

As an example, and as noted in our written testimony submitted to the Senate Committee on Finance, AstraZeneca agreed with Express Scripts that for IRESSA, an oral treatment for certain types of lung cancer, we will fully reimburse Express Scripts for discontinued use before the third fill, including if discontinuation occurs because patients did not respond to treatment.

While most of these agreements have been focused on securing patient access to our medicines and delivering better patient outcomes, where payers are willing, we are also looking to more directly address patient out-of-pocket affordability through these innovative arrangements.

As an example, we recently announced the initiation of a value-based agreement for University of Pittsburgh Medical Center (UPMC) Medicare patients who are prescribed BRILINTA. This value-based contract, which was effective as of January 1, 2019, is groundbreaking in two ways. First, the contract lowers the out-of-pocket costs for a UPMC Medicare Part D patient to approximately \$10 for a 30-day supply. Second, what UPMC pays for BRILINTA will vary based on patient outcomes, tying the cost of the medicine to its real-world clinical performance.

We are currently exploring another value-based agreement in Medicare Part D. In addition to having a significant outcomes-based component, this arrangement would reduce patient out-of-pocket costs. This type of agreement allows patients to access their medicines at a lower out-of-pocket cost and payers to control their overall healthcare costs through paying for outcomes.

4. Last year, Senator Portman and I did an investigation on the pricing of an opioid overdose reversal drug called EVZIO, manufactured by Kaléo. Kaléo increased the price of EVZIO from \$575 in 2014 to \$4,100 in 2017. We found that the best price Medicare was able to get for EVZIO, about \$4,000, was much higher than the price other federal programs and private insurers were able to get. It seemed that Kaléo was able to get this higher price of \$4,000 from Medicare by helping doctors fill out paperwork showing that the drug was medically necessary, even though there are cheaper alternatives on the market. As a result of the investigation, Kaléo announced it will bring a generic version of the drug to market at only \$168 per pack.

**Are any of your companies providing medical necessity paperwork to doctors in order to get your drugs covered by Medicare?**

AstraZeneca policies prohibit completing medical necessity paperwork for doctors or their staff as described in your inquiry.

5. In 2017, the Rand Corporation estimated that biosimilar drugs, which are competitors to complex, biologic drugs, could save the United States more than \$50 billion over the next decade. Some of you have also argued that increasing the use of biosimilar drugs would help lower drugs costs for consumers and taxpayers.



**What is delaying the uptake of biosimilar drugs in the United States?  
What policies do you recommend to increase the development of  
biosimilar drugs?**

AstraZeneca believes that competition is a key component to reducing costs, and that is why we support the expanded use of biosimilars in the U.S. As a global company, we operate in countries, particularly those in the European Union, where biosimilar competition is particularly robust. We support a similarly vigorous biosimilars market in the U.S.

There are several challenges to biosimilar uptake in the U.S., including contracting and rebating dynamics and difficulty in obtaining interchangeability status. We therefore appreciate the efforts of the FDA to increase the availability of biosimilars in the U.S., including the FDA's development of a Biosimilars Action Plan. We support efforts to streamline and improve the efficiency of the biosimilars approval pathway for the benefit of patients. Such efforts could include increased transparency into the patents applicable to biologic medicines.

We also support reimbursement policies that facilitate the uptake of biosimilars. Such policies include Medicare reimbursement rates that ensure that biosimilars can compete on equal footing with innovator medicines, and reductions to cost-sharing amounts for biosimilars. We also believe the elimination of rebates will help biosimilars compete with innovator medicines.

**IX. Senator Cardin**

1. The United States is one of the only countries in the world to allow prescription drug manufacturers to advertise directly to consumers through magazines, billboards, radio, and television commercials. While I will not argue that it is beneficial to educate consumers about an unfamiliar disease and encourage them to seek medical help, most commercials from all of your companies recommend asking about a specific brand name drug, not a medical condition. Furthermore, even if your advertisements follow all FDA rules and list medication side effects, they also almost always list these while a smiling, apparently healthy person is walking on a beach. Researchers say that this type of imagery, combined with viewing hours of drug commercials each month, leads consumers to underestimate the risks associated with medications. For the past decade, studies have shown that aggressive direct-to-consumer advertising is associated with rising drug prices and an increase in inappropriate drug prescriptions.

**Since researchers have concluded that consumers are misunderstanding the benefits and risks described in your ads, what further policies could help you and your colleagues ensure that you are educating patients in a clear manner?**

Our advertising complies with regulatory requirements governing direct-to-consumer (DTC) advertising and AstraZeneca believes that DTC advertising is important to raising brand and disease awareness, fostering patient education, and enhancing the dialogue between patients and their

physicians. Unfortunately, these positive impacts of healthcare communication efforts are often left out of the DTC debate.

2. **Pharmaceutical Companies Continue to Raise Prices.** As you are well aware, high prescription drug prices are the number one concern for Americans and their families. According to the Organization for Economic Cooperation and Development, the average American spends around \$1,208 annually on prescription drugs. There have been several instances where brand name or even generic drugs that have been on the market for years continue to increase in price. One of the most well known examples is Mylan's increase of the price of EpiPen from less than \$100 in 2007 to more than \$600 in 2016. Another example, is the ever-increasing price of insulin. Sanofi increased the price of a vial of Lantus from \$88.20 in 2007 to \$307.20 in 2017. And those are just a small sample of price increases.

**Why don't we see price decreases for drugs that have been on the market for years without new formulations or added benefit?**

As an initial matter, it is important to note the distinction between list and net prices. Over the past several years, discounts and rebates for our therapies have increased overall, both in the commercial sector and Part D. In recent years, in our primary care portfolio, which includes the majority of our therapies, we have seen flat to declining net effective prices to AstraZeneca for most of our medicines. Flat to declining net prices is a trend across the industry.

However, the current system makes list price decreases challenging.

Therefore, to accomplish meaningful change in terms of lowering list price, the system must be restructured to eliminate rebates. Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector, and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

3. **Pay for Delay.** Pay for delay is a tactic that more and more branded drug manufacturers have been using to stifle competition from lower-cost generic manufacturers. This allows you to sidestep competition by offering patent settlements that pay generic companies not to bring lower-cost alternatives to market. These "pay-for-delay" patent settlements benefit both brand-name pharmaceutical companies by helping them avoid costly patent litigation and generic manufacturers by rewarding them a hefty sum to delay entering the market with a cheaper drug alternative. However, these deals do not benefit

consumers. According to an FTC study, these anticompetitive deals cost consumers and taxpayers \$3.5 billion in higher drug costs every year.

a. **Does your company partake in pay-for-delay settlements?**

AstraZeneca does not enter into settlements that pay generic competitors to delay entry into the market. In the absence of a settlement, a generic would not necessarily prevail in the patent litigation and therefore would not be able to enter the market. Indeed, AstraZeneca has entered into many early-entry patent settlements that permit generic competitors to enter the market before expiration of AstraZeneca's patent rights by allowing generic manufacturers to license innovator patents.

All of AstraZeneca's patent settlements fully comply with the law. These settlements provide increased clarity and stability to both parties, allowing innovators like AstraZeneca to continue investing substantially in new medicines for patients and frequently allowing generic competitors to enter the market before expiration of AstraZeneca's patent rights.

b. **Why would a pharmaceutical company enter into a pay-for delay agreement?**

AstraZeneca does not enter into agreements that pay generic competitors to delay entry into the market.

c. **Do you think these agreements stifle competition and prevent generic alternatives to your branded medications?**

AstraZeneca does not enter into agreements that pay generic competitors to delay entry into the market. However, AstraZeneca has entered into many early-entry patent settlements that permit generic competitors to enter the market before expiration of AstraZeneca's patent rights by allowing generic manufacturers to license innovator patents. These do not stifle competition but instead permit early entry by resolving patent disputes that would otherwise prevent generic alternatives to branded medication.

4. **Value-Based Pricing.** One idea I wanted to get your thoughts on today, is the idea of value-based pricing. This is an idea where a company could link the single price it charges for a given drug to an assessment of how well it works. Some value-based pricing arrangements could allow insurers and patients to receive rebates from drug manufacturers if a drug failed to work (outcome-based pricing). Another version would involve "indication-based pricing" in which drug companies charge different prices for the same drug when it is used to treat different conditions.

Dr. Soriot, we have heard that AstraZeneca has been participating in a value-based program in collaboration with the University of Pittsburgh Medical Center.

**Could you talk more about your research in value-based pricing and how you believe this could be possible solution to some of the high drug prices?**

We believe medicines are part of the solution to controlling healthcare costs. They not only improve patient outcomes and increase quality of life, but also reduce downstream costs. Value-based agreements allow us to reimburse the healthcare system if our medicines do not deliver as intended. This solution demonstrates our willingness to stand behind the value of our medicines.

AstraZeneca is working closely with payers and health systems to explore innovative solutions to improve access and affordability that demonstrate the value our medicines bring to patients and the healthcare system. Our value-based agreements aim to manage the totality of treatment costs and keep people healthy and out of the hospital. For several years, AstraZeneca has been exploring these types of solutions through value-based agreements where we are willing to work with healthcare stakeholders to tie payment to patient outcomes.

To date, we have entered into approximately 40 value-based agreements across our therapeutic areas with a variety of payers.

Our research in value-based agreements has been focused on addressing the comprehensive value of a medicine in terms of medical cost offsets and the economic impact of achieving certain health benefits with a medicine in a specific population. Our experience in this area consists of health economics and outcomes research (HEOR) and real-world evidence (RWE) studies which correlate improved outcomes and overall better health to a direct, positive economic impact, realized by both the payer and the patient. We use HEOR and RWE data to establish the metrics of the value-based agreement. Another important part of our value-based agreement research is how we measure the impact of a value-based agreement, so we can learn what works and what does not work for future iterations of value-based agreements.

In addition, by aligning payments for medicines more directly with their value in improving health outcomes and/or reducing the need for other healthcare services (such as hospitalizations), value-based arrangements make pharmaceutical manufacturers accountable for the results our medicines achieve and can help improve patients' health and maximize the benefits of healthcare spending. Over time, proliferation of value-based agreements can shift utilization toward medicines with greater clinical value and greater ability to reduce hospitalizations and other costly services, resulting in better health outcomes and lower overall healthcare spending.

As manufacturers develop more complex, personalized, and promising treatments—such as gene therapies, cell therapies, or immuno-therapies—it

will be increasingly important for health plans to enter into value-based agreements so that they and our healthcare system may recognize the full value of those treatments and make them available to patients at affordable out-of-pocket amounts. Value-based agreements serve an important role in linking the price of a medicine to beneficiaries' demonstrated real world outcomes using that medicine.

While most of these agreements have been focused on securing patient access to our medicines, some have also helped payers identify which patient types are most likely to benefit from our medicines and deliver improved patient outcomes. Partnering to drive this type of clarity can reduce overall drug spend in meaningful ways. Where payers are willing, we are also looking to more directly address patient out-of-pocket affordability through these innovative arrangements.

As you mention, we recently announced the initiation of a value-based agreement for University of Pittsburgh Medical Center (UPMC) Medicare patients who are prescribed BRILINTA. This value-based contract, which was effective as of January 1, 2019, is groundbreaking in two ways. First, the contract lowers the out-of-pocket costs for a UPMC Medicare Part D patient to approximately \$10 for a 30-day supply. Second, what UPMC pays for BRILINTA will vary based on patient outcomes, tying the cost of the medicine to its real-world clinical performance.

Through the partnership of payers and policymakers, we look forward to a future where implementation of value-based agreements across public and private payers is widespread. Value-based agreements are one proactive solution; they are not the only solution.

5. **Drug Rebate Rule.** In January, the Department of Health and Human Services' (HHS) Office of Inspector General (OIG) promulgated a new regulation to remove regulatory safe harbor protections under the Anti-Kickback Statute (AKS) for rebates on prescription drugs rebates paid by manufactures to PBMs under Medicare Part D and for Medicaid managed care organizations (MCOs). The OIG proposal attempts to ban most rebates by eliminating their regulatory protections. The rule is predicted to increase net drug costs in its early years. The CMS actuaries estimate it would cost \$196 billion over 10 years. Despite this high price tag, the beneficiary benefits are limited. The proposed rule notes that under the CMS Actuary's analysis, the majority of beneficiaries would see an increase in their total out-of-pocket payments and premium costs; reductions in total cost sharing will exceed total premium increases.

I wanted to ask a question about the Administration's rebate rule, which I understand that many of the drug manufacturers, and your main trade association, strongly support. According to an analysis of the rule by the Office of Actuaries at CMS, drug manufacturers are likely to initially retain 15 percent of the current rebates as higher net drug prices.

**Given that estimate, can you provide the Committee with any assurances that prices will not increase under this proposed rule?**

Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector, and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

**X. Senator Brown**

1. According to an article recently published in the Journal of the American Medical Association, medical marketers spend nearly \$30 billion dollars in 2016, up from \$17 billion in 1997. Direct-to-Consumer (DTC) advertising had the biggest percentage increase: from \$2.1 billion, or 11.9% of all medical marketing, in 1997 to \$9.6 billion, or 32% of total spending, in 2016.

**Can each of you please provide what your ratio of spending on sales and marketing to research and development is today?**

In 2018, we spent \$5.9 billion on R&D and \$6.1 billion on Sales & Marketing, globally. Our Sales & Marketing figures include all costs incurred in selling, marketing, promoting, and distributing our products.

2. **Price-Gouging.** Sanofi, as I understand it, has made a pledge to the public to limit its price increases to the national health expenditures growth projection.

- a. **Would your company commit to a cap on annual price increases as part of your PhRMA membership criteria?**

Our decisions around pricing would always need to remain independent of PhRMA membership criteria.

- b. **What policies would you propose to help ensure lower launch prices for new drugs?**

As we stated at the Senate Committee on Finance hearing, AstraZeneca has put forward a number of proposals to address drug pricing, including:

- Moving away from the current rebate system, while continuing to work with payers and PBMs to ensure robust negotiations; and
- Encouraging biosimilars and eliminating policy and commercial barriers to their greater use.

As described below, we also support efforts to increase transparency in the biopharmaceutical supply chain and drug pricing specifically.

3. **Transparency.** In many of your testimonies, you mentioned that the current system of pharmacy benefit manager (PBM) back-end rebates do not rarely results in a scenario where the PBM passes on savings to consumers at the point of sale (POS). The Administration recently proposed a rule to eliminate the anti-kickback statute safe harbor protections for these drug rebates.

**Do you agree that greater transparency should be required to understand how manufacturers and PBMs are negotiating prices and rebates to ensure that savings are passed down to beneficiaries?**

Yes, AstraZeneca agrees that greater transparency is needed. We therefore generally support the policies included in the current versions of the SPIKE and C-THRU Acts.

There are a variety of state-level drug pricing transparency laws and regulations. We believe that having a consistent, federal standard for drug pricing transparency requirements, like those included in the SPIKE Act, should pre-empt state level laws to reduce confusion and compliance burden.

4. **PBMs.** An *Axios* article from March 7, 2019 highlights the fact that, while “pharmaceutical companies put a lot of the blame for high drug prices on pharmacy benefit managers,” many large pharmaceutical companies “rely on PBMs to manage their own health care benefits.”

- a. **In your role as an employer, does your company contract with a pharmaceutical benefit manager (PBM) to administer the prescription drug benefits for your employees and negotiate lower drug costs on your behalf?**

AstraZeneca prescription drug benefits are managed by Express Scripts.

- b. **All witnesses: for those of you who do use a PBM to help manage the prescription drug benefit for your employees, how do you utilize the rebates your PBM negotiates to lower health care costs or drug costs for your employee plans and what does your company do with that savings? Specifically, do the savings go toward lowering premiums?**

AstraZeneca provides generous healthcare benefits to its employees. Today, we provide a point-of-sale discount on prescription medicines in the form of low out-of-pocket costs for our employees. We cap our employees’ out-of-pocket costs on prescription medicines at \$50 per fill to ensure they do not forgo their prescriptions due to high out-of-pocket costs.

- c. **For those of you who do use a PBM to help manage the prescription drug benefit for your employees, does your PBM offer point-of-sale rebates to your employees?**

While AstraZeneca does not currently offer point-of-sale rebates to employees, we are exploring opportunities to evolve our benefits in the future.

## **XI. Senator Whitehouse**

- 1. Please describe any policy changes you support that would result in your company lowering the list prices of its drugs.**

The current rebate construct is the key challenge in reducing list prices and we would support legislation that would eliminate rebates in Part D and the commercial sector. Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector, and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

- 2. How much does your company's research and development portfolio rely on taxpayer-funded research conducted by the National Institutes of Health (NIH)? How many of your company's products are based, at least in part, on NIH research, and how many are the result of research funded solely by your company?**

We collaborate with the National Institutes of Health and the National Cancer Institute, and these partnerships can lead to important advances for patients. However, biopharmaceutical companies conduct the vast majority of R&D needed to bring new medicines to patients and they bear the associated costs and risks.

- 3. In each of the last five years, how much has your company spent on research and development versus the advertising and marketing of your products?**

Last year alone, we invested nearly \$6 billion in R&D, which represents 28% of our total product sales, well above the industry average.

Our Sales & Marketing figures include all costs incurred in selling, marketing, promoting, and distributing our products.



Year	R&D Investment	Sales & Marketing
2018	\$5.9 billion	\$6.1 billion
2017	\$5.8 billion	\$5.6 billion
2016	\$5.9 billion	\$5.8 billion
2015	\$6.0 billion	\$6.6 billion
2014	\$5.6 billion	\$7.1 billion

4. During the hearing, you mentioned that your company would be likely to lower the list prices of its drugs if the recent proposal by the Trump administration to change the current system of rebates was extended to the private market.

a. **If the policy was extended to the private market, how large would the list price reductions be relative to the size of the rebates your company is currently providing?**

Assuming the HHS rebate rule is finalized largely as proposed, AstraZeneca intends to comply with its requirements and use point-of-sale discounts. Our goal is to maintain net prices broadly in line with today, recognizing our ability to do so may be dependent on external factors and market response such as how plans evolve their benefit design and the total degree of transparency under the new model.

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector, and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

b. **How will this proposal affect how your company sets the list prices for new drug products?**

We believe that eliminating rebates across Medicare Part D and commercial will generally result in lower initial list prices than in the absence of reform, although the impact on specific medicines will vary based on the competitive dynamics for that medicine. Reform only in Part D and not commercial is unlikely to impact initial list price setting practices, as the current structure does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector).

- c. **If the proposal is finalized and not extended to the private market, will your company make any list price reductions? If so, how large would the reductions be relative to the size of the rebates your company is currently providing?**

AstraZeneca would plan to reduce list prices, pending reforms across all payers, including in the commercial sector in addition to Part D, as the current construct does not allow for two separate list prices (i.e., one list price for Part D and a different list price for the commercial sector). Therefore, we also support efforts to eliminate rebates in the commercial sector, and recommend that Congress explore such legislation. While eliminating rebates is an important step, benefit designs must also be evaluated.

## **XII. Senator Hassan**

1. In June of 2018, the Medicaid and CHIP Payment and Access Commission (MACPAC) unanimously recommended under Recommendation 1.1 in their annual report to Congress that Congress remove the statutory requirement that manufacturers blend the average manufacturer price (AMP) of a brand drug and its authorized generic.<sup>3</sup> This requirement created an unintended loophole. Rather than use the price of the authorized generic, drug companies can sell its authorized generic to a corporate subsidiary at an artificially lower price, and use that lower price to bring down the AMP, which in turn lowers the rebate obligation.

**Does your company engage in this practice? Has your company ever engaged in this practice in the past?**

No. In limited circumstances, AstraZeneca has made authorized generics available, but does so through a third-party distributor, not an AstraZeneca subsidiary.

## **XIII. Senator Cortez Masto**

1. **As a portion of your revenue, for what percentage of the drugs in your portfolio do you offer no rebates? Based on the drugs in your pipeline, do you foresee that portion growing? For those drugs, is your list price equal to your net price?**

All of our medicines are rebated under the statutory requirements of Medicaid, Federal Supply Schedule, 340B, and the Part D coverage gap discount program. For our highly innovative, targeted therapies, we do not typically provide additional rebates other than through our value-based agreements, where such discounts are based on patient outcomes. Therefore, due to statutory rebates and other fees and discounts, the net price is lower than list price for all medicines.

2. **Do you invest more in R&D than you generate in U.S. sales revenue? Please include specific figures.**

---

<sup>3</sup> MACPAC: Improving Operations of the Medicaid Drug Rebate Program: <https://www.macpac.gov/wp-content/uploads/2018/06/Improving-Operations-of-the-Medicaid-Drug-Rebate-Program.pdf>

In 2018, AstraZeneca's U.S. revenue was \$6.88 billion. We invested \$5.9 billion in R&D, globally.

3. **Do you invest more in R&D than you spend on marketing and administration? What company functions do you consider to be included in administration? Please include specific figures.**

In 2018, we spent \$5.9 billion on R&D and \$10 billion on Selling, General & Administrative (SG&A) costs globally, which is inclusive of Sales & Marketing costs of \$6.1 billion.

Selling, General and Administrative expenses are defined as fixed costs of selling products and services and costs of central services and administration, which are not included in inventory values.

General and administrative costs include costs of central services and administration, such as: Human Resources, Finance, Facilities, Purchasing, Strategy & Business Development, Legal, Corporate Affairs, and other corporate expenses.

Our Sales & Marketing figures include all costs incurred in selling, marketing, promoting, and distributing our products.

4. **Do you invest more in R&D than you spend on marketing and sales? What company functions do you consider to be included in sales? Please include specific figures.**

In 2018, we spent \$5.9 billion on R&D and \$6.1 billion on Sales & Marketing, globally.

Our Sales & Marketing figures include all costs incurred in selling, marketing, promoting, and distributing our products.

5. **Why do you advertise for the drugs you manufacture? What factors do you consider in choosing which drugs you advertise?**

We consider many factors when making decisions regarding the advertising of our medicines, including the opportunity to raise brand and disease awareness, patient education, and the enhancement of the patient/physician dialogue.

We believe that healthcare communications efforts can have a positive impact on patient health. AstraZeneca made a decision several years ago to use our direct-to-consumer (DTC) advertisements to share another important message with patients: We were the first company to include messages about our affordability programs in all of our DTC TV advertisements, making clear to patients that if they cannot afford their medicines, AstraZeneca may be able to help. We continue this practice today, which we believe is reflective of AstraZeneca's commitment to patient access and affordability.

Organization	Program Title	Date	Amount
CARDIOVASCULAR RESEARCH FOUNDATION	Chronic Total Occlusion and Left Main Summit 2014: A Live Demonstration Course	01/07/2014	\$5,000.00
TORRANCE MEMORIAL MEDICAL CENTER	Cardiology Update 2014: Conventional Wisdom & Beyond	01/08/2014	\$2,500.00
SCRIPPS HEALTH	Grand Rounds in Cardiovascular Diseases	01/09/2014	\$8,027.93
UNIVERSITY OF CHICAGO	Sixth Annual Morton Arnsdorf Cardiovascular Research Day at the University of Chicago	01/12/2014	\$3,000.00
FLORIDA OSTEOPATHIC MEDICAL ASSOCIATION DISTRICT SOCIETY 2	15th Annual Cardiovascular & Medicine Symposium	01/15/2014	\$5,000.00
AMERICAN COLLEGE OF CARDIOLOGY - PUERTO RICO CHAPTER	25th Annual Meeting ACC Puerto Rico Chapter	01/16/2014	\$5,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Improving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome (ACS)	01/23/2014	\$25,000.00
UNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA	6th ANNUAL CARDIOVASCULAR AND STROKE SYMPOSIUM	01/23/2014	\$5,000.00
SAINT JOSEPH'S HOSPITAL - ATLANTA	Antithrombotic Protocol for Acute Coronary Syndrome	01/23/2014	\$2,737.62
GORDON RESERACH CONFERENCE	Gordon Research Seminar - "Lipoprotein Metabolism"	01/26/2014	\$1,700.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Rheumatology Best Practices 6th Annual Rheumatology Highlights Report- "Translating an International Meeting into Clinical Practice"	01/26/2014	\$9,795.58
KERN ASPEN LIPID CONFERENCE	Evolving Concepts of HDL Function in Cardiometabolic Diseases and Beyond	01/26/2014	\$7,000.00
ST. JOSEPH'S REGIONAL MEDICAL CENTER	Acute Coronary Syndrome: Evidence-Based Management in the Present Era	01/27/2014	\$2,225.00
NATIONAL LIPID ASSOCIATION	Lipid Academy Series of 2	01/28/2014	\$20,000.00
NATIONAL LIPID ASSOCIATION	Masters in Lipidology Series of 2	01/28/2014	\$20,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	Rheumatology Grand Rounds	01/29/2014	\$5,000.00
DUKE UNIVERSITY	Overview of the Duke Health Systems Acute Coronary Syndromes suggested algorithm of care	01/29/2014	\$5,439.84
PENNSYLVANIA ACADEMY OF FAMILY PHYSICIANS FOUNDATION	PAFP/F Smoking Cessation and Asthma Outcomes CME	01/29/2014	\$13,666.00
JOHNS HOPKINS UNIVERSITY	Advances in the Diagnosis and Treatment of the Rheumatic Diseases	01/30/2014	\$30,000.00
EMORY UNIVERSITY	Emory Symposium on Coronary Atherosclerosis Prevention and Education (ESCAPE)	01/30/2014	\$5,000.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION	Clinical Pearls for COPD	01/30/2014	\$5,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Practical Strategies to Improve Patient Outcomes in the Prevention and Treatment of COPD	01/30/2014	\$25,000.00
ST. JOSEPH'S REGIONAL MEDICAL CENTER	COPD	02/04/2014	\$2,200.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE 23rd Annual Scientific and Clinical Congress	02/04/2014	\$16,130.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION	Cardiovascular Pharmacology: Latest Updates in Caring for the Cardiac Patient	02/04/2014	\$5,000.00
MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION	Cardiology at the Bix	02/04/2014	\$5,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	ACC s 63rd Annual Scientific Session (ACC.14) Prevention Learning Pathway & Prevention Pilot Program	02/05/2014	\$100,000.00

Organization	Program Title	Date	Amount
LA BIOMED	Cardiology Grand Rounds: Updates in ACS	02/05/2014	\$5,000.00
NEBRASKA ACADEMY OF PHYSICIAN ASSISTANTS	Ten Things You Didn't Learn About COPD in Class (Even If You Were Paying Attention)	02/05/2014	\$5,500.00
MINNESOTA SOCIETY OF HEALTH-SYSTEM PHARMACISTS	MSHP Annual Meeting 2014: Evidenced-based Updates in the Management of Dyslipidemia	02/05/2014	\$2,533.00
CARDIOVASCULAR RESEARCH FOUNDATION	20th Annual Interventional Cardiology Fellows Course	02/05/2014	\$15,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Best of ACC.14: Take Home Messages for the Clinicians	02/05/2014	\$50,000.00
ENDOCRINE SOCIETY	ENDO 2014 Educational Sessions	02/06/2014	\$40,000.00
ALL NYC EMERGENCY MEDICINE CONFERENCE, INC	All NYC Emergency Medicine Conference;In the Footsteps of Giants	02/06/2014	\$5,000.00
AMERICAN COLLEGE OF PHYSICIANS; PUERTO RICO CHAPTER	Annual Scientific Meeting	02/09/2014	\$10,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	Optimizing PCI Outcomes: A Vision for 2014	02/09/2014	\$5,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	14th Annual Targeted Therapies of Lung Cancer Meeting	02/10/2014	\$12,500.00
TENNESSEE ACADEMY OF PHYSICIAN ASSISTANTS	Breast and Ovarian Cancer	02/10/2014	\$6,000.00
PURDUE UNIVERSITY	A 2014 NATIONAL EDUCATIONAL INITIATIVE ON THERAPEUTICS & RHEUMATOLOGY FOR RHEUMATOLOGY STATE SOCIETIES	02/12/2014	\$30,000.00
WEST PENN ALLEGHENY HEALTH SYSTEM, INC.	Cardiovascular Medicine Update	02/17/2014	\$10,000.00
MEDSTAR WASHINGTON HOSPITAL CENTER	12th International Congress on Targeted Anticancer Therapies (TAT)	02/18/2014	\$25,000.00
THE BIBIKHAN FOUNDATION	7th Annual Cardiovascular Update - "A Practical Tutorial"	02/18/2014	\$5,000.00
SOCIETY OF GYNECOLOGIC ONCOLOGY	SGO 45th Annual Meeting on Women's Cancer	02/19/2014	\$25,000.00
GORDON RESEARCH CONFERENCES	Gordon Research Conferences on Cardiac Regulatory Mechanisms	02/19/2014	\$5,000.00
BAYLOR UNIVERSITY MEDICAL CENTER DBA A. WEBB ROBERTS CENTER	Emerging Therapeutic Options for Medullary Thyroid Cancer and Differentiated Thyroid Cancer	02/20/2014	\$17,460.00
ACADEMIA MEDICA DEL SUR-FONDO EDUCACION MEDICA CONTINUADA	Cardiomtabolic Health Congress 2014	02/20/2014	\$20,000.00
DUKE UNIVERSITY MEDICAL CENTER	13th Annual Southeastern Fellows Research Skills Retreat	02/25/2014	\$5,498.41
THE UNIVERSITY OF CHICAGO	19th Annual University of Chicago Phase II Consortium (UC P2C) Symposium	02/25/2014	\$5,000.00
INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS	60th Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH)	02/25/2014	\$25,000.00
THE UNIVERSITY OF CHICAGO	Making Sense of the Sequence: Genomics Primer for Clinical Cancer Genetic Practitioners	02/25/2014	\$5,000.00
WEST VIRGINIA ACADEMY OF FAMILY PHYSICIANS	Dyslipidemia and Atherosclerosis - Reducing the Risk	02/25/2014	\$2,500.00
AMERICAN ACADEMY OF PEDIATRICS	PediaLink Influenza Course Series	02/26/2014	\$37,800.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	20th Annual Symposium	02/26/2014	\$15,000.00
NATIONAL ASSOCIATION OF FREE & CHARITABLE CLINICS	2014 NAFC Annual Summit	02/27/2014	\$30,000.00
VANDERBILT UNIVERSITY	Cardiology 2014: Advances in Science and Practice	02/27/2014	\$5,000.00
THE BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM	Cardiovascular Medicine and Prevention Update for Primary Care	02/27/2014	\$5,000.00
SOCIETY FOR VASCULAR MEDICINE	Society for Vascular Medicine 25th Anniversary and Scientific Sessions	03/02/2014	\$5,000.00
AMERICAN ASSOCIATION FOR THORACIC SURGERY	94th Annual Meeting American Association for Thoracic Surgery	03/04/2014	\$10,000.00

Organization	Program Title	Date	Amount
CHI ST. LUKE'S HEALTH	Cardiology Grand Rounds	03/05/2014	\$3,857.58
MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION	Cardiovascular Interventions and Practice Guidelines	03/05/2014	\$5,000.00
UNIVERSITY OF ROCHESTER	27th Cardiology Spring Update 2014	03/05/2014	\$4,805.00
UNIVERSITY OF WASHINGTON	Clinical Cardiology Pearls for Primary Care Providers	03/05/2014	\$4,000.00
AMERICAN ACADEMY OF PAIN MANAGEMENT	Faces and Cases: Assessing and Managing People With Complex Chronic Pain	03/06/2014	\$50,000.00
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	Pediatric Asthma & Allergy Updates for Primary Care Providers	03/06/2014	\$5,000.00
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	Boston Bacterial Meeting 2014	03/06/2014	\$2,500.00
CARDIOVASCULAR RESEARCH FOUNDATION	TCTMD 2014 Post Conference Web Cast Series	03/09/2014	\$100,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	DAPT Dilemmas: A Case-based Roundtable Tutorial	03/09/2014	\$66,913.46
ASSOCIATION OF BLACK CARDIOLOGISTS	40th Anniversary Annual Scientific Sessions The Ecology of Cardiovascular Disease in 2014: Trends, Challenges and Targets for 2025	03/11/2014	\$20,000.00
THE HOPE FOUNDATION	Spring 2014 SWOG Group Meeting	03/18/2014	\$10,000.00
AMERICAN LUNG ASSOCIATION OF THE UPPER MIDWEST	ALASD Asthma Educator Institute	03/18/2014	\$2,500.00
AMERICAN SOCIETY OF CONSULTANT PHARMACISTS FL CHAPTER	Getting to Goal: The Pharmacist's Role in Managing Dyslipidemia and Atherosclerosis	03/19/2014	\$5,950.00
THE RESEARCH FOUNDATION	Cal For Grants CGA CV 1404 - Time Critical Diagnosis (TCD) Symposium	03/19/2014	\$2,000.00
EMORY UNIVERSITY	Emory Practical Intervention Course (EPIC 2014)	03/19/2014	\$3,000.00
GORDON RESEARCH CONFERENCES	Gordon Research Conference and Seminar on Hemostasis	03/20/2014	\$5,000.00
PENNSYLVANIA ALLERGY AND ASTHMA ASSOCIATION	2014 Annual Meeting of the Pennsylvania Allergy and Asthma Association	03/20/2014	\$5,000.00
ONCOLOGY NURSING SOCIETY	Oncology Nursing Society 39th Annual Congress	03/20/2014	\$25,000.00
RICHMOND UNIVERSITY MEDICAL CENTER	Lipid Management 2014 Guidelines and Beyond	03/20/2014	\$1,400.00
JOHNS HOPKINS UNIVERSITY	5th Annual Johns Hopkins Cardiovascular Research Retreat	03/23/2014	\$2,500.00
AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY	Fall 2014 Symposium Of The Los Angeles Society Of Allergy, Asthma & Clinical Immunology	03/23/2014	\$5,000.00
UNIVERSITY OF FLORIDA	Vascular Biology Working Group US Chapter Meeting	03/23/2014	\$15,000.00
THE SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS	2014 SCAI Transradial Interventional Program (TRIP) Series	03/23/2014	\$15,000.00
ASPEN LUNG CONFERENCE	Thomas L. Petty Aspen Lung Conference: Rebuilding the Injured Lung	03/24/2014	\$5,000.00
INTERNATIONAL SOCIETY ON HYPERTENSION IN BLACKS INC.	ISHIB 2014 Annual Conference-Medical and Social Determinants of Cardiometabolic Health	03/24/2014	\$10,000.00
ARKANSAS ACADEMY OF FAMILY PHYSICIANS	67th Annual Scientific Assembly of the Arkansas Academy of Family Physicians	03/24/2014	\$3,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	Current Advances in Cardiovascular Care 2014	03/24/2014	\$5,000.00
ST. PETER'S HOSPITAL	Cardiology Teaching Day	03/25/2014	\$3,000.00
CHARLES R. DREW UNIVERSITY OF MEDICINE & SCIENCE	18th Annual Conference	03/26/2014	\$25,000.00
GORDON RESEARCH CONFERENCES	2014 GRC on Heterocyclic Compounds	03/27/2014	\$2,500.00
THE ROCKEFELLER UNIVERSITY	Leptin and Metabolic Disease: A Special Symposium on the 20th Anniversary of the Discovery of Leptin	03/30/2014	\$25,000.00

Organization	Program Title	Date	Amount
AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY	CSAAI's A Midsummer Night's Wheeze 2014	03/30/2014	\$5,000.00
UNIVERSITY OF NEW MEXICO	PeerView Live, Using Evidence-Based Treatment to Optimize Control of Elevated Serum Triglycerides (150202699)	04/01/2014	\$353,000.00
THOMAS JEFFERSON UNIVERSITY	Jefferson Critical Care Symposium: A Multidisciplinary Review of Current Evidence & Controversies	04/01/2014	\$5,000.00
AMERICAN ASSOCIATION OF ENDOCRINE SURGEONS	35th Annual Meeting of the American Association of Endocrine Surgeons	04/01/2014	\$3,000.00
GORDON RESEARCH CONFERENCES	2014 Bioorganic Chemistry Gordon Research Conference	04/02/2014	\$1,000.00
THE NEW YORK CARDIOLOGICAL SOCIETY, INC.	Seventh Annual Cardiac Care Associate Symposium 2014	04/03/2014	\$3,050.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	15th Annual Intensive Review of Cardiology	04/03/2014	\$4,706.02
WASHINGTON UNIVERSITY	Cardiology Update	04/06/2014	\$4,000.00
DIGNITY HEALTH ST. BERNARDINE MEDICAL CENTER	16th Annual Cardiac Symposium	04/06/2014	\$6,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2014 Conquer Cancer Foundation of ASCO Merit Awards	04/09/2014	\$24,000.00
MUNSTER MEDICAL RESEARCH FOUNDATION DBA COMMUNITY HOSPITAL	New Frontiers in Cardiovascular Disease 2014	04/09/2014	\$4,200.00
GORDON RESEARCH CONFERENCES	2014 Gordon Research Conference: Enzymes CoEnzymes and Metabolic Pathways	04/09/2014	\$2,000.00
AMERICAN COLLEGE PHYSICIANS - MISSISSIPPI CHAPTER	2014 Mississippi/Louisiana ACP Educational and Scientific Meeting	04/09/2014	\$5,000.00
ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI	Live Symposium of Complex Coronary, Valvular & Vascular Cases	04/10/2014	\$10,000.00
NATIONAL FOUNDATION FOR INFECTIOUS DISEASES	Clinical Vaccinology Course	04/13/2014	\$25,000.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS	The AAPA 2014 Annual Conference - Cardiology Track	04/13/2014	\$7,500.00
NEW JERSEY ACADEMY OF FAMILY PHYSICIANS	Cardiovascular Controversies JNC8 and Cholesterol Treatment Guidelines (2014 Scientific Assembly)	04/13/2014	\$5,000.00
HUMBOLDT-DEL NORTE COUNTY MEDICAL SOCIETY	Asthma Update	04/14/2014	\$4,000.00
DANNEMILLER, INC	Contemporary Perspectives in COPD: A Pulmonologist s Guide to Individualized Patient Care	04/16/2014	\$50,000.00
OKLAHOMA UNIVERSITY HEALTH SCIENCE CENTER - OUHSC	17th Annual Primary Care Update	04/16/2014	\$3,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2014 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA)	04/17/2014	\$60,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	6th Annual E-Journal Club: The Insights on Biologics and New Agents for Rheumatic Diseases	04/17/2014	\$9,352.86
NATIONAL FOUNDATION FOR INFECTIOUS DISEASES	17th Annual Conference on Vaccine Research	04/21/2014	\$15,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION	2014 ECOG-ACRIN Spring Group Meeting	04/21/2014	\$5,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	Contemporary T2DM Management: Focus on Safety and Efficacy	04/21/2014	\$229,200.00
THE CHEST FOUNDATION	The CHEST Foundation Diversity Research/Women's Respiratory Health Awards Program	04/21/2014	\$35,000.00
MISSOURI ACADEMY OF PHYSICIAN ASSISTANTS	Hyperlipidemia	04/21/2014	\$5,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO	Lipidomics Impact on Cell Biology, Inflammation and Metabolic Disease	04/22/2014	\$2,500.00
NATIONAL MINORITY QUALITY FORUM	11th Annual National Summit on Health Disparities	04/23/2014	\$30,000.00

Worksheet: Grants 2014 to Mar 20 2019

Organization	Program Title	Date	Amount
DUKE UNIVERSITY	2014 Carolinas COPD Symposium	04/24/2014	\$20,000.00
MICHIGAN STATE MEDICAL SOCIETY FOUNDATION	Rheumatology Update	04/24/2014	\$3,000.00
MAIN LINE HEALTH	Atherosclerosis: Prevention of Progression	04/24/2014	\$5,000.00
CASE MANAGEMENT SOCIETY OF AMERICA	CMSA 2014 Annual Conference and Expo	04/27/2014	\$15,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2014 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	04/27/2014	\$25,000.00
AMERICAN HEART ASSOCIATION, INC	Arteriosclerosis, Thrombosis, and Vascular Biology Scientific Sessions 2014	04/27/2014	\$20,000.00
SCRIPPS HEALTH	25th Annual Cardiovascular Interventions	04/27/2014	\$5,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Interventional Cardiology Board Preparatory Educational Package	04/27/2014	\$5,000.00
TEXAS ONE VOICE: A COLLABORATIVE FOR HEALTH AND HUMAN SERVICES	Designing Healthcare in Texas How the Past and Present will Guide the Future	04/28/2014	\$1,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	Cardiology Update 2014: A Patient Management Approach	04/28/2014	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2014 ASCO Annual Meeting Lung Cancer Track	05/04/2014	\$56,000.00
FOUNDATION FOR CARE MANAGEMENT	Dyslipidemia and New Cholesterol Guidelines: What the Primary Care Provider Needs to Know	05/06/2014	\$25,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	Update in Allergy, Asthma & Immunology	05/06/2014	\$10,000.00
FLORIDA ACADEMY OF PHYSICIAN ASSISTANTS	Update in the Management of Dyslipidemia	05/06/2014	\$5,000.00
VASSAR BROTHERS MEDICAL CENTER	44th Annual Cardiology Education Day	05/06/2014	\$5,000.00
ZOE ROSE MEMORIAL FOUNDATION DBA PREEMIE PARENT ALLIANCE	2014 Premie Parent Summit	05/06/2014	\$10,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE 23rd Annual Scientific and Clinical Congress	05/07/2014	\$25,000.00
LOUISIANA SOCIETY OF ALLERGY, ASTHMA & IMMUNOLOGY	LSAAI 41st Annual Meeting	05/07/2014	\$5,000.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	AAFP Assembly 60 Minute Lecture titled Chronic Obstructive Pulmonary Disorder (COPD) and Pulmonary Function Testing	05/07/2014	\$13,000.00
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PROGRAM	2014 ASCO REVIEW	05/08/2014	\$5,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	Aspen Allergy Conference	05/08/2014	\$10,000.00
AMERICAN DIABETES ASSOCIATION	29th Annual Clinical Conference on Diabetes - Reducing Risks: Primary and Secondary	05/11/2014	\$20,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	20th Annual UCLA Symposium Pulmonary Function and Exercise Testing: Practical Approaches for the Healthcare Practitioner	05/11/2014	\$5,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	The Changing Allergy Practice	05/11/2014	\$5,000.00
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS, PUERTO RICO CHAPTER	Caribbean Congress on Emergency Medicine	05/12/2014	\$5,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	19th Annual Diabetes Day: Diabetes Therapy	05/13/2014	\$6,613.34
THE REGENTS UNIVERSITY OF CALIFORNIA	UCLA Family Medicine Refresher Course	05/13/2014	\$7,500.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	ASCO Review	05/13/2014	\$4,000.00
SOCIEDAD PUERTORRIQUENA DE ENDOCRINOLOGIA Y DIABETOLOGIA	Puerto Rican Endocrinology and Diabetes Society Scientific Meeting	05/14/2014	\$10,000.00
NATIONAL MEDICAL ASSOCIATION	Asthma as a Model Chronic Illness	05/14/2014	\$25,000.00
GORDON RESEARCH CONFERENCES	2014 Lipoprotein Metabolism Gordon Research Conference	05/14/2014	\$2,500.00



Organization	Program Title	Date	Amount
ONCOLOGY NURSING SOCIETY	Pharmacology Update: Integrating Advances into Practice	05/14/2014	\$5,000.00
AMERICAN ASSOCIATION OF SERVICE COORDINATORS	2014 National Service Coordinator Conference	05/14/2014	\$5,000.00
MAYO CLINIC ARIZONA	Cardiology Update 2014: The Heart of the Matter	05/15/2014	\$10,000.00
AMERICAN CHEMICAL SOCIETY - DIVISION OF MEDICINAL CHEMISTRY	2014 ACS National Medicinal Chemistry Symposium	05/18/2014	\$1,000.00
CHICAGO ASTHMA CONSORTIUM	Emergency Management of Asthma	05/18/2014	\$2,000.00
SUFFOLK ACADEMY OF MEDICINE	31st Update in Allergy & Immunology Symposium	05/19/2014	\$3,000.00
EMORY UNIVERSITY	Discussing Cases with Diabetes Experts	05/19/2014	\$20,000.00
NATIONAL MEDICAL ASSOCIATION	Evidence-Based Diagnosis and Management of Asthma & COPD: Practical Tools to Improve Patient Care	05/19/2014	\$23,405.00
NORTH SHORE LONG ISLAND JEWISH HEALTH SYSTEM	Post American Society of Clinical Oncology Update 2014	05/19/2014	\$3,000.00
LAHEY CLINIC HOSPITAL, INC.	Cardiovascular Disease: State of the Art 2014	05/19/2014	\$6,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	2014 Cardiovascular Board Review for Certification and Recertification Educational Package	05/19/2014	\$5,000.00
NEW JERSEY ACADEMY OF FAMILY PHYSICIANS	The Current Standards Of Care and Treatment of Diabetes (2014 Scientific Assembly)	05/21/2014	\$2,500.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2014 Conquer Cancer Foundation of ASCO Career Development Award (CDA)	05/21/2014	\$250,000.00
NORTHWESTERN UNIVERSITY	16th Annual Lynn Sage Breast Cancer Symposium	05/21/2014	\$10,000.00
PENNSYLVANIA SOCIETY OF PHYSICIAN ASSISTANTS	Lipid Management The Skinny on the Fat	05/21/2014	\$5,000.00
DUKE UNIVERSITY	1st Annual Duke Preventive Cardiology Symposium	05/29/2014	\$10,000.00
ALZHEIMER'S ASSOCIATION	2014 Alzheimer's Association International Conference	05/29/2014	\$95,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	2014 Updates in Oncology: With Proceedings from International Medical Meetings	05/29/2014	\$5,000.00
SOCIETY FOR NEUROSCIENCE	Young Investigator Award	06/01/2014	\$25,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	The Role of the Kidney in Glucose Homeostasis and Diabetes	06/03/2014	\$149,025.00
VIVA PHYSICIANS	VIVA 14: Vascular InterVentional Advances	06/03/2014	\$20,000.00
SOCIETY OF TOXICOLOGIC PATHOLOGY	TRANSLATIONAL PATHOLOGY: Relevance of Toxicologic Pathology to Human Health	06/04/2014	\$3,000.00
UHS PROFESSIONAL EDUCATION PROGRAMS, INC.	Gout and Hyperuricemia - Clinical Spectrum and Management Update	06/04/2014	\$100,825.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	AAFP Assembly 60 Minute Lecture titled Acute Coronary Syndrome and Angina (Fundamentals)	06/04/2014	\$10,000.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	AAFP Assembly 60 Minute Lecture titled Acute Coronary Syndrome and Angina (Advanced)	06/04/2014	\$10,000.00
THE NEPHCURE FOUNDATION	10th International Podocyte Conference	06/04/2014	\$5,000.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	Mount Sinai Division of Occupational Medicine seminar series	06/09/2014	\$2,500.00
SWEDISH MEDICAL CENTER FOUNDATION	Cardiology Update for Primary Care	06/09/2014	\$5,000.00
JOSLIN DIABETES CENTER	The Institute of Lifestyle Medicine 2014 Educational Activities	06/11/2014	\$15,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	ACS/STEMI: Focus on Acute Care	06/11/2014	\$60,000.00
PENN STATE COLLEGE OF MEDICINE	20th Annual Pennsylvania Immunization	06/18/2014	\$7,000.00
AMERICAN SOCIETY FOR PAIN MANAGEMENT NURSING	ASPMN 24th National Conference	06/18/2014	\$10,000.00
AMERICAN PHARMACISTS ASSOCIATION	APhA Pharmacy-Based Immunization Delivery	06/18/2014	\$2,500.00

Organization	Program Title	Date	Amount
WASHINGTON UNIVERSITY	Mentors in Medicine	06/22/2014	\$50,000.00
PONCE MEDICAL SCHOOL FOUNDATION INC	Advances in Dyslipidemia and Atherosclerosis Management	06/24/2014	\$5,000.00
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	Cardiovascular Disease Track at ACEP 2014 Scientific Assembly	06/25/2014	\$15,000.00
THE BRIGHAM & WOMEN'S HOSPITAL INC.	BWH Thyroid Visiting Professor and Endocrine Grand Rounds Speaker	06/26/2014	\$3,000.00
WASHINGTON UNIVERSITY	Clinical Allergy for the Practicing Physician	06/26/2014	\$5,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	Fall Programs	06/26/2014	\$5,000.00
GORDON RESEARCH CONFERENCES	2014 Gordon Research Seminar on Synaptic Transmission	06/26/2014	\$500.00
GREENWOOD LEFLORE HOSPITAL	Call for Grants: CGA Educating the Delta on Asthmatic Patients	06/29/2014	\$2,500.00
GORDON RESEARCH CONFERENCE	Gordon Research Conference on Multi-Drug Efflux Systems	06/29/2014	\$2,000.00
GORDON RESEARCH CONFERENCES	Gordon Research Conference: DNA Topoisomerases in Biology & Medicine	06/29/2014	\$2,000.00
ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES	Heart to Heart: Updates on Cardiovascular Disease and the Management of Cholesterol and Hypertension	06/30/2014	\$14,000.00
CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION	Molecular Therapeutics of Cancer Conference 2014	06/30/2014	\$5,000.00
VANDERBILT UNIVERSITY	Vanderbilt University Hematology Oncology Educational Symposium	07/08/2014	\$3,000.00
CHILDREN'S HOSPITAL CORPORATION	Translating Neural Circuits and Pathways into Treatments	07/08/2014	\$3,000.00
PENNSYLVANIA SOCIETY OF PHYSICIAN ASSISTANTS	Breast Cancer-Fight Like a Girl	07/09/2014	\$3,000.00
PROMEDICA ACADEMIC HEALTH CENTER CORPORATION	After the Diagnosis: Helping Cardiopulmonary Patients Succeed - Approaches to Stay Ahead of the Curve	07/09/2014	\$2,500.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2014 Breast Cancer Symposium	07/09/2014	\$10,000.00
NURSE PRACTITIONER ASSOC. FOR CONTINUING EDUCATION	Hyperlipidemia and Hypertension in 2014: What's New in Treatment Guidelines	07/09/2014	\$5,000.00
DIABLO SOCIETY OF HEALTH SYSTEM PHARMACISTS	Cost-Effective Genotype-Guided Antiplatelet Therapy with Ticagrelor	07/10/2014	\$5,600.00
ALAMO CITY CANCER COUNCIL	12th Annual Breast Cancer Conference Update	07/10/2014	\$1,500.00
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER SAN ANTONIO SCHOOL OF MEDICINE	37TH Annual San Antonio Breast Cancer Symposium	07/10/2014	\$10,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Best Practices in the Prevention and Management of Chronic Obstructive Pulmonary Disease (COPD)	07/15/2014	\$25,000.00
CEDARS-SINAI MEDICAL CENTER	Advances in Care for the New Millennium: 20th Anniversary BRCA Gene Symposium	07/17/2014	\$3,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Current Treatments and Novel Strategies in the Management of Acute Coronary Syndrome (ACS)	07/17/2014	\$25,000.00
MARSHA RIVKIN CENTER FOR OVARIAN CANCER RESEARCH	10th Biennial Ovarian Cancer Research Symposium	07/22/2014	\$5,000.00
FLORIDA ASSOCIATION OF CONSULTANT PHARMACISTS	Optimizing Oral Antiplatelet Therapy in Acute Coronary Syndrome	07/22/2014	\$9,600.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Foundations for Practice Excellence: Core Curriculum for the Cardiovascular Clinician 2014	07/22/2014	\$10,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	12th Annual World Congress on Insulin Resistance Diabetes and Cardiovascular Disease - WCIRDC	07/23/2014	\$100,000.00
AMERICAN ASSOCIATION OF ENDOCRINE SURGEONS FOUNDATION	Program Title Masters Course in Endocrine Surgery	07/23/2014	\$3,000.00

Organization	Program Title	Date	Amount
CARDIOVASCULAR RESEARCH FOUNDATION	Acute Coronary Syndromes, Pharmacotherapy and Shock/Hemodynamic Support	07/24/2014	\$20,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	FDA Town Hall and Clinical Trial Design and Interpretation	07/24/2014	\$20,000.00
MINNESOTA PHARMACISTS ASSOCIATION	MPhA Annual Meeting: MTM in Cardiology Clinic	07/24/2014	\$2,150.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS IN ALLERGY, ASTHMA & IMMUNOLOGY	6th Annual Allergy, Asthma & ENT CME Conference	07/29/2014	\$5,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY	Severe Asthma Workshop at the 2014 ACAAI Annual Scientific Meeting	07/29/2014	\$22,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	16th World Conference on Lung Cancer	07/29/2014	\$30,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY	The Affordable Care Act and Asthma Control	07/29/2014	\$22,000.00
DANA-FARBER CANCER INSTITUTE	Dana-Farber Cancer Institute's 10th Annual Postdoctoral and Graduate Student Retreat	07/31/2014	\$2,400.00
NATIONAL ASSOCIATION FOR HEALTHCARE QUALITY	2014 NAHQ 39th Annual Educational Conference	07/31/2014	\$15,000.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	2014 Top Ten Advances in Clinical Cardiology	07/31/2014	\$10,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	COPD/Asthma Track at CHEST 2014	07/31/2014	\$25,800.00
DREXEL UNIVERSITY	Hypertension HighLights-ASH 2014	08/03/2014	\$5,000.00
ASSOCIATION OF REPRODUCTIVE HEALTH PROFESSIONALS	No Gout About It: Targeted Provider Education and Training to Screen, Diagnosis, and Manage Gout among Female Patients	08/03/2014	\$9,500.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Tumor Immunology and Immunotherapy: A New Chapter	08/03/2014	\$10,000.00
THE OHIO STATE UNIVERSITY	Sixth Annual Contemporary Multidisciplinary Cardiovascular Conference	08/05/2014	\$5,000.00
WAYNE STATE UNIVERSITY	Update in Rheumatology	08/05/2014	\$5,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	COPD Interactive Educational Game	08/06/2014	\$20,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Updates in the Treatment of Hypertriglyceridemia: A Closer Look at the Role of Omega-3 Fatty Acids	08/06/2014	\$25,000.00
NATIONAL JEWISH HEALTH	19th Annual Allied Health Regional Conference	08/07/2014	\$2,500.00
WESTERN SOCIETY OF ALLERGY, ASTHMA & IMMUNOLOGY	WSAAI 53rd Annual Scientific Session	08/07/2014	\$15,000.00
DELAWARE ACADEMY OF PHYSICIAN ASSISTANTS	Acute Coronary Syndromes: Acute Myocardial Infarction and Unstable Angina	08/07/2014	\$3,500.00
AMERICAN PHARMACISTS ASSOCIATION	Addressing Racial and Ethnic Healthcare Disparities in Diabetes	08/10/2014	\$25,000.00
THOMAS JEFFERSON UNIVERSITY	Current Issues in Coronary and Structural Heart Disease: A Multidisciplinary Approach	08/10/2014	\$10,000.00
UNIVERSITY OF WASHINGTON CME OFFICE	University of Washington Topics in Allergy and Immunology Teaching Series 2014-2015	08/11/2014	\$5,000.00
FOUNDATION OF THE NATIONAL LIPID ASSOCIATION	The Foundation of the National Lipid Association Hunninghake FH Abstract Award	08/11/2014	\$50,000.00
NATIONAL ASSOCIATION OF NEONATAL NURSES	NANN 30th Annual Educational Conference	08/13/2014	\$10,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO)	ASTRO 56th Annual Meeting	08/17/2014	\$3,000.00
AMERICAN SOCIETY OF NEPHROLOGY	SGLT2 Inhibitor Therapy in Patients with Mild to Moderate Diabetic Kidney Disease	08/17/2014	\$170,000.00

Organization	Program Title	Date	Amount
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	Multidisciplinary Breast Rounds	08/17/2014	\$4,500.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	Contemporary T2DM Management: Focus on Safety and Efficacy (Live Program)	08/17/2014	\$376,125.00
MISSISSIPPI HEALTHCARE ALLIANCE	STEMI Protocols	08/17/2014	\$1,464.83
AMERICAN ASSOCIATION OF DIABETES EDUCATORS	Practical Applications of Pramlintide in Type 1 Diabetes	08/19/2014	\$144,399.00
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	Novel Treatments for the Management of Type 2 Diabetes: Focus on SGLT2 Inhibitors	08/19/2014	\$252,000.00
THE SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS	SCAI 2014 Interventional Cardiology Fellows Courses	08/19/2014	\$50,000.00
OLIGONUCLEOTIDE THERAPEUTICS SOCIETY	10th Annual Meeting of the Oligonucleotide Therapeutics Society	08/19/2014	\$10,000.00
SOCIETY FOR THE IMMUNOTHERAPY OF CANCER	Advances in Cancer Immunotherapy -Series of 5 Regional Programs	08/19/2014	\$75,000.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS	The Sixth Annual Hospital Medicine Boot Camp	08/19/2014	\$7,500.00
UNIVERSITY OF CINCINNATI	CALL for Grants Application (CGA) CV14-1st Annual Cincinnati Collaborative Cardiovascular Consortium (C4): Practical and Contemporary Cardiology 2014	08/21/2014	\$25,800.00
WAYNE STATE UNIVERSITY	Pulmonary, Critical Care and Sleep Medicine Update 2014	08/27/2014	\$3,000.00
INTERNATIONAL SOCIETY FOR AEROSOLS IN MEDICINE	ISAM TEXTBOOK OF AEROSOL MEDICINE	08/27/2014	\$10,000.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION (NPACE)	Asthma and COPD 2014	08/27/2014	\$5,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	CHEST 2014 Lung Cancer Track	08/27/2014	\$24,150.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	Medical Oncology and Hematology 2014: Multidisciplinary Approaches that Improve Coordination of Care	08/28/2014	\$3,000.00
NATIONAL JEWISH HEALTH	37th Annual Pulmonary and Allergy Update	08/28/2014	\$5,000.00
NOT-FOR-PROFIT HOSPITAL CORPORATION	Management and Prevention of Acute Exacerbation of COPD (AECOPD)	08/28/2014	\$2,400.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	New Jersey-AACE 7th Annual Meeting	08/31/2014	\$5,000.00
WILLIAM BEAUMONT HOSPITAL	Practical & Progressive Updates in Primary Care Medicine	08/31/2014	\$2,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	47th Annual New York Cardiovascular Symposium: Major Topics in Cardiology Today	08/31/2014	\$15,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC Fellowships	09/02/2014	\$43,000.00
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	Update in Rheumatology 2014	09/02/2014	\$7,500.00
CHILDREN'S HEALTHCARE OF ATLANTA	Respiratory Update 2014	09/02/2014	\$3,000.00
UNIVERSITY OF MARYLAND, BALTIMORE FOUNDATION	Patient-Focused Drug Development	09/02/2014	\$10,000.00
THE ANGIOGENESIS FOUNDATION	World Congress on Angiogenesis	09/02/2014	\$5,000.00
JOHNS HOPKINS UNIVERSITY	New Therapeutic Insights/Advances in Allergic Diseases	09/02/2014	\$20,000.00
GORDON RESEARCH CONFERENCES	Mammalian DNA Repair Gordon Research Conference and Seminar 2015	09/02/2014	\$5,000.00
ILLINOIS ACADEMY OF FAMILY PHYSICIANS	Health Care Reform and Care Coordination	09/04/2014	\$2,000.00
EXCELLENCE IN RHEUMATOLOGY EDUCATION	Rheumatology Winter Clinical Symposium 2015	09/04/2014	\$25,000.00
SOCIETY OF INFECTIOUS DISEASES PHARMACISTS	Society of Infectious Diseases Pharmacists Research Grant Program	09/04/2014	\$5,000.00
CARDIOVASCULAR INSTITUTE OF PHILADELPHIA	CVI s 21st Annual Cardiology Update: Clinical Management of Heart Disease 2014	09/09/2014	\$10,000.00

Organization	Program Title	Date	Amount
PROVIDENCE HOLY CROSS MEDICAL CENTER	Acute Coronary Syndrome	09/09/2014	\$1,900.00
DUKE UNIVERSITY	14th Annual Southeastern Fellows Research Skills & Training Workshop	09/14/2014	\$10,000.00
PHILLIPS GILMORE ONCOLOGY COMMUNICATIONS, INC.	Atlanta Lung Cancer Symposium 2014	09/14/2014	\$3,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION	2014 ECOG-ACRIN Fall Group Meeting	09/14/2014	\$5,000.00
THE NEW YORK ACADEMY OF SCIENCES	Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach	09/14/2014	\$10,000.00
MEDICAL COLLEGE OF WISCONSIN	8th Annual Translational Oncology Research Symposium	09/15/2014	\$3,000.00
FRIENDS OF CANCER RESEARCH	Friends of Cancer Research 2014 programs	09/15/2014	\$100,000.00
UNIVERSITY OF FLORIDA	Vascular Biology Working Group Global Chapter Meeting	09/15/2014	\$15,000.00
ORLANDO HEALTH	Advancements in the Early Detection and Treatment of Breast and Gynecologic Malignancies	09/15/2014	\$3,000.00
YALE UNIVERSITY	Severe Asthma 2014: A Personalized Approach To Treatment	09/17/2014	\$5,000.00
EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION	Asthma and Allergy 2014: What's New, What's Hot	09/17/2014	\$3,000.00
AMERICAN COLLEGE OF GASTROENTEROLOGY	2014 ACG Presidential Poster Award	09/17/2014	\$25,000.00
PARTNERS HEALTHCARE SYSTEM INC.	2014 Personalized Medicine Conference	09/17/2014	\$15,000.00
PERSONALIZED MEDICINE COALITION	Turning the Tide Against Cancer 2014 National Conference	09/17/2014	\$5,000.00
CEDARS-SINAI MEDICAL CENTER	Rheumatology Grand Rounds 2014	09/21/2014	\$5,000.00
AMERICAN THYROID ASSOCIATION	Early Riser Symposium: Medullary Thyroid Cancer	09/21/2014	\$125,900.00
SAFETY PHARMACOLOGY SOCIETY	14th Annual Safety Pharmacology Society Annual Meeting	09/21/2014	\$3,000.00
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	19th Annual ASHP Conference for Leaders in Health-System Pharmacy	09/23/2014	\$10,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	Scenes and Seminars on Hypoglycemia Management: Multidisciplinary Approaches to Improving Safety for Patients with Diabetes	09/23/2014	\$35,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	2014 NCCN Congress Series : Utilizing Guidelines to Customize Patient Care in Non-Small Cell Lung Cancer	09/23/2014	\$25,000.00
CITY OF HOPE NATIONAL MEDICAL CENTER	Multidisciplinary Approaches to Cancer Symposium	09/25/2014	\$3,000.00
THE DEUEL CONFERENCE ON LIPIDS	The 2015 Deuel Conference on Lipids	09/30/2014	\$15,000.00
AMERICAN COLLEGE OF RHEUMATOLOGY	2014 ACR/ARHP Annual Meeting Gout Educational Track	09/30/2014	\$50,000.00
NORTH AMERICAN SOCIETY FOR PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION	NASPGHAN Research Skills Workshop	09/30/2014	\$4,000.00
SOCIETY FOR THE IMMUNOTHERAPY OF CANCER	SITC Workshop on Combination Immunotherapy: Where Do We Go From Here?	10/03/2014	\$100,000.00
LETTERS & SCIENCES	PARP Inhibition for BRCA 1/2 Mutation-Associated Cancers & Triple Negative BC Advances in Risk Reduction & Treatment	10/07/2014	\$275,478.44
CHILDREN'S HOSPITAL CORPORATION	Taking on Tomorrow: Global Pediatric Innovation Summit and Awards 2014	10/07/2014	\$5,000.00
ENZYME MECHANISMS CONFERENCE, INC	24th Enzyme Mechanisms Conference	10/07/2014	\$3,000.00
NAMI MARYLAND	2014 NAMI Maryland Annual Education Conference	10/07/2014	\$5,000.00
GORDON RESEARCH CONFERENCES	Inhibition in the CNS Gordon Research Conference and Seminar	10/07/2014	\$5,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Cardiometabolic Clinical Community on CardioSource/ACC.org	10/08/2014	\$150,000.00
NATIONAL ASSOCIATION DIRECTORS OF NURSING ADMINISTRATION/LTC, INC.	Managing Pain in LTC Residents: Addressing Opioid-Induced Constipation	10/09/2014	\$25,000.00

Organization	Program Title	Date	Amount
AMERICAN HEART ASSOCIATION	Heart Innovation Forum	10/09/2014	\$15,000.00
MEDICAL SOCIETY OF NEW JERSEY	Medical Society of New Jersey 2015 Physician Advocacy Conference	10/09/2014	\$2,500.00
PEDIATRIC ENDOCRINE SOCIETY	PES Parent, Patient and Physician WEB Education Program for Lipodystrophy in Children, Adolescents, and Adults	10/13/2014	\$50,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	7th Focus on Lung Cancer Conference and 4rd CANPrevent Lung Cancer	10/13/2014	\$3,000.00
SOCIETY FOR TRANSLATIONAL ONCOLOGY	Merrill J. Egorin Workshop in Cancer Therapeutics and Drug Development	10/13/2014	\$10,000.00
SOCIETY FOR TRANSLATIONAL ONCOLOGY	The Oncologist CME Online Journal Curriculum: Lung Cancer	10/13/2014	\$10,000.00
PERSONALIZED MEDICINE COALITION	Integrating Personalized Medicine into Health Care: Solutions Summit 2015	10/15/2014	\$5,000.00
BIOMEDICAL SCIENCE CAREERS PROGRAM	Hope Scholarship 2015-2016	10/16/2014	\$7,500.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Fact vs Fact: The Cholesterol Guidelines Debate	10/21/2014	\$25,000.00
A. WEBB ROBERTS CENTER OF BAYLOR HEALTH CARE SYSTEM, DALLAS	The 41st Annual Williamsburg Conference on Heart Disease	10/22/2014	\$5,000.00
NATIONAL ASSOCIATION OF NURSE PRACTITIONERS IN WOMEN'S HEALTH	COPD: What NPs in Women's Health Need to Know	10/22/2014	\$20,000.00
SOCIETY FOR THE IMMUNOTHERAPY OF CANCER	SITC 29th Annual Meeting	10/22/2014	\$10,000.00
DAIBETES TECHNOLOGY SOCIETY	Diabetes Technology Meeting 2014	10/22/2014	\$10,000.00
AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS	2014-2015 AAPS Sustaining Sponsorship	10/30/2014	\$45,000.00
AMERICAN PSYCHIATRIC NURSES ASSOCIATION	APNA 28th Annual Conference-Building Connections: PMH Nursing Perspectives	10/30/2014	\$5,000.00
PEDIATRIC ENDOCRINE SOCIETY	PES Consensus statement on the Management of Lipodystrophy in Children, Adolescents, and Adults	10/30/2014	\$92,200.00
LETTERS AND SCIENCES	Ovarian Cancer - Evolution & Evidence of Emerging Strategies (ISSS)	10/30/2014	\$287,365.00
THE CVA MEDICAL EDUCATION FOUNDATION	Cardiovascular Update 2015	11/02/2014	\$5,000.00
UNIVERSITY OF MICHIGAN	Vaccines: Past, Present, and Future	11/04/2014	\$10,000.00
SOCIETY OF TOXICOLOGY	Society of Toxicology Annual Meeting	11/04/2014	\$2,000.00
NATIONAL COMMISSION FOR THE CERTIFICATION OF CME PROFESSIONALS	CCMEP Certification Exam for Healthcare CE Professionals	11/04/2014	\$10,000.00
MEDSTAR WASHINGTON HOSPITAL CENTER	Cardiovascular Research Technologies CRT 2015	11/05/2014	\$50,000.00
NATIONAL KIDNEY FOUNDATION	Primary Care Practitioner (PCP) Attitudes and Practices: Testing Type-2 Diabetic Patients for Chronic Kidney Disease (CKD) Survey	11/05/2014	\$50,000.00
AMERICAN DIABETES ASSOCIATION	Pathway To Stop Diabetes	11/07/2014	\$2,500,000.00
AMERICAN PHARMACISTS ASSOCIATION	Optimizing the Management of Acute Coronary Syndromes through the Transitions of Care.	11/10/2014	\$11,250.00
TEMPLE UNIVERSITY	43rd Annual Philadelphia Workshop on Hemostasis, Thrombosis and Atherosclerosis	11/10/2014	\$5,000.00
NOT-FOR-PROFIT HOSPITAL CORPORATION	Recognizing and Treating Acute Coronary Syndrome-Current Guideline Based Management	11/11/2014	\$3,400.00
CARDIOVASCULAR RESEARCH FOUNDATION	Chronic Total Occlusion Summit 2015: A Live Demonstration Course	11/11/2014	\$10,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC International Mentorship Program	11/12/2014	\$16,000.00

Organization	Program Title	Date	Amount
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)	15th Annual Targeted Therapies of Lung Cancer meeting	11/12/2014	\$25,000.00
AMERICAN HEART ASSOCIATION, INC	Scientific Sessions 2014 Acute Coronary Syndrome Track	11/13/2014	\$30,000.00
THE JOHNS HOPKINS UNIVERSITY	The Johns Hopkins University Allergy and Clinical Immunology Fellowship Program	11/13/2014	\$138,261.57
REGENTS OF THE UNIVERSITY OF CALIFORNIA	The 2nd Annual UCLA Diabetes Symposium	11/16/2014	\$5,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Annual Meeting- 2015	11/17/2014	\$50,000.00
AMERICAN SOCIETY OF HEMATOLOGY	American Society of Hematology Scholar Awards	11/17/2014	\$25,000.00
AMERICAN SOCIETY OF HEMATOLOGY	The American Society of Hematology's Bridge Award Program	11/17/2014	\$25,000.00
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY (AAAAI)	2015 AAAAI Annual Meeting Allied Health Programming	11/18/2014	\$30,000.00
AMERICAN PSYCHIATRIC NURSES ASSOCIATION	Psychiatric Nursing E Series: Bipolar Disorder Across the Lifespan	11/21/2014	\$60,400.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS PR CHAPTER	New Paradigms in the Practice of Endocrinology	12/01/2014	\$2,500.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Improving Outcomes through Evidence-Based Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD)	12/01/2014	\$25,000.00
THE GYNECOLOGIC ONCOLOGY GROUP	3rd Semi Annual Meeting of NRG ONCOLOGY (Formerly GOG,NSABP,RTOG)	12/02/2014	\$10,000.00
FLORIDA ALLERGY, ASTHMA & IMMUNOLOGY SOCIETY	Florida Allergy, Asthma & Immunology Society 2015 Annual CME Conference	12/02/2014	\$10,825.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)	16th World Conference on Lung Cancer - ISS Association fee	12/02/2014	\$200,000.00
NATIONAL ASSOCIATION OF SCHOOL NURSES, INC.	Evidence-based asthma care in schools	12/02/2014	\$23,795.71
THE METHODIST HOSPITAL	Cardiovascular Fellows' Bootcamp Laying the Foundation	12/03/2014	\$15,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 20th Annual Conference General Session: Advancing the Standard of Cancer Care™	12/03/2014	\$85,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	Advances in the Treatment of Ovarian and Cervical Cancers: Expert-Facilitated Small Group Discussions of Challenging Cases	12/03/2014	\$100,000.00
The Mount Sinai Hospital	Complex Coronary Cases	12/03/2014	\$10,000.00
JOHNS HOPKINS UNIVERSITY	The Johns Hopkins University School of Medicine eDiabetes Review Volume 2	12/03/2014	\$150,000.00
ROME FOUNDATION	Rome IV: The Functional Gastrointestinal Disorders	12/04/2014	\$100,000.00
UNIVERSITY OF KENTUCKY COLLEGE OF MEDICINE	9th Platelet Colloquium	12/04/2014	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Conquer Cancer Foundation of ASCO Merit Awards	12/04/2014	\$30,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Conquer Cancer Foundation of ASCO International Innovation Grant	12/04/2014	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	NCCN 2015 Annual Nursing Program: Advancing Oncology Nursing at the 20th NCCN Annual Conference	12/04/2014	\$10,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	2015 NCCN Oncology Fellows Program: New Horizons in Quality Cancer Care at the 20th Annual Conference	12/04/2014	\$10,000.00
STENO DIABETES CENTER A/S	28th European Diabetic Nephropathy Study Group Annual Meeting	12/04/2014	\$20,000.00

Organization	Program Title	Date	Amount
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	Improving Patient Outcomes: Maximizing the Role of the GLP-1 Based Therapies in Our Patients with Type 2 Diabetes	12/04/2014	\$110,000.00
ENDOCRINE SOCIETY	ENDO 2015 Thyroid Sessions	12/04/2014	\$55,000.00
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	XVI Curso Intensivo de Diabetes, Endocrinologia y Enfermedades Metabolicas	12/07/2014	\$10,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	Advances in Medical and Surgical Management of Thyroid Cancer	12/07/2014	\$10,000.00
AMERICAN PAIN SOCIETY	2015 Fundamentals of Pain Management: An Interdisciplinary Primer	12/07/2014	\$35,000.00
HEMATOLOGY/ONCOLOGY PHARMACY ASSOCIATION	2015 HOPA 11th Annual Conference	12/07/2014	\$25,000.00
LUMEN FOUNDATION	Lumen Global 2015	12/08/2014	\$75,000.00
NATIONAL ASSOCIATION OF NEONATAL NURSES	Mentoring Program Toolkit for Novice Nurse Practitioners	12/08/2014	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Conquer Cancer Foundation of ASCO Career Development Award (CDA)	12/08/2014	\$250,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Conquer Cancer Foundation of ASCO International Development and Education Award (IDEA)	12/08/2014	\$10,500.00
THE ENDOCRINE SOCIETY	Applying the Evidence for GLP-1 Receptor Agonists in Type 2 Diabetes: Practice Perspectives	12/08/2014	\$525,980.00
FORCE - FACING OUR RISK OF CANCER EMPOWERED	Joining FORCEs Against Hereditary Cancer Conference	12/08/2014	\$50,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Lipid Management Today: Unanswered Questions and Unquestioned Answers - Live Clinical Focus Session at ACC.15	12/08/2014	\$50,000.00
AMERICAN PHARMACISTS ASSOCIATION	Access to Care: Addressing Health Literacy in Diabetes	12/09/2014	\$11,250.00
THE ENDOCRINE SOCIETY	Diabetes Diagnosis and Management 2015	12/09/2014	\$50,000.00
ENDOCRINE SOCIETY	Endocrine Fellows Conference: Type 1 Diabetes Care and Management	12/09/2014	\$70,000.00
CLINICAL AND PATIENT EDUCATORS ASSOCIATION	Clinical Issues in Type 2 Diabetes: Discussions and Debates Around GLP-1 Receptor Agonists	12/09/2014	\$368,966.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	ACC s 64th Annual Scientific Session - ACC.15 Acute Coronary Syndromes Clinical Learning Pathway	12/09/2014	\$100,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Conquer Cancer Foundation Young Investigator Award	12/10/2014	\$60,000.00
ENDOCRINE SOCIETY	Diabetes Masters Series 2015 : Solving the Puzzle: Putting the Pieces Together to Provide Quality T2DM Care	12/10/2014	\$235,867.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 ASCO Annual Meeting Lung Cancer Track	12/10/2014	\$112,000.00
INSTITUTE FOR MEDICAL AND NURSING EDUCATION	Who s on First? What s on Second? Identifying a Line-up of Newer Agents to Individualize Care for Your Patient with T2DM	12/10/2014	\$316,029.80
PENNSYLVANIA STATE UNIVERSITY	Controlling Severe Asthma Today and Tomorrow	12/11/2014	\$236,659.94
CHILDREN'S HOSPITAL CORPORATION	2015 Weinstein Cardiovascular Development Conference	12/11/2014	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC	2015-2016 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	12/11/2014	\$35,000.00
ENDOCRINE SOCIETY	ENDO 2015 Diabetes Sessions	12/14/2014	\$30,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	Case Challenges in T2D: Applying the AACE Algorithm to Practice	12/14/2014	\$181,705.00
THE CHEST FOUNDATION	The CHEST Foundation COPD Research Grant Program	12/15/2014	\$180,000.00



Organization	Program Title	Date	Amount
JOSLIN DIABETES CENTER, INC.	SGLT-2 Inhibitors in Type 2 Diabetes: Incorporating New Approaches Into Practice Through an Interdisciplinary Exploration	12/15/2014	\$321,885.00
AMERICAN OSTEOPATHIC ASSOCIATION	The Path to Better T2DM Outcomes, A Coordinated Approach to Patient-centered Care	12/15/2014	\$263,394.54
UNIVERSITY OF CINCINNATI	Optimizing Outcomes in Type 2 Diabetes: Integrating Longer Acting GLP-1 Receptor Agonists	12/21/2014	\$62,825.00
RICHMOND UNIVERSITY MEDICAL CENTER	Treatment-Refractory Gout	12/22/2014	\$1,100.00
DUKE UNIVERSITY SCHOOL OF MEDICINE	Regional Systems Accelerator: Implementation of The American Heart Association's Mission: Lifeline-AMI Discharge and Follow Up Demonstration Project	01/04/2015	\$3,500,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	You Say Do, I Say Don't: Controversial Debates in ACS - Live Clinical Focus Session at ACC.15	01/06/2015	\$150,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	ACC.15 Prevention Learning Pathway	01/07/2015	\$75,000.00
AMERICAN HEART ASSOCIATION, INC	American Heart Association Cardiovascular Genome Phenome Study (CV-GPS)	01/08/2015	\$2,000,000.00
AMERICAN HEART ASSOCIATION, INC	American Heart Association's Guideline Transformation and Optimization (GTO) Program	01/11/2015	\$6,000,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	Post Conference CME Webcast Series 2015	01/14/2015	\$100,000.00
GASTROINTESTINAL AND LIVER ASSOCIATION OF THE AMERICAS (GALA)	The 2015 US GI and Liver Association of the Americas (GALA) Conference Series	01/14/2015	\$35,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	ACC's 64th Annual Scientific Session (ACC.15) TCT@ACC-i2 Learning Pathway	01/14/2015	\$25,000.00
GORDON RESEARCH CONFERENCES	2015 Gordon Research Conference on the Molecular and Cellular Biology of Lipids.	01/14/2015	\$5,000.00
GEORGIA ASSOCIATION OF PHYSICIAN ASSISTANTS	Cardiology Track - How PAs Can Impact Patient Outcomes Across Cardiovascular Diseases (Part of GAPA 2015 Spring Conference)	01/14/2015	\$5,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	Endocrine University: Disease Management and Technology Skills for Fellows-in-Training (Thyroid Module)	01/15/2015	\$5,000.00
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER SAN ANTONIO SCHOOL OF MEDICINE	16th Annual Practical Applications of New Agents in Oncology	01/15/2015	\$3,000.00
NATIONAL LIPID ASSOCIATION	National Lipid Association 2015 Lipid Academy	01/15/2015	\$15,000.00
NATIONAL LIPID ASSOCIATION	2015 Masters in Lipidology	01/15/2015	\$15,000.00
EMORY UNIVERSITY	Atlanta Clinical Cardiology Update	01/18/2015	\$15,000.00
SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS	SCAI 2015 Scientific Sessions	01/27/2015	\$85,000.00
ENDOCRINE SOCIETY	Thyroid Endocrine Self-Assessment Program 2015	01/28/2015	\$10,000.00
SCRIPPS HEALTH	Scripps 35th Annual Conference: Clinical Hematology and Oncology 2015	01/29/2015	\$5,000.00
NORTHEASTERN UNIVERSITY	Boston Symposium on Organic and Bioorganic Chemistry (BSOBC)	01/29/2015	\$2,500.00
CARDIOVASCULAR RESEARCH FOUNDATION	ACS/STEMI: Focus on Acute Care at SCAI 2015	01/29/2015	\$60,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Exploring Optimal Antiplatelet Therapies in the Management of Acute Coronary Syndrome (ACS)	01/29/2015	\$25,000.00

Organization	Program Title	Date	Amount
CARDIOVASCULAR RESEARCH FOUNDATION	21st Annual Interventional Cardiology Fellows Course	01/29/2015	\$25,000.00
UNIVERSITY OF FLORIDA	Vascular Biology Working Group US Chapter Meeting	01/29/2015	\$15,000.00
IOWA PHYSICIAN ASSISTANT SOCIETY	Update on Lipid Management	01/29/2015	\$6,500.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	Cardiovascular Risk Reduction: Leading the Way in Prevention (21st Annual Symposium)	02/01/2015	\$25,000.00
PRIMARY CARE NETWORK, INC.	Are Gout Goals Achievable? The Provider/Patient Alliance	02/02/2015	\$619,095.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	PCNA-Triglycerides	02/02/2015	\$179,540.00
NATIONAL LIPID ASSOCIATION	National Lipid Association 2015 Scientific Meeting Series	02/02/2015	\$120,000.00
AMERICAN HEART ASSOCIATION	Chest Pain Coordinator Boot Camp	02/02/2015	\$15,000.00
THE BOARD OF REGENTS OF THE UNIVERSITY OF WISCONSIN SYSTEM	Cardiovascular Medicine and Prevention Update for Primary Care	02/08/2015	\$5,000.00
UNIVERSITY OF KANSAS MEDICAL CENTER	6th Expert Strategies in Endoscopy, Gastrointestinal and Liver Disorders	02/09/2015	\$5,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA/CME	2nd Cardiovascular Symposium	02/11/2015	\$5,000.00
AMERICAN PHARMACISTS ASSOCIATION	APhA2015 Rise in Oral Oncologic Medications Creates New Challenges in Adherence	02/11/2015	\$22,500.00
EMORY UNIVERSITY	EPIC SEC Emory Practical Intervention Course Southeast Consortium	02/11/2015	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	Advances in the Treatment of Ovarian and Cervical Cancers: Expert-Facilitated Small Group Discussions of Challenging Cases	02/11/2015	\$232,693.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	Moore's Cancer Center 11th Industry/Academia Translational Oncology Symposium	02/12/2015	\$3,000.00
SCRIPPS HEALTH	The Future of Genomic Medicine VIII	02/12/2015	\$10,000.00
DELAWARE ACADEMY OF PHYSICIAN ASSISTANTS	Hyperlipidemia	02/12/2015	\$2,780.00
THE MASSACHUSETTS GENERAL HOSPITAL	29th Harvard Critical Issues in Tumor Microenvironment: Angiogenesis Metastasis and Immunology Course	02/17/2015	\$5,000.00
KERN ASPEN LIPID CONFERENCE	Emerging Therapies for Cardiovascular Diseases: A Dialogue Between Academic & Pharmaceutical Research	02/17/2015	\$10,000.00
FLORIDA ASSOCIATION OF CONSULTANT PHARMACISTS	Acute Coronary Syndrome; Strategies to Optimize Transitions in Care and Reduce Readmissions	02/17/2015	\$8,325.00
ST. JOSEPH'S REGIONAL MEDICAL CENTER	COPD	02/18/2015	\$1,900.00
CARDIOVASCULAR RESEARCH FOUNDATION	Issues with DAPT Series 2015	02/18/2015	\$50,000.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION (NPACE)	The Challenges of Asthma and COPD in Primary Care	02/19/2015	\$5,000.00
NORTHWESTERN UNIVERSITY	The 8th Annual Women's Cardiovascular Health Symposium	02/19/2015	\$2,500.00
AMERICAN HEART ASSOCIATION	Atlanta Mission: Lifeline Meeting	02/19/2015	\$2,500.00
AMERICAN ASSOCIATION OF NURSE PRACTITIONERS	How to Talk to Your Patients about Opioid-induced Constipation: A Dialogue about New Advances	02/22/2015	\$231,590.00
AMERICAN THYROID ASSOCIATION	American Thyroid Association Satellite Symposium: ATA Guidelines on Medullary Thyroid Cancer and Pediatric Thyroid Cancer Highlights, Controversies a	02/22/2015	\$25,000.00
THOMAS JEFFERSON UNIVERSITY	3rd Annual Jefferson Lung Cancer Symposium 2015	02/22/2015	\$3,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	What's New in Asthma/COPD Syndrome	02/22/2015	\$95,085.00

Worksheet: Grants 2014 to Mar 20 2019

Organization	Program Title	Date	Amount
WEST PENN ALLEGHENY HEALTH SYSTEM	Cardiovascular Medicine Update 2015	02/22/2015	\$10,000.00
AMERICAN DIABETES ASSOCIATION	62nd Annual Advanced Postgraduate Course 2015	02/23/2015	\$10,000.00
SOCIETY OF GYNECOLOGIC ONCOLOGY	SGO Annual Meeting on Women's Cancer	02/23/2015	\$50,000.00
BAYLOR UNIVERSITY MEDICAL CENTER DBA A. WEBB ROBERTS CENTER	The 18th Annual Tyler Breast Cancer Conferecne 2015	02/23/2015	\$3,000.00
PENNSYLVANIA ACADEMY OF FAMILY PHYSICIANS FOUNDATION	PAFP/F Live and Enduring CME Primary and Secondary Prevention of ASCVD	02/23/2015	\$5,000.00
ONCOLOGY NURSING SOCIETY	Oncology Nursing Society 40th Annual Congress	02/23/2015	\$25,000.00
AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS	2015-2016 AAPS Sustaining Sponsorship	02/23/2015	\$50,000.00
ASPEN LUNG CONFERENCE	Thomas L. Petty Aspen Lung Conference:Asthma 2015: Mechanisms to Personalized Medicine	02/24/2015	\$15,000.00
ST. FRANCIS HOSPITAL - U.S. CATHOLIC CONFERENCE	Intravascular Coronary Imaging and Physiology 2015: A Clinical Workshop	02/26/2015	\$7,000.00
NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS	NAPNAP Conference Sponsorship	02/26/2015	\$7,500.00
AMERICAN ASSOCIATION FOR THORACIC SURGERY	95th Annual Meeting American Association for Thoracic Surgery	02/26/2015	\$10,000.00
NATIONAL KIDNEY FOUNDATION INC	Session Support: CKD MANAGEMENT ALONG THE CONTINUUM: FROM PREDIALYSIS TO POLICY	02/26/2015	\$20,000.00
CITY OF HOPE NATIONAL MEDICAL CENTER	15th Annual Rachmiel Levine Diabetes and Obesity Symposium	03/01/2015	\$5,000.00
AMERICAN THORACIC SOCIETY	ATS 2015 International Conference, Fellows Track Symposium	03/01/2015	\$25,000.00
AMERICAN THORACIC SOCIETY	ATS 2015 International Conference - Selected Topics in Asthma	03/01/2015	\$10,000.00
NATIONAL JEWISH HEALTH	Improving the Quality of Care for Patients with Asthma	03/01/2015	\$10,000.00
ST. JOSEPH'S REGIONAL MEDICAL CENTER	Year in Review in Acute Coronary Syndromes	03/01/2015	\$3,700.00
THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA DBA THE UNIVERSITY OF NEBRASKA MEDICAL CENTER	COPD9USA	03/02/2015	\$40,000.00
AMERICAN THORACIC SOCIETY	ATS 2015 International Conference - Selected Topics in COPD	03/02/2015	\$72,919.82
NATIONAL JEWISH HEALTH	Best Practices in Managing Patients with COPD: Emerging Therapies and Patient Education Strategies	03/02/2015	\$72,161.00
CARDIOVASCULAR RESEARCH FOUNDATION	DAPT Dilemmas: A Case-Based Roundtable Tutorial	03/02/2015	\$69,100.00
ALZHEIMER'S ASSOCIATION	2015 Alzheimers Association Research Roundtable	03/02/2015	\$50,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 ASCO Annual Meeting Gynecologic Cancer Track: Scientific and Educational Program	03/02/2015	\$56,000.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS	AAPA Conference 2015 - CardiologyTrack	03/02/2015	\$5,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	The Post-ACS Patient: Adherence to Critical Therapies in the Short- and Long-Term	03/04/2015	\$100,000.00
NATIONAL ASSOCIATION OF FREE & CHARITABLE CLINICS	2015 Charitable Health Care Education & Training Symposium	03/04/2015	\$30,000.00
GORDON RESEARCH CONFERENCES	High Throughput Chemistry & Chemical Biology	03/04/2015	\$2,500.00
NEW YORK ACADEMY OF SCIENCES	Non-Motor Symptoms: Unraveling the "Invisible" Face of Parkinson s Disease	03/04/2015	\$2,000.00
SOCIETY FOR PHYSICIAN ASSISTANTS IN PEDIATRICS	SPAP's 9th Annual Conference	03/08/2015	\$1,500.00
JDRF INTERNATIONAL	TypeOneNation Research Summit	03/08/2015	\$4,500.00

Organization	Program Title	Date	Amount
GORDON RESEARCH CONFERENCE	Solving Knowledge Gaps in Drug Metabolism and Pharmacokinetic Prediction, Improving Translational Medicine	03/08/2015	\$3,000.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION (NPACE)"	Clinical Pearls in Managing Diabetes in 2015	03/09/2015	\$2,500.00
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	Cardiovascular Medicine 2015: Updates for the Practitioner	03/09/2015	\$11,500.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	Diabetes Sessions at Endocrine University: Disease Management & Technology Skills for Endocrinology Fellows in Training	03/10/2015	\$25,000.00
NEBRASKA ACADEMY OF PHYSICIAN ASSISTANTS	Gout 2015	03/10/2015	\$1,500.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2015 Oncology Case Manager and Medical Director Program	03/10/2015	\$20,000.00
GORDON RESEARCH CONFERENCES	Preclinical Form & Formulation for Drug Discovery GRC/GRS	03/11/2015	\$500.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Annual Meeting- 2015	03/12/2015	\$25,000.00
THE HOPE FOUNDATION	2015 SWOG Group Meetings	03/12/2015	\$5,000.00
AMERICAN HEAD AND NECK SOCIETY	American Head and Neck Society 2015 Annual Meeting	03/12/2015	\$10,000.00
BOSTON CHILDREN'S HOSPITAL	Pediatric Asthma & Allergy Updates for Primary Care Providers	03/16/2015	\$3,000.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION (NPACE)	Managing Asthma and COPD in 2015	03/16/2015	\$1,500.00
HEALTHCARE ALLIANCE FOR MEDICAL EDUCATION	Essentials in Primary Care	03/16/2015	\$8,400.00
WEST VIRGINIA ACADEMY OF FAMILY PHYSICIANS	Opioid Induced Constipation	03/17/2015	\$3,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	2015 ECOG-ACRIN Spring Group Meeting	03/18/2015	\$5,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 ASCO Annual Meeting Breast Cancer Track: Scientific and Educational Program	03/18/2015	\$84,000.00
AMERICAN COLLEGE OF OSTEOPATHIC FAMILY PHYSICIANS	Diabetes is Primary Addressing Primary Care Clinical Gaps in Diabetes Management by Partnering With Experts	03/19/2015	\$15,000.00
MERCY HEALTH SYSTEM SEPA	Care Transitions Conference	03/19/2015	\$5,000.00
THE MEDICAL UNIVERSITY OF SOUTH CAROLINA	10th Annual Symposium entitled the Nephrology Update for Primary Care and Hospital Medicine	03/19/2015	\$5,000.00
ALZHEIMER'S ASSOCIATION	2015 Alzheimer's Association International Conference	03/23/2015	\$95,000.00
SOCIETY FOR TRANSLATIONAL ONCOLOGY	2015 Annual Meeting	03/23/2015	\$25,000.00
SWEDISH MEDICAL CENTER FOUNDATION	Thyroid Cancer and Parathyroid Disease - A Practical Approach	03/24/2015	\$3,000.00
ASSOCIATION OF WOMEN'S HEALTH, OBSTETRIC AND NEONATAL NURSES (AWHONN)	AWHONN Annual Convention	03/24/2015	\$7,500.00
GORDON RESEARCH CONFERENCES	2015 Proteins Gordon Conference	03/24/2015	\$3,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE 24th Annual Scientific & Clinical Congress (Diabetes portion)	03/25/2015	\$30,000.00
THE ASSOCIATION FOR FRONTOTEMPORAL DEGENERATION (AFTD)	AFTD's Annual Education Conference	03/25/2015	\$1,000.00
TRINITAS REGIONAL MEDICAL CENTER	Lung Cancer	03/25/2015	\$1,750.00
INSTITUTE FOR PATIENT ACCESS	2015 Premature Infant Health Summit	03/25/2015	\$125,000.00
SOCIETY FOR NEUROSCIENCE	Young Investigator Award	03/25/2015	\$25,000.00
ST. DOMINIC - JACKSON MEMORIAL HOSPITAL	STOP STEMI and STOP STROKE program by Pulsara	03/25/2015	\$25,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	Anti-cancer Drug Action and Drug Resistance:	03/26/2015	\$10,000.00
YALE UNIVERSITY	2015 New England Thyroid Club Program	03/26/2015	\$3,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE 24th Annual Scientific & Clinical Congress (Thyroid sessions)	03/26/2015	\$25,000.00

Organization	Program Title	Date	Amount
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Cleveland Breast Cancer 2015: Collaborating For A Cure	03/26/2015	\$5,000.00
OKLAHOMA HEART RESEARCH & EDUCATION FOUNDATION	26th Annual Update in Cardiology	03/26/2015	\$2,500.00
CEDARS-SINAI MEDICAL CENTER	3rd Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine	03/29/2015	\$5,000.00
CASE MANAGEMENT SOCIETY OF AMERICA	CMSA 2015 Conference & Expo	03/29/2015	\$15,000.00
SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS FOUNDATION	SCAI Complex Peripheral Vascular Interventions Course	03/29/2015	\$15,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Bringing Science to Clinical Practice: Best of ACC 2015	03/29/2015	\$50,000.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	Live Symposium of Complex Coronary Valvular and Vascular Cases	03/29/2015	\$10,000.00
ASOCIACIÓN PUERTORRIQUEÑA DE GRADUADOS DE UNIVERSIDADES ESPAÑOLAS- APGUE	Metabolic Syndrome Update: Challenges in Preventive Medicine	03/30/2015	\$1,500.00
UNIVERSITY OF PITTSBURGH	Breast Symposium 2015: Updates in the Management of Breast Cancer/Breast Disease	03/30/2015	\$3,250.00
JOHNS HOPKINS UNIVERSITY	6th Annual Johns Hopkins Cardiovascular Research Retreat	03/30/2015	\$2,500.00
SOCIETY FOR VASCULAR MEDICINE	Society for Vascular Medicine 26th Annual Scientific Sessions	03/30/2015	\$5,000.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION (NPACE)	Updates in COPD 2015	03/30/2015	\$3,200.00
THE CHRIST HOSPITAL	THE FETCH Conference	03/31/2015	\$5,000.00
THE CHEST FOUNDATION	The CHEST Foundation Lung Cancer Clinical Research Grant Program	03/31/2015	\$30,000.00
NEW YORK MEDICAL COLLEGE	Systemic Treatment of Lung Cancer	03/31/2015	\$2,500.00
THE CENTER OF EXCELLENCE IN EDUCATION	8th Annual Cardiovascular Update- A Practical Tutorial	03/31/2015	\$5,000.00
ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER	4th Annual Arizona Diabetes Series: Focus on Treatment Advances, Patient-Centered Care, Obesity and Other Comorbidities	04/01/2015	\$15,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	Annual Meeting of the Felix Rutledge Society	04/01/2015	\$5,000.00
GOUT & URIC ACID EDUCATION SOCIETY	Gout & Uric Acid Education Society Roundtable: Elevating the Severity of Gout and Improving Access to Public Education and Treatment	04/01/2015	\$70,000.00
VIVA PHYSICIANS	VIVA 15: Vascular InterVentional Advances	04/01/2015	\$20,000.00
UNIVERSITY OF WASHINGTON	University of Washington Allergy and Immunology Fellowship	04/02/2015	\$20,000.00
WASHINGTON ACADEMY OF PHYSICIAN ASSISTANTS	26th Annual Recertification Review Course and Spring Conference	04/06/2015	\$1,500.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Advances in Lung Cancer: A Multidisciplinary Approach	04/07/2015	\$5,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	Molecular, Structural & Clinical Aspects of VK & VK-Dependent Proteins	04/08/2015	\$10,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	FASEB conference on Genetic Recombination & Genome Rearrangements	04/08/2015	\$5,000.00
SCRIPPS WHITTIER DIABETES INSTITUTE	Emerging Therapeutic Trends to Optimize Diabetes Care	04/09/2015	\$30,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	2015 Interventional Cardiology Board Preparatory Course	04/09/2015	\$5,000.00
AMERICAN FEDERATION FOR MEDICAL RESEARCH	2015 Eastern Regional Meeting of the American Federation for Medical Research	04/12/2015	\$2,500.00
PONCE MEDICAL SCHOOL FOUNDATION INC.	Overcoming Obstacles to Reduce Acute Coronary Syndrome	04/12/2015	\$10,000.00
SOUTH CAROLINA ASTHMA ALLIANCE	Midlands Regional Asthma Conference	04/12/2015	\$3,000.00
PHARMACY QUALITY ALLIANCE (PQA, INC.)	Measuring What Matters: Improving Care and Driving the Next Generation of Performance Measures	04/13/2015	\$12,500.00

Organization	Program Title	Date	Amount
METABOLIC ENDOCRINE EDUCATION FOUNDATION	The Comprehensive Management of DM - Focus on SGLT2 Inhibitors and Combination Therapy - Emerging Concepts of Renal Effects	04/13/2015	\$283,155.00
ASTHMA & ALLERGY FOUNDATION OF AMERICA, ALASKA CHAPTER	Wheezin', Sneezin' & Itchin' in Alaska	04/14/2015	\$5,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Individualizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes (T2DM)	04/14/2015	\$25,000.00
MIDMICHIGAN MEDICAL CENTER - MIDLAND	Valley Diabetes Symposium	04/15/2015	\$2,500.00
TRUSTEES OF BOSTON UNIVERSITY DBA BOSTON UNIVERSITY SCHOOL OF MEDICINE	Opioid Induced Constipation: A Neglected Complication	04/15/2015	\$117,200.00
PARTNERS HEALTHCARE SYSTEM	World Medical Innovation Forum	04/15/2015	\$50,000.00
MASSACHUSETTS INSTITUTE OF TECHNOLOGY	CANCER COMPLEXITY: Heterogeneity in Tumor Progression and Drug Response	04/15/2015	\$5,000.00
AMERICAN SOCIETY OF NEPHROLOGY	ASN Kidney Week - CKD Learning Pathway Support	04/16/2015	\$55,000.00
NATIONAL ASSOCIATION FOR HEALTHCARE QUALITY	Leading Care Transitions: Improving Quality in Safety Across the Healthcare Continuum	04/19/2015	\$15,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	12th FASEB Summer Research Conference on 'Proteases in Hemostasis and Vascular Biology'	04/19/2015	\$7,000.00
AMERICAN SOCIETY FOR PAIN MANAGEMENT NURSING	ASPMN 25th National Conference	04/20/2015	\$20,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	5th International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma	04/20/2015	\$3,000.00
GORDON RESEARCH CONFERENCES	2015 Medicinal Chemistry Gordon Research Conference	04/20/2015	\$3,000.00
AMERICAN THORACIC SOCIETY	ATS 2015 International Conference - Selected Topics in Lung Cancer	04/21/2015	\$50,000.00
OKLAHOMA UNIVERSITY HEALTH SCIENCES CENTER	18th Annual Primary Care Update 2015 Asthma	04/21/2015	\$1,500.00
OKLAHOMA UNIVERSITY HEALTH SCIENCE CENTER COLLEGE OF MEDICINE	18th Annual Primary Care Update 2015- Ovarian Cancer	04/21/2015	\$1,500.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	LIPID MAPS Meeting: Lipidomics Impact on Cancer, Metabolic and Inflammatory Diseases	04/21/2015	\$7,500.00
CARDIOVASCULAR RESEARCH FOUNDATION	Knights of the Roundtable 2015: Challenging AMI Therapies	04/21/2015	\$50,000.00
HOUSTON METHODIST HOSPITAL	Cardiovascular Fellows' Bootcamp-Laying the Foundation	04/21/2015	\$15,000.00
UNIVERSITY OF PITTSBURGH	Seventh Annual Multidisciplinary Thyroid Cancer Symposium: Integrating the New ATA Guidelines into Clinical Practice	04/22/2015	\$3,250.00
AMERICAN ASSOCIATION OF ENDOCRINE SURGEONS	36th Annual Meeting of the American Association of Endocrine Surgeons	04/22/2015	\$3,000.00
DUKE UNIVERSITY HEALTH SYSTEM	Closing the Gap on Medication Management, Discharge Preparedness and Readmissions	04/22/2015	\$20,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	ASCO Review	04/23/2015	\$3,000.00
SWEDISH MEDICAL CENTER FOUNDATION	Annual Oncology Symposium: Personalized Medicine - Genetic Testing, Targeted Molecular Therapy and Whole Patient Care	04/23/2015	\$3,000.00
OKLAHOMA UNIVERSITY HEALTH SCIENCE CENTER COLLEGE OF MEDICINE	18th Annual Primary Care Update: COPD	04/23/2015	\$1,500.00
WASHINGTON UNIVERSITY	Update on Gynecologic Cancer	04/23/2015	\$4,000.00
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, ST. LOUIS	Cardiology Update	04/23/2015	\$4,000.00

Organization	Program Title	Date	Amount
NEW YORK ACADEMY OF SCIENCES	Emerging Approaches to Cancer Immunotherapy	04/27/2015	\$5,000.00
LYMPHOMA RESEARCH FOUNDATION	Lymphoma Research Foundation Immune Checkpoint Inhibitor Workshop	04/27/2015	\$15,000.00
YALE UNIVERSITY	Yale Cancer Center Oncology Series - 2015	04/28/2015	\$5,000.00
MOUNT CARMEL HEALTH SYSTEM	2015 ASCO REVIEW	04/28/2015	\$3,000.00
COLUMBIA UNIVERSITY DEPARTMENT OF SURGERY	Breast Cancer Management 2015	04/28/2015	\$3,000.00
NORTHWESTERN UNIVERSITY	4th Annual Chicago Cardiovascular Update	04/28/2015	\$6,000.00
DIGNITY HEALTH ST. BERNARDINE MEDICAL CENTER	17th Annual Cardiac Symposium: Advances in Cardiovascular Disease 2015	04/29/2015	\$6,000.00
GORDON RESEARCH CONFERENCES	2015 Gordon Conference on Heterocyclic Compounds	04/29/2015	\$2,500.00
INTERNATIONAL SOCIETY FOR COMPUTATIONAL BIOLOGY INC	Regulatory and Systems Genomics, with DREAM Challenges Conference	04/29/2015	\$2,500.00
YALE UNIVERSITY	Yale ASCO Review 2015	04/30/2015	\$3,000.00
UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE	OBESITY & METABOLISM: An Emerging Frontier in Lung Health and Disease	04/30/2015	\$5,000.00
SWEDISH MEDICAL CENTER FOUNDATION	The Transradial Approach: A Case-based and Hands-on Training Course	04/30/2015	\$5,000.00
MONTEFIORE MEDICAL CENTER	Achieving Balance: Practical Management Strategies for Opioid-Induced Constipation	05/03/2015	\$161,500.00
CALIFORNIA SOCIETY OF ALLERGY, ASTHMA, AND IMMUNOLOGY	CSAAI 23rd Annual Educational Meeting	05/05/2015	\$3,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	Advanced Thyroid Master Class	05/06/2015	\$5,000.00
CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION	Molecular Therapeutics of Cancer Conference, 2015	05/06/2015	\$5,000.00
NORTH SHORE LONG ISLAND JEWISH HEALTH SYSTEM INC	Post American Society of Clinical Oncology 2015	05/07/2015	\$3,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	Update in Allergy, Asthma & Immunology	05/12/2015	\$5,000.00
ALBERT EINSTEIN HEALTHCARE NETWORK	Complex Angioplasty Symposium Exchange Philadelphia	05/14/2015	\$5,000.00
SOCIETY FOR TRANSLATIONAL ONCOLOGY	The Oncologist CME Online Journal Curriculum: Breast Cancer	05/17/2015	\$10,000.00
ANENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Poster Perspectives: Research Developments in NSCLC / 2015 ASCO	05/18/2015	\$25,000.00
WESTERN ASSOCIATION GYNECOLOGIC ONCOLOGISTS	Hitting the targets in Gynecologic Cancer	05/18/2015	\$12,500.00
AMERICAN THYROID ASSOCIATION	ATA Early Riser Symposium: New Modalities to Treat Medullary Thyroid Cancer	05/19/2015	\$129,500.00
CARDIOVASCULAR RESEARCH FOUNDATION	Issues with DAPT: A Case-based Roundtable with the Experts	05/19/2015	\$25,000.00
LAHEY CLINIC HOSPITAL, INC.	Cardiovascular Disease State of the Art 2015	05/19/2015	\$6,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	ACC Cardiovascular Board Review for Certification and Recertification	05/19/2015	\$5,000.00
CANCER RESEARCH INSTITUTE	Immunotherapy for the Oncology Nurse	05/19/2015	\$75,000.00
GORDON RESEARCH CONFERENCES	Gordon Research Conference; Hormone dependent cancer	05/20/2015	\$5,000.00
NORTHEASTERN UNIVERSITY	Boston Symposium on Organic and Bioorganic Chemistry (BSOBC)	05/21/2015	\$3,500.00
AMERICAN SOCIETY OF NEPHROLOGY	Anemia, Erythropoiesis, and the Nephrologist	05/21/2015	\$190,000.00
CANCER RESEARCH INSTITUTE	2015 International Cancer Immunotherapy Conference	05/24/2015	\$50,000.00
ZOE ROSE MEMORIAL FOUNDATION	2015 Preemie Parent Summit	05/24/2015	\$10,000.00
THE GOG FOUNDATION INC	4th Semi Annual Meeting of NRG Oncology (formerly GOG, NSABP, RTOG)	05/26/2015	\$20,000.00

Organization	Program Title	Date	Amount
CLINICAL CARE OPTIONS	Immunotherapy for Cancer Track: CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*	05/26/2015	\$25,000.00
ACADEMIA MEDICA DEL SUR	Non-Small Cell Lung Cancer: Current Therapy and Promising New Regimens	05/26/2015	\$3,000.00
AMERICAN NEUROGASTROENTEROLOGY AND MOTILITY SOCIETY	ANMS 10th Postgraduate Course in Gastroenterology and Neurogastroenterology in Clinical Practice	05/26/2015	\$6,400.00
CEO ROUNDTABLE ON CANCER, INC.	Prostate Cancer DREAM Challenge Winning Teams Educational Grant	05/27/2015	\$30,000.00
C-CHANGE	Big Data in Cancer Care	05/27/2015	\$25,000.00
THE GOG FOUNDATION	Rational Combination Targeted Therapies for Gynecologic Cancers	05/27/2015	\$10,000.00
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	Lung Cancer 2015: New Discoveries, New Directions	05/27/2015	\$3,000.00
NOT-FOR-PROFIT HOSPITAL CORPORATION	Lung Cancer Screening in 2015	05/27/2015	\$1,900.00
OLIGONUCLEOTIDE THERAPEUTICS SOCIETY	11th Annual Meeting of the Oligonucleotide Therapeutics Society	05/31/2015	\$7,500.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Best of ASCO Meetings	05/31/2015	\$15,000.00
AMERICAN ASSOCIATION OF DIABETES EDUCATORS	IMPROVING OUTCOMES FOR WOMEN WITH TYPE 2 DIABETES INDIVIDUALIZING EVIDENCE-BASED CARE	06/02/2015	\$101,800.00
NATIONAL KIDNEY FOUNDATION	Chronic Kidney Disease & the Primary Care Practitioner:	06/02/2015	\$75,000.00
UNIVERSITY OF MARYLAND BALTIMORE FOUNDATION, INC.	17th Annual International Meeting of the Institute of Human Virology	06/02/2015	\$15,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	2015 Updates in Oncology: With Proceedings from International Medical Meetings	06/03/2015	\$5,000.00
MELANOMA RESEARCH FOUNDATION	Melanoma Research Foundation CURE OM Junior Fellowship	06/03/2015	\$112,280.00
AMERICAN OSTEOPATHIC ASSOCIATION	Optimizing Anti-platelet Therapy and Secondary Prevention Strategies in Acute Coronary Syndromes The Role of the Primary Care Practice (150203494)	06/04/2015	\$357,790.00
INTERNATIONAL SOCIETY FOR STEM CELL RESERACH	Workshop on Clinical Translation	06/09/2015	\$30,000.00
NURSE PRACTITIONER ASSOCIATES FOR CONTINUING EDUCATION (NPACE)	The Latest in Asthma and COPD	06/10/2015	\$5,000.00
AMERICAN PHARMACISTS ASSOCIATION FOUNDATION	IMPACT Care Transformation Institute	06/10/2015	\$74,987.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	Advances in Breast Cancer Research	06/11/2015	\$10,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	Advances in Ovarian Cancer Research	06/11/2015	\$10,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY	Symposium - Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS)	06/11/2015	\$50,000.00
CASE MANAGEMENT SOCIETY OF AMERICA	Improving Medication Adherence in the COPD Patient through Greater Patient Engagement	06/11/2015	\$6,265.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	California Chapter of the American Association of Clinical Endocrinologists Presents: Hot Topics in Diabetes and Endocrinology for Primary Care	06/16/2015	\$20,000.00
FLORIDA ACADEMY OF PHYSICIAN ASSISTANTS INC	Update on COPD and Asthma Management	06/16/2015	\$4,300.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	2015 AAFP FMX Assembly 60 Minute Lecture titled Acute Coronary Syndrome and Angina	06/16/2015	\$13,000.00



Organization	Program Title	Date	Amount
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	ACEP Pediatric Emergency Medicine Special Interest Section Annual Meeting	06/17/2015	\$2,500.00
FOUNDATION FOR GYNECOLOGIC ONCOLOGY	FGO Genetics Summit	06/18/2015	\$35,000.00
FRIENDS OF CANCER RESEARCH	2015 Friends of Cancer Research Programs	06/22/2015	\$100,000.00
DIVISION OF MEDICINAL CHEMISTRY	Division of Medicinal Chemistry Program American Chemical Society 250th National Meeting	06/23/2015	\$2,500.00
RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA	Vasculata 2015	06/24/2015	\$10,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	Preventing Exacerbations of COPD	06/24/2015	\$48,000.00
ASSOCIATION OF ASTHMA EDUCATORS	The Asthma Team: Making Wishes Come True	06/24/2015	\$5,000.00
THE MASSACHUSETTS GENERAL HOSPITAL	30th Annual Critical Issues In Tumor Microenvironment: Angiogenesis, Metastasis and Immunology	06/24/2015	\$5,000.00
NATIONAL MEDICAL ASSOCIATION	The National Medical Association Asthma Update: Evidence-Based Diagnosis and management of Asthma - Practical Tools to Improve Patient Care	06/24/2015	\$3,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Reducing Exacerbations in the Treatment and Management of Chronic Obstructive Pulmonary Disease (COPD)	06/25/2015	\$12,500.00
ONCOLOGY NURSING SOCIETY	Pharmacology Updates in Oncology Practice Conference	06/30/2015	\$15,000.00
UC BERKELEY FOUNDATION	IGI CRISPR Workshop: Routes to Designer Biology	06/30/2015	\$10,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	13th Annual World Congress on Insulin Resistance Diabetes and Cardiovascular Disease - WCIRDC	07/01/2015	\$100,000.00
PARTNERS HEALTHCARE PERSONALIZED MEDICINE	2015 Personalized Medicine Conference	07/02/2015	\$25,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Improving Patient Outcomes with Novel Treatments in the Management of Hypertriglyceridemia	07/02/2015	\$25,000.00
NEW YORK CITY SOCIETY OF HEALTH-SYSTEM PHARMACISTS	Practical considerations for using novel oral antiplatelet agents in patients with acute coronary syndromes	07/07/2015	\$9,500.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	EGFR Diagnostic Expert Consensus meeting	07/09/2015	\$201,000.00
UB FOUNDATION ACTIVITIES, INC	Recent Advances in the pathophysiology and management of type 2 diabetes	07/09/2015	\$2,500.00
AMERICAN PHARMACISTS ASSOCIATION	APhA's Pharmacist and Patient Centered Diabetes Care Certificate Training Program National Offerings	07/14/2015	\$25,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics	07/14/2015	\$25,000.00
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	Mid-Atlantic Nephrology Young Investigators' Forum	07/14/2015	\$49,381.58
SOUTH DAKOTA ACADEMY OF PHYSICIAN ASSISTANTS	COPD: diagnosis and optimum treatment	07/14/2015	\$3,500.00
SOUTHERN SOCIETY FOR CLINICAL INVESTIGATION	15th Annual SSCI Nephrology Young Investigators' Forum	07/15/2015	\$43,940.49
YALE UNIVERSITY	2015 London Cardiovascular Device Innovation Summit	07/16/2015	\$5,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	Updates in Rheumatology 2015	07/19/2015	\$5,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	13th Annual Nephrology Young Investigator's Forum	07/21/2015	\$34,698.53
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2015 SITC International Symposium on Cancer Immunotherapy	07/22/2015	\$50,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC 2015 Global Regulatory Summit	07/22/2015	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN/SCCA 2015 Thoracic Oncology Symposium	07/26/2015	\$10,000.00

Organization	Program Title	Date	Amount
SOCIETY FOR IMMUNOTHERAPY OF CANCER	Named Postdoctoral Cancer Immunotherapy in NSCLC Clinical Fellowship Award	07/26/2015	\$120,000.00
NATIONAL ASSOCIATION FOR CONTINUING EDUCATION	Gout: Bridging Knowledge Gaps in Diagnosis and Treatment	07/26/2015	\$163,946.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC	2015 NCCN Immuno-Oncology Webinar Series for Pharmacists	07/26/2015	\$35,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	EPC - Updates in Pulmonary Disease: Current, Relevant & Interactive	07/28/2015	\$10,000.00
NATIONAL KIDNEY FOUNDATION	11th Annual National Young Investigator's Forum	07/29/2015	\$50,000.00
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	Immuno-Oncology: A Revolution in Cancer Treatment	07/29/2015	\$30,000.00
GEORGIA CHAPTER OF THE AMERICAN COLLEGE OF CARDIOLOGY	2015 Scientific Meeting	07/30/2015	\$5,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Improving Outcomes with Individualized Treatment Strategies in the Management of Advanced Non Small-Cell Lung Cancer (NSCLC)	08/02/2015	\$25,000.00
HACKENSACK UNIVERSITY MEDICAL CENTER	Fifth Annual Heart & Vascular Symposium	08/03/2015	\$5,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	Early Intervention in The Continuum of Hyperglycemia - The Role of Initial Combination Therapy	08/06/2015	\$149,515.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	Primer on Tumor Immunology and Cancer Immunotherapy	08/10/2015	\$15,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN/SCCA 2015 Thoracic Oncology Symposium	08/11/2015	-\$2,005.40
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Breast Cancer Symposium: Enhancing Clinical Care through Collaboration	08/11/2015	\$10,000.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	Management of Gout: Individualizing the Approach	08/11/2015	\$242,009.00
BREATHE CALIFORNIA OF LOS ANGELES COUNTY	Advancing the diagnosis and management of COPD with a focus on COPD exacerbations	08/16/2015	\$3,000.00
GLOBAL ACADEMY FOR MEDICAL EDUCATION	8th Annual Perspectives in Rheumatic Diseases presented by Rheumatology News, Internal Medicine News, Family Practice News	08/17/2015	\$35,000.00
NORTHWESTERN UNIVERSITY	17th Annual Lynn Sage Breast Cancer Symposium	08/17/2015	\$10,000.00
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	Cardiovascular Disease Track at ACEP 2015 Scientific Assembly	08/17/2015	\$10,000.00
NATIONAL ASSOCIATION OF NEONATAL NURSES	NANN 31st Annual Educational Conference	08/19/2015	\$10,000.00
UNIVERSITY OF CINCINNATI	2ND ANNUAL CINCINNATI COLLABORATIVE CARDIOVASCULAR SYMPOSIUM (C4)	08/19/2015	\$25,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE/ACE Scientific and Clinical Review of DKA and the Effects of SGLT2 Inhibitors	08/20/2015	\$99,804.71
AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY	TAS: Allergy, Asthma & Immunology Conference	08/23/2015	\$1,000.00
NAMI MARYLAND	NAMI Maryland 2015 Annual Education Conference	08/25/2015	\$5,000.00
CONNECTICUT PHARMACISTS ASSOCIATION	Insights, Pearls, and Perspectives - An Update in the Management of Chronic Obstructive Pulmonary Disease	08/25/2015	\$5,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY	Plenary Session - Updates in Severe Asthma	08/25/2015	\$50,000.00
UNIVERSITY OF FLORIDA	Vascular Biology Working Group Global Chapter Meeting	08/26/2015	\$10,000.00
PENN STATE UNIVERSITY	Skin, Bones, Hearts & Private Parts	08/26/2015	\$5,000.00
AMERICAS HEALTH FOUNDATION	Roundtable Discussion on Decreasing the Burden of Influenza in Latin America	08/27/2015	\$37,462.15
DANA-FARBER CANCER INSTITUTE INC	11 th Annual Postdoctoral and Graduate Student Retreat	08/27/2015	\$2,500.00

Organization	Program Title	Date	Amount
IOWA PHYSICIAN ASSISTANT SOCIETY	COPD Board Review Track	08/27/2015	\$2,000.00
BAYLOR COLLEGE OF MEDICINE	Breast Cancer Research & Education Program	08/30/2015	\$3,000.00
BAYLOR COLLEGE OF MEDICINE	Metastatic Breast Cancer Conference	08/30/2015	\$3,500.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	Top Ten Advances in Clinical Cardiology	08/30/2015	\$10,000.00
ASSOCIATION OF COMMUNITY CANCER CENTERS	In the Era of Value: The Importance of Patient Navigation, Psychosocial Distress Screening, and Survivorship Care Planning Programs in the Community C	09/01/2015	\$125,000.00
PENNSYLVANIA STATE UNIVERSITY	Constipation: Improving Outcomes With Individualized, Evidence-based Treatment	09/02/2015	\$142,387.00
SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY	2nd Annual Current Issues in Coronary and Structural Heart Disease: A Multidisciplinary Approach	09/03/2015	\$5,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	48th Annual New York Cardiovascular Symposium: Major Topics in Cardiology Today	09/08/2015	\$15,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	ASTRO's 57th Annual Meeting	09/09/2015	\$10,000.00
NATIONAL JEWISH HEALTH	38th Annual Pulmonary and Allergy Update	09/14/2015	\$5,000.00
ST. JOSEPH'S REGIONAL MEDICAL CENTER	Acute Myocardial Infarction: Guidelines, Controversies and Updates	09/14/2015	\$1,700.00
TRUSTEES OF BOSTON UNIVERSITY	Head & Neck Cancer Symposium: From Pathways to Therapies	09/15/2015	\$3,000.00
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	Cancer Genetics: Going Beyond the Guidelines	09/15/2015	\$3,000.00
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	38TH Annual San Antonio Breast Cancer Symposium	09/15/2015	\$25,000.00
BAYLOR UNIVERSITY MEDICAL CENTER	The 42nd Annual Williamsburg Conference on Heart Disease	09/15/2015	\$8,500.00
UNIVERSITY OF WASHINGTON	Comprehensive Hematology & Oncology Review	09/15/2015	\$3,500.00
NATIONAL COMMITTEE FOR QUALITY ASSURANCE	NCQA Quality Talks and 25th Anniversary	09/15/2015	\$25,000.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	Acute Myocardial Infarction: Guidelines, Controversies and Updates	09/15/2015	\$1,400.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2015 Breast Cancer Symposium Proceedings	09/16/2015	\$25,000.00
UT HEALTH SCIENCE CENTER SAN ANTONIO	38th Annual San Antonio Breast Cancer Symposium -Basic Science Forum/Poster Discussion Session	09/16/2015	\$35,000.00
AULTMAN HOSPITAL	Aultman Hospital's 15th Annual Cancer Conference	09/17/2015	\$2,500.00
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	Recognizing Diabetic Emergencies: Will You Be Ready?	09/20/2015	\$209,619.96
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	Best of the World Conference on Lung Cancer	09/21/2015	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	CancerLinQ: Real-time Learning Intelligence Network for Quality	09/21/2015	\$400,000.00
LUNG CANCER INITIATIVE OF NC	Advanced Laboratory Testing Across Cancer Types: Everything you need to know	09/22/2015	\$3,000.00
CAROLINAS HEALTHCARE SYSTEM	27th Annual Fall Foliage Cancer Conference "Update on Lung Cancer"	09/22/2015	\$3,000.00
SCRIPPS HEALTH	TRANSFORMING MEDICINE: Evidence-Driven mHealth	09/23/2015	\$2,000.00
WESTERN SOCIETY OF ALLERGY, ASTHMA AND IMMUNOLOGY	WSAAI 54th Annual Scientific Session	09/23/2015	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2016 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA)	09/23/2015	\$120,000.00

Organization	Program Title	Date	Amount
ASSOCIATION OF AMERICAN CANCER INSTITUTES	2015 AACI/CCAF Annual Meeting	09/28/2015	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2016 Conquer Cancer Foundation of ASCO Merit Awards	09/29/2015	\$40,000.00
NATIONAL ASSOCIATION OF HISPANIC NURSES	2016 NAHN Leadership Meeting	09/29/2015	\$10,000.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	2015 AAFP FMX Assembly 60 Minute Lecture titled Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Function Testing	09/30/2015	\$5,000.00
NORTHWESTERN UNIVERSITY	2nd Annual Case-Based Coronary and Structural Heart Intervention Update	09/30/2015	\$5,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	44th Annual Philadelphia Workshop on Hemostasis, Thrombosis and Artherosclerosis	10/04/2015	\$5,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	ECOG-ACRIN Fall 2015 Group Meeting	10/05/2015	\$5,000.00
PHARMACY QUALITY ALLIANCE (PQA, INC)	Getting to the Core: Building and Implementing Core Measures	10/05/2015	\$3,500.00
BAYLOR UNIVERSITY MEDICAL CENTER	Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Prospective	10/07/2015	\$5,000.00
CEDARS SINAI MEDICAL CENTER	4th Annual New Therapeutics in Oncology: The Road to Personalized Medicine	10/07/2015	\$5,000.00
PENN STATE UNIVERSITY	Skin, Bones, Hearts and Private Parts (two conferences)	10/07/2015	\$5,000.00
INDIANA UNIVERSITY	Performance Improvement with Point of Care Clinical Decision Making App in non-ST segment elevation myocardial infarction (NSTEMI) patients	10/07/2015	\$5,000.00
MEDSTAR WASHINGTON HOSPITAL CENTER	Update In Rheumatology 2015: New Diagnostic Tests and Treatments for Clinical Practice	10/08/2015	\$15,000.00
NEW YORK STATE OSTEOPATHIC MEDICAL SOCIETY	New York State Osteopathic Medical Students Health Policy Initiative	10/08/2015	\$2,500.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	2015 Oncologic Emergency Medicine Conference	10/11/2015	\$5,000.00
AMERICAN PANCREATIC ASSOCIATION	46th Annual Meeting of the American Pancreatic Association	10/11/2015	\$10,000.00
WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE	2nd Annual Update in Rheumatology	10/15/2015	\$3,000.00
WAYNE STATE UNIVERSITY	State of the Art Management of Lung Cancer Symposium	10/15/2015	\$3,000.00
MEDICAL UNIVERSITY OF SOUTH CAROLINA	2nd Annual Comprehensive Stroke and Cerebrovascular Update	10/18/2015	\$10,000.00
AMERICAN COLLEGE OF RHEUMATOLOGY	2015 Musculoskeletal Ultrasound Course for Rheumatologists	10/19/2015	\$25,000.00
LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER IN NEW ORLEANS	LSUHSC Cardiovascular Centers Joint Retreat	10/20/2015	\$3,500.00
AMERICAN ASSOCIATION OF DIABETES EDUCATORS	Achieving Partnerships and Improving Outcomes in Your Diabetes Patients	10/20/2015	\$389,000.00
THE ENDOCRINE SOCIETY	The Truth of the Matter: An Evidence-Based Review of the Newer Antihyperglycemic Agents for T2DM: a hot seat Program	10/21/2015	\$284,438.73
GORDON RESEARCH CONFERENCES	2016 Basal Ganglia Gordon Research Conference: Emerging Views of Cellular and Circuit Diversity Within the Basal Ganglia	10/21/2015	\$2,500.00
MEDSTAR WASHINGTON HOSPITAL CENTER	Lung Cancer 2015: A Shifting Management Paradigm with	10/22/2015	\$3,000.00
NATIONAL QUALITY FORUM	NQF Measure Incubator	10/22/2015	\$100,000.00
GORDON RESEARCH CONFERENCES	2016 Gordon Research Conference on Heterocyclic Compounds	10/26/2015	\$2,500.00
AMERICAN HEART ASSOCIATION, INC.	Scientific Sessions 2015 Dedicated Track on Acute Coronary Syndrome: Current and Emerging Interventions and Future Directions	10/26/2015	\$30,000.00

Organization	Program Title	Date	Amount
INOVA HEALTH CARE SERVICES	Inova Heart and Vascular Institute 2016 Interventional Cardiology Symposium	11/03/2015	\$15,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	17th Annual Intensive Course on Diabetes, Endocrinology, and Metabolic Diseases	11/04/2015	\$20,000.00
WORLDWIDE INITIATIVE FOR DIABETES EDUCATION	Novel Therapies in Type 2 Diabetes Mellitus	11/05/2015	\$77,050.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE/ACE Comprehensive Diabetes Algorithm 2015 Mobile App	11/05/2015	\$79,500.00
GORDON RESEARCH CONFERENCE	GRC Mutagenesis meeting 2016	11/05/2015	\$3,500.00
ONCOLOGY NURSING SOCIETY	InPractice Oncology Nursing	11/09/2015	\$49,000.00
PARTNERS HEALTHCARE SYSTEM INC	World Medical Innovation Forum	11/22/2015	\$50,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer	11/22/2015	\$25,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	Cardiovascular Risk Reduction: Leading the Way in Prevention (22nd Annual Symposium)	11/22/2015	\$10,000.00
NATIONAL LIPID ASSOCIATION	National Lipid Association 2016 Lipid Academy Course Series	11/22/2015	\$15,000.00
NATIONAL LIPID ASSOCIATION	National Lipid Association 2016 Masters in Lipidology Course Series	11/22/2015	\$15,000.00
THE DEUEL CONFERENCE ON LIPIDS	The 2016 Deuel Conference on Lipids	11/24/2015	\$20,000.00
AMERICAN PHARMACISTS ASSOCIATION	APhA2016 Respiratory Update: Guidelines, Novel Inhalers and More	11/25/2015	\$11,500.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	2016 World Congress on Continuing Professional Development: Advancing Learning and Care in the Health Professions	12/01/2015	\$10,000.00
NASPGHAN FOUNDATION	Appropriate Use of Proton Pump Inhibitors in the Treatment of Pediatric Patients with GERD	12/01/2015	\$185,000.00
TRUSTEES OF BOSTON UNIVERSITY	A COPD Quality Improvement Consortium	12/01/2015	\$139,644.64
FOUNDATION FOR GYNECOLOGIC ONCOLOGY	Evolution and Revolution of PARP Targeting in Gynecologic Malignancies	12/03/2015	\$200,000.00
AMERICAN FEDERATION FOR MEDICAL RESEARCH	2016 Western Regional Meeting	12/03/2015	\$5,000.00
UNIVERSITY OF WASHINGTON	University of Washington Allergy and Immunology Fellowship	12/06/2015	\$19,942.22
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2016 Congress Series : Breast Cancer	12/09/2015	\$25,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	2016 Multidisciplinary Head and Neck Cancer Symposium	12/10/2015	\$10,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 21st Annual Conference General Session: Advancing the Standard of Cancer Care™	12/10/2015	\$75,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Annual Meeting- 2016	12/10/2015	\$125,000.00
AMERICAN FEDERATION FOR MEDICAL RESEARCH	2016 Southern Regional Meeting	12/10/2015	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2016 Nursing Program: Advancing Oncology Nursing at the NCCN 21st Annual Conference	12/13/2015	\$25,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	16th Targeted Therapy meeting on Lung Cancer	12/13/2015	\$82,500.00
AMERICAN GASTROENTEROLOGICAL ASSOCIATION	Opioid-Induced Constipation: Recognition and Optimal Management	12/13/2015	\$192,601.00
KANAWHA COUNTY EMERGENCY AMBULANCE AUTHORITY	Mobile Integrated Health Program: Emphasis on Community Paramedicine	12/14/2015	\$50,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	PDL1 Atlas	12/14/2015	\$120,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2016 Conquer Cancer Foundation of the American Society of Clinical Oncology Mission Endowment	12/15/2015	\$500,000.00

Organization	Program Title	Date	Amount
CATAMOUNT MEDICAL EDUCATION, LLC	PatientGPS : Clinical Paths in the Management of Patients with COPD	12/16/2015	\$74,841.86
AMERICAN PHARMACISTS ASSOCIATION	APhA 2016 Hot Topics in Dyslipidemia	12/16/2015	\$20,000.00
THE SCRIPPS RESEARCH INSTITUTE	27th Annual Frontiers in Chemistry Symposium at The Scripps Research Institute	12/16/2015	\$1,500.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	Behind the Guidelines: Insights into the Standard of Care in Oncology 2016	12/17/2015	\$10,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2016 Oncology Fellows Program: New Horizons in Quality Cancer Care at the NCCN 21st Annual Conference	12/17/2015	\$25,000.00
NATIONAL LIPID ASSOCIATION	National Lipid Association 2016 Scientific Meeting Series	12/17/2015	\$30,000.00
PEDIATRIC INFECTIOUS DISEASES SOCIETY EDUCATION AND RESEARCH FOUNDATION (PIDSERF)	Pediatric Infectious Diseases Society Fellowship Awards Program	12/20/2015	\$55,000.00
THE VANDERBILT UNIVERSITY	Cardiology 2016: Advances in Science and Practice	12/20/2015	\$5,000.00
FOUNDATION FOR CONTINUING EDUCATION IN THE HEALTH PROFESSIONS	Quality Improvement Education (QIE) Initiative National Training and Education	12/22/2015	\$20,000.00
MARYLAND SOCIETY FOR THE RHEUMATIC DISEASES	Update on Gout and Pseudogout	01/04/2016	\$1,625.00
THE GOG FOUNDATION	5th Semi Annual Meeting of NRG Oncology (formerly GOG, NSABP, RTOG)	01/05/2016	\$20,000.00
CEDARS-SINAI MEDICAL CENTER	The James R. Klinenberg, MD Symposium on Rheumatic Diseases: Hot Topics in Rheumatology	01/05/2016	\$5,000.00
LUNGEVITY FOUNDATION	LUNGeVity Foundation Scientific and Clinical Research Roundtable	01/06/2016	\$25,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	Chronic Total Occlusion Summit 2016	01/07/2016	\$10,000.00
LUMEN FOUNDATION	Lumen Global 2016	01/10/2016	\$35,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	St. Francis Imaging Course 2016	01/10/2016	\$5,000.00
AMERICAN HEART ASSOCIATION, INC.	Epidemiology and Prevention - Lifestyle and Cardiometabolic Health 2016 Scientific Sessions	01/12/2016	\$10,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Beyond Revascularization for CLI-The Role of Pharmacotherapy Satellite Symposium	01/14/2016	\$22,696.65
CARDIOVASCULAR INSTITUTE OF PHILADELPHIA	CVI s 4th Annual Interventional Cardiovascular Medicine: The Crossroads of Interventional and Clinical Cardiology	01/14/2016	\$2,500.00
UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY	Testing to Target in Non-Small Cell Lung Cancer: Managed Care Perspectives	01/19/2016	\$288,885.00
SOCIETY FOR VASCULAR MEDICINE	Society for Vascular Medicine 27th Annual Scientific Sessions	01/20/2016	\$20,000.00
OHIOHEALTH	1st Bi-Annual OhioHealth Acute Cardiovascular Care Conference	01/20/2016	\$2,500.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	Immunotherapy of Cancer for the Workshop on Biomarkers	01/24/2016	\$40,000.00
NORTHEAST GEORGIA MEDICAL CENTER INC	8th Annual Northeast Georgia Regional STEMI Summit	01/25/2016	\$2,500.00
CALIFORNIA THORACIC SOCIETY	COPD: A TEAM APPROACH	01/26/2016	\$5,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	Issues with DAPT: A case-based guide to optimal antiplatelet therapies	01/28/2016	\$50,000.00
GASTROINTESTINAL AND LIVER ASSOCIATION OF THE AMERICAS INC	The 2016 US GI and Liver Association of the Americas (GALA) Conference Series	01/28/2016	\$16,000.00
GORDON RESEARCH CONFERENCES	2016 Lipoprotein Metabolism Gordon Research Conference and Gordon Research Seminar	01/28/2016	\$5,000.00
AMERICAN ACADEMY OF PAIN MEDICINE	AAPM 32nd Annual Meeting 2016	01/31/2016	\$25,000.00
DUKE UNIVERSITY	DCRI Evidence to Practice Series: Interventional Cardiology	02/01/2016	\$10,000.00

Organization	Program Title	Date	Amount
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	ACC s 65th Annual Scientific Session (ACC.16) Acute Coronary Syndromes Clinical Learning Pathway	02/01/2016	\$50,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	LIPID MAPS Meeting: Lipidomics Impact on Metabolic, Cancer, Cardiovascular and Inflammatory Diseases	02/01/2016	\$5,000.00
SCOTTSDALE HEALTHCARE FOUNDATION	2016 Scottsdale Interventional Forum (SIF 2016)	02/02/2016	\$2,500.00
UNIVERSITY OF FLORIDA	Vascular Biology Working Group U.S. Chapter Meeting	02/02/2016	\$15,000.00
EMORY UNIVERSITY	EPIC SEC Emory Practical Intervention Course - Southeast Consortium	02/03/2016	\$20,000.00
THE ENDOCRINE SOCIETY	DMS 2016: Initiating the Conversation: Sharing Perspectives on Advances in T2DM Treatment to Improve Patient-Centered Care	02/07/2016	\$235,318.22
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2016 ASCO Annual Meeting Lung Cancer Track	02/07/2016	\$56,000.00
SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS FOUNDATION	SCAI 2016 Scientific Sessions	02/14/2016	\$25,000.00
SOCIETY OF HOSPITAL MEDICINE	Hospital Medicine 2016	02/14/2016	\$15,000.00
AMERICAN HEAD AND NECK SOCIETY	American Head and Neck Society 9th International Conference on Head and Neck Cancer	02/17/2016	\$50,000.00
GLOBAL EDUCATION GROUP -	Clinical Issues in Type 2 Diabetes: Consensus and Controversies Around Intensifying Noninsulin Therapy.	02/18/2016	\$411,613.00
NYU POST-GRADUATE MEDICAL SCHOOL	Seminar in Advanced Rheumatology	03/01/2016	\$5,000.00
NEW MEXICO THORACIC SOCIETY	44th Annual New Mexico Lung Disease Symposium - 50 Shades of Blue	03/01/2016	\$5,000.00
MEDSTAR WASHINGTON HOSPITAL CENTER	14th International Congress on Targeted Anticancer Therapies	03/01/2016	\$10,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	FASEB Conference on Genome Engineering Cutting-Edge Research and Application	03/01/2016	\$6,000.00
DIVISION OF MEDICINAL CHEMISTRY	Division of Medicinal Chemistry Program 251st ACS National Meeting	03/01/2016	\$2,500.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Personalizing Therapy for Improved Patient Outcomes in the Management of Advanced Non Small-Cell Lung Cancer (NSCLC)	03/01/2016	\$35,000.00
THE AMERICAN THORACIC SOCIETY	ATS 2016 International Conference - Selected Topics in Lung Cancer	03/01/2016	\$20,000.00
THE ASSOCIATION FOR FRONOTOTEMPORAL DEGENERATION	Building an Infrastructure to Support FTLD Therapeutic Development	03/01/2016	\$2,500.00
WASHINGTON ACADEMY OF PHYSICIAN ASSISTANTS	27th Annual Recertification Review Course and Spring Conference	03/01/2016	\$1,750.00
ONCOLOGY NURSING SOCIETY	41st Annual Oncology Nursing Society Congress and Pharmacology Highlights regional program	03/01/2016	\$35,000.00
GORDON RESEARCH CONFERENCES	Chemical Approaches for Unraveling Biology	03/01/2016	\$2,500.00
GORDON RESEARCH CONFERENCE	Medicinal Chemistry Gordon Research Conference	03/01/2016	\$3,000.00
NATIONAL ASSOCIATION OF FREE & CHARITABLE CLINICS	2016 Charitable Health Care Symposium	03/01/2016	\$30,000.00
THE HOPE FOUNDATION	2016 SWOG Group Meetings	03/01/2016	\$10,000.00
HEMATOLOGY/ONCOLOGY PHARMACY ASSOCIATION	2016 Hematology/Oncology PHarmacy Association	03/01/2016	\$25,000.00
MEDICAL LEARNING INSTITUTE INC	New Developments in the Treatment of COPD: Updates From San Francisco (150203884)	03/03/2016	\$65,763.00
AMERICAN NEUROGASTROENTEROLOGY AND MOTILITY SOCIETY	11th Postgraduate Course on GI Motility and Neurogastroenterology in Clinical Practice	03/03/2016	\$10,000.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANT	AAPA Conference 2016 - Allergy/Immunology and Pulmonology Track	03/03/2016	\$5,000.00

Organization	Program Title	Date	Amount
GORDON RESEARCH CONFERENCE	Gordon Research Conference on Cyclic Nucleotide Phosphodiesterases: Mechanisms of PDE Nano-Domain Control and Impacts on Disease	03/07/2016	\$3,000.00
AMERICAN THORACIC SOCIETY	ATS 2016 International Conference - Selected Topics in COPD	03/07/2016	\$70,000.00
MASSACHUSETTS GENERAL HOSPITAL	CoNNCT Workshop (Collaborative Novel-Novel Cancer Therapies)	03/07/2016	\$2,000.00
COLLEGIUM INTERNATIONALE ALLERGOLOGICUM	31st Symposium of the Collegium Internationale Allergologicum	03/08/2016	\$10,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Improving Outcomes in the Management and Treatment of Asthma	03/08/2016	\$25,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Identifying New Strategies to Optimize the Management and Treatment of COPD	03/08/2016	\$25,000.00
NORTHEASTERN SECTION OF THE AMERICAN CHEMICAL SOCIETY, INC.	NESACS Advances in Chemical Sciences Symposium	03/08/2016	\$1,500.00
AMERICAN THORACIC SOCIETY INC	ATS 2016 International Conference - Selected Topics in Asthma	03/08/2016	\$30,000.00
YALE UNIVERSITY	4th Annual Yale COPD Symposium	03/08/2016	\$15,000.00
FLORIDA ALLERGY, ASTHMA & IMMUNOLOGY SOCIETY	Florida Allergy, Asthma & Immunology Society 2016 Annual CME Conference	03/14/2016	\$15,000.00
UNIVERSITY OF CONNECTICUT	Keep your patients "moving" - An Overview of Treatment Options for Constipation	03/14/2016	\$25,000.00
UHS PROFESSIONAL EDUCATIONAL PROGRAMS, INC	32nd Annual Congress of Clinical Rheumatology	03/14/2016	\$10,000.00
NATIONAL KIDNEY FOUNDATION	CKD-Related Anemia and Cardiovascular Risk	03/17/2016	\$100,050.00
UHS-PROFESSIONAL EDUCATION PROGRAMS INC	1st Annual Advances in Pain Care	03/23/2016	\$5,000.00
GORDON RESEARCH CONFERENCE	Gordon Research Conference on Cyclic Nucleotide Phosphodiesterases: Mechanisms of PDE Nano-Domain Control and Impacts on Disease	03/23/2016	\$1,000.00
OUHSC COLLEGE OF MEDICINE OFFICE OF CPD	19th Annual Primary Care Update	03/24/2016	\$1,500.00
TENNESSEE ACADEMY OF PHYSICIAN ASSISTANTS	Spring Fling 2016 - Asthma and COPD	03/27/2016	\$3,000.00
AMERICAN THORACIC SOCIETY INC	ATS 2016 International Conference - Fellow Track Symposium	03/28/2016	\$10,000.00
COLORADO ALLERGY AND ASTHMA SOCIETY	Biologics in the Treatment of Respiratory Disease	03/29/2016	\$3,000.00
BOARD OF REGENTS FOR UNIVERSITY OF NEBRASKA	Updates in Rheumatology: Gout and Hyperuricemia	03/29/2016	\$10,000.00
CANCER RESEARCH INSTITUTE	2016 International Cancer Immunotherapy Conference	04/06/2016	\$50,000.00
AMERICAN PAIN SOCIETY	2016 Pain Care for Primary Care	04/07/2016	\$10,000.00
ALZHEIMER'S ASSOCIATION	2016 Alzheimer's Association Research Roundtable	04/10/2016	\$50,000.00
CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION	Molecular Therapeutics of Cancer Conference 2016	04/10/2016	\$1,500.00
AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS	AAPS Sustaining Sponsorship	04/10/2016	\$50,000.00
DINORA INC.	Lupus 2016	04/10/2016	\$25,000.00
INTERNATIONAL SOCIETY OF PHARMACOMETRICS	American Conference on Pharmacometrics	04/10/2016	\$3,000.00
HOWARD UNIVERSITY HOSPITAL	11th Kenneth Austin Annual Rheumatology Symposium	04/11/2016	\$3,375.00
ECOG RESEARCH AND EDUCATION FOUNDATION	2016 ECOG-ACRIN Spring Group Meeting	04/11/2016	\$5,000.00
AMERICAN HEART ASSOCIATION, INC.	Arteriosclerosis, Thrombosis and Vascular Biology Peripheral Vascular Disease 2016	04/11/2016	\$15,000.00
AMERICAN UROLOGICAL ASSOCIATION EDUCATION & RESEARCH INC	AUA2016 Highlights in Bladder Cancer	04/11/2016	\$25,000.00



Organization	Program Title	Date	Amount
NATIONAL KIDNEY FOUNDATION	National Kidney Foundation s Ninth Annual Mid-Atlantic First Year Renal Fellows Symposium	04/11/2016	\$5,000.00
THOMAS JEFFERSON UNIVERSITY	5th Annual Palliative Care Spring Symposium	04/11/2016	\$3,000.00
COLUMBUS NCORP	2016 ASCO REVIEW	04/12/2016	\$2,000.00
ALZHEIMER'S ASSOCIATION	2016 Alzheimer's Association International Conference	04/12/2016	\$45,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	2016-2017 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	04/12/2016	\$49,008.06
WASHINGTON UNIVERSITY	Advances in Lung Cancer	04/13/2016	\$3,000.00
TRANSLATIONAL RESEARCH IN ONCOLOGY-US, INC.	TRIO-US & UCLA Annual Research Conference	04/14/2016	\$3,000.00
YALE UNIVERSITY	Yale ASCO Review 2016	04/17/2016	\$2,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC 31st Annual Meeting	04/17/2016	\$300,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2016 Primer on Tumor Immunology and Cancer Immunotherapy	04/17/2016	\$50,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC Fellowship/Young Investigator Award	04/18/2016	\$43,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	ASTRO 2016 58th Annual Meeting	04/18/2016	\$10,000.00
NORTHWESTERN UNIVERSITY	18th Annual Lynn Sage Breast Cancer Symposium	04/18/2016	\$10,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	GAIN (EnGAging an Inter-Disciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment)	04/19/2016	\$500,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	11th Biennial Ovarian Cancer Research Symposium	04/21/2016	\$10,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	14th Annual World Congress on Insulin Resistance Diabetes and Cardiovascular Disease -WCIRDC	04/21/2016	\$75,000.00
C-CHANGE	Catalyzing Change in Big Data and Value in Cancer Care	04/24/2016	\$50,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2016 ASCO Pre-Annual Meeting Seminar: How to Integrate Tumor Immunotherapy into Your Clinical Practice	04/24/2016	\$5,000.00
UNIVERSITY OF FLORIDA FOUNDATION INC	Southern Salt, Water, and Kidney Club 57th Annual Scientific Meeting	04/24/2016	\$3,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2016 Best of ASCO Meetings	04/24/2016	\$30,000.00
AMERICAN SOCIETY FOR PAIN MANAGEMENT NURSING	ASPMN 26th National Conference	04/24/2016	\$15,000.00
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO SOM	American Society of Clinical Oncology (ASCO) 2016 Review	04/24/2016	\$2,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	ASCO Review	04/25/2016	\$2,000.00
DUKE UNIVERSITY	15th Annual Southeastern Fellows Research Skills & Training Workshop	04/27/2016	\$10,000.00
CEDARS-SINAI MEDICAL CENTER	2nd Annual Acing the GI Board Exam: The Ultimate High-Speed Review Course	05/02/2016	\$5,000.00
AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.	Harnessing the Body's Immune System to Treat Cancer: the Promise of Immunotherapy	05/03/2016	\$220,000.00
AMERICAN HEART ASSOCIATION, INC.	Scientific Sessions 2016 Dedicated Track on Acute Coronary Syndromes	05/03/2016	\$35,000.00
INTERNATIONAL SOCIETY OF NEPHROLOGY	ISN Global Kidney Health Summit	05/04/2016	\$30,000.00
NORTHEASTERN UNIVERSITY	Boston Symposium on Organic and Bioorganic Chemistry (BSOBC)	05/04/2016	\$2,500.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	11th Biennial Ovarian Cancer Research Symposium,	05/04/2016	\$15,000.00
WORLD ALLERGY ORGANIZATION	WAO International Scientific Conference 2016: Travel Grants	05/09/2016	\$30,000.00

Organization	Program Title	Date	Amount
THE GOG FOUNDATION	6th Semi Annual Meeting of NRG Oncology (formerly GOG, NSABP, RTOG)	05/10/2016	\$5,000.00
AMERICAN ASSOCIATION OF PHYSICIANS OF INDIAN ORIGIN (AAPI)	Cardiovascular Seminar	05/10/2016	\$5,000.00
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	Cardiovascular Disease Track at ACEP 2016 Scientific Assembly	05/12/2016	\$20,000.00
AMERICAN SOCIETY OF NEPHROLOGY	Expanding the Therapeutic Armamentarium for Treatment of Anemia of Kidney Disease	05/15/2016	\$190,000.00
BLADDER CANCER ADVOCACY NETWORK	2016 Bladder Cancer Think Tank	05/15/2016	\$25,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	2016 PCNA Fall Learning Series: Diabetes & CVD: Managing Patients with High-Risk and Co-Morbid Conditions	05/16/2016	\$5,000.00
ASSOCIATION OF AMERICAN CANCER INSTITUTES	2016 AACI/CCAF Annual Meeting	05/18/2016	\$10,000.00
UNIVERSIDAD CENTRAL DEL CARIBE, INC.	Role of the Multidisciplinary Care Team in Personalizing Treatment for Non-Small Cell Lung Cancer: Addressing Tissue Acquisition, Diagnosis, and Perso	05/19/2016	\$2,000.00
THE LEUKEMIA & LYMPHOMA SOCIETY, INC.	2016 Waldenstrom's Roadmap Symposium	05/24/2016	\$3,000.00
AMERICAN SOCIETY OF HEMATOLOGY	ASH Scholar Award	05/25/2016	\$50,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Conference on Tumor Immunology and Immunotherapy	05/25/2016	\$35,000.00
SCRIPPS HEALTH	13th Annual Oncology Update	05/26/2016	\$2,000.00
DANA FARBER CANCER INSTITUTE	International Workshop on Waldenstroms macroglobulinemia & symposia on Multiple myeloma (IWWM9)	06/02/2016	\$10,000.00
FRIENDS OF CANCER RESEARCH	2016 Friends of Cancer Research Programs	06/05/2016	\$100,000.00
PARTNERS HEALTHCARE SYSTEM, INC	Massachusetts General Hospital Multidisciplinary Breast Rounds	06/08/2016	\$4,771.88
VIVA PHYSICIANS, INC.	VIVA 16: Vascular InterVentional Advances	06/12/2016	\$25,000.00
UNIVERSITY OF COLORADO DENVER, CENTER FOR WOMEN'S HEALTH HEALTH RESEARCH	Sex Differences Across the Lifespan: A Focus on Metabolism	06/16/2016	\$35,000.00
THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	Immunotherapy: Transformation of Therapies for Blood Cancer a satellite symposium held in conjunction with the 2016 ASH Annual Meeting	06/20/2016	\$40,000.00
VIVA PHYSICIANS, INC.	The Blockbuster at VIVA 16	06/21/2016	\$69,100.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	COPD Learning Track	06/22/2016	\$40,000.00
ENDOCRINE FELLOWS FOUNDATION	Third Annual Endocrine Fellows Foundation Research Meeting	06/23/2016	\$278,000.00
AMERICAN CANCER SOCIETY INC	American Cancer Society Post-Doctoral Research Fellowship Program	06/30/2016	\$163,500.00
AMERICAN COLLEGE OF OSTEOPATHIC INTERNISTS, INC	Breathing New Air into the Treatment of COPD and Asthma	07/03/2016	\$10,000.00
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO SCHOOL OF MEDICINE- OFFICE OF CME	39th Annual San Antonio Breast Cancer Symposium	07/03/2016	\$75,000.00
NATIONAL JEWISH HEALTH	Evaluation and Treatment of Severe Asthma: The Role of Biologic and Directed Therapies	07/04/2016	\$94,011.50
NATIONAL MEDICAL ASSOCIATION	Chronic Obstructive Pulmonary Disease Interdisciplinary Diagnostic and Treatment Symposium	07/04/2016	\$150,000.00
GORDON RESEARCH CONFERENCE	Gordon Research Seminar in Microbial Toxins and Pathogenesis	07/10/2016	\$1,440.00
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY	34th Annual Aspen Allergy Conference	07/13/2016	\$5,200.00
GORDON RESEARCH CONFERENCE	2016 Protein Processing Trafficking & Secretion	07/13/2016	\$5,000.00

Organization	Program Title	Date	Amount
SOCIETY FOR IMMUNOTHERAPY OF CANCER	New Cancer Immunotherapy Agents in Development	07/14/2016	\$35,000.00
AMINISTRATORS OF THE TULANE EDUCATIONAL FUND	16th Annual SSCI Nephrology Young Investigators' Forum	07/14/2016	\$49,939.06
NEW YORK ACADEMY OF SCIENCES	Targeting Inflammation and Podocytopathy in Chronic Kidney Disease	07/18/2016	\$15,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC 2016 Workshop on Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy	07/19/2016	\$150,000.00
MASSACHUSETTS GENERAL HOSPITAL	31th Annual Critical Issues In Tumor Microenvironment: Angiogenesis, Metastasis and Immunology	07/21/2016	\$10,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	Transcatheter Cardiovascular Therapeutics (TCT) 2016	07/21/2016	\$10,000.00
PEPTIDE THERAPEUTICS FOUNDATION	11th Annual Peptide Therapeutics Symposium	07/26/2016	\$15,000.00
AMERICAN SOCIETY OF NEPHROLOGY	ASN Kidney Week - CKD Learning Pathway Support	07/27/2016	\$20,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR DNA Repair: Tumor Development and Therapeutic Response	07/31/2016	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK INC.	NCCN 2016 Congress Series : Immunotherapies in Cancer	08/01/2016	\$50,000.00
CEDARS SINAI MEDICAL CENTER	Pancreatic Cancer Conference	08/03/2016	\$3,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK INC	NCCN 2016 Congress Series : Utilizing Guidelines to Customize Patient Care in Non-Small Cell Lung Cancer	08/04/2016	\$25,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	Managing Severe Asthma in Adults and Children Workshop	08/04/2016	\$12,500.00
ILLINOIS ACADEMY OF FAMILY PHYSICIANS	Tenth Annual Family Medicine Chief Residents 2016 Summit: Intensifying Diabetes Management	08/07/2016	\$54,768.91
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	Advanced Non-Small Cell Lung Cancer Patient Management Simulator	08/10/2016	\$100,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE 2016 Balance of Evidence: Considering the Clinical Impact of Newer Antihyperglycemic Agents for the Treatment of Type 2 Diabetes	08/11/2016	\$233,374.80
HOUSTON METHODIST HOSPITAL	4th Annual Houston Methodist Cancer Symposium	08/11/2016	\$3,000.00
THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES	AASLD/EASL HBV Treatment Endpoints Workshop	08/14/2016	\$3,000.00
ASTHMA & ALLERGY FOUNDATION OF AMERICA, ALASKA CHAPTER	Wheezin', Sneezin' & Itchin' in Alaska	08/15/2016	\$5,000.00
DANA-FARBER CANCER INSTITUTE INC	Dana-Farber Cancer Institute's 12 th Annual Postdoctoral and Graduate Student Retreat	08/15/2016	\$2,500.00
GLOBAL VIRUS NETWORK INC	3rd Annual Short Course for emerging leaders in Medical Virology of the Global Virus Network	08/16/2016	\$5,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	Eastern Pulmonary Conference 2016	08/21/2016	\$8,000.00
CURATORS OF THE UNIVERSITY OF MISSOURI	2017 Midwest Nephrology Fellows Research Day	08/25/2016	\$35,260.00
GORDON RESEARCH CONFERENCES	Mammalian DNA Repair Gordon Research Conference and Seminar	08/25/2016	\$2,000.00
NATIONAL JEWISH HEALTH	The 21st Annual Regional Allied Health Conference: Current Perspectives in Asthma, Allergy and Pulmonary Practice	08/28/2016	\$3,000.00
LUNGEVITY FOUNDATION	LUNGeVity Foundation Science and Clinical Research Roundtable, Part II	08/28/2016	\$25,000.00
REGENT OF THE UNIVERSITY OF CALIFORNIA	14th Annual Nephrology Young Investigator s Forum	08/29/2016	\$49,509.01
UNIVERSITY OF MARYLAND BALTIMORE FOUNDATION, INC.	18th Annual International Meeting of the Institute of Human Virology	09/01/2016	\$5,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC 17th Wolrd Conference on Lung Cancer - International Mentorship Awards	09/04/2016	\$82,500.00

Organization	Program Title	Date	Amount
USF HEALTH PROFESSIONS CONFERENCING CORPORATION	Update in Allergy and Immunology 2016 Symposium & Rhinolarngoscopy Hands-On Workshop	09/07/2016	\$3,000.00
UNIVERSITY OF NEW MEXICO	Update and Review of Internal Medicine	09/07/2016	\$2,500.00
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	GI Motility and Functional GI Disease: Evidence vs. Consensus	09/08/2016	\$1,500.00
AMERICAN COLLEGE OF TOXICOLOGY	ACT's 37th Annual Meeting	09/08/2016	\$5,000.00
PERSONALIZED MEDICINE COALITION	12th Annual Personalized Medicine Conference	09/11/2016	\$5,000.00
UNIVERSITY OF SOUTHERN CALIFORNIA	1st Annual Southern California Kidney Symposium: "Slowing the Progression of Kidney Disease: From Bench to Bedside"	09/13/2016	\$5,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Optimizing Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC): Integrating Novel Personalized Therapy into the Treatment Paradigm	09/21/2016	\$35,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	2016 JADPRO Live at APSHO	09/22/2016	\$100,000.00
PARTNERS HEALTHCARE SYSTEM, INC.	Massachusetts General Hospital Multidisciplinary Breast Rounds 2016-2017	09/22/2016	\$5,000.00
UNIVERSITY OF FLORIDA	Vascular Biology Working Group Global Chapter Meeting	09/22/2016	\$7,800.00
JOHNS HOPKINS UNIVERSITY	Allergy Grand Rounds	09/25/2016	\$2,846.55
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Fellowship in Ovarian Cancer Research	09/25/2016	\$126,500.00
PHARMACY QUALITY ALLIANCE (PQA, INC)	PQA Leadership Summit 2016 The I's Have It! Insights into Innovations, Integration and Implementation Strategies for Medication Use Measurement	09/25/2016	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK INC	NCCN 2017 Congress Series : Breast Cancer with Updates from the 2016 San Antonio Breast Cancer Symposium	09/27/2016	\$25,000.00
THE SCRIPPS RESEARCH INSTITUTE	28th Annual Frontiers in Chemistry Symposium	09/27/2016	\$1,500.00
THE GOG FOUNDATION INC	7th Semi Annual Meeting of NRG Oncology (formerly; GOG, NSABP, RTOG)	09/28/2016	\$20,000.00
International Federation of Head and Neck Oncologic Societies	Global CME program of IFHNOS	09/28/2016	\$25,000.00
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY	PICI Cancer Immunotherapy Workshops	09/28/2016	\$30,000.00
SOCIEDAD PUERTORRIQUE A DE ENDOCRINOLOG A Y DIABETOLOGIA	Endocrinology Now and Then SPED s 40th Anniversary	10/02/2016	\$5,000.00
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	Cancer Genetics: Finding Meaning in Tumor and Germline Genomes	10/03/2016	\$5,000.00
NATIONAL KIDNEY FOUNDATION	12th Annual National Young Investigator's Forum	10/03/2016	\$50,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	The Fourth International Conference on Cancer and the Heart	10/05/2016	\$5,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy	10/05/2016	\$25,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	14th Annual World Congress on Insulin Resistance Diabetes and Cardiovascular Disease (WCIRDC)	10/05/2016	\$25,000.00
CEDARS-SINAI MEDICAL CENTER	5th Annual New Therapeutics in Oncology: The Road to Personalized Medicine	10/06/2016	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK INC	Behind the Guidelines: Insights into the Standard of Care in Oncology 2017	10/06/2016	\$25,000.00
NATIONAL KIDNEY FOUNDATION INC	Chronic Kidney Disease and Cardiovascular Disease: Best Practices to Improve Outcomes	10/06/2016	\$139,980.00

Organization	Program Title	Date	Amount
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	Fall 2016 ECOG-ACRIN Group Meeting	10/09/2016	\$5,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC 17th World Conference on Lung Cancer	10/09/2016	\$170,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 Conquer Cancer Foundation of ASCO Merit Awards	10/10/2016	\$40,000.00
PARTERS HEALTHCARE SYSTEM, INC	Massachusetts General Hospital Cancer Center Grand Rounds	10/10/2016	\$5,000.00
UNIVERSIDAD CENTRAL DEL CARIBE, INC.	Redefining Cancer Treatment Paradigms in Non-Small Cell Lung Cancer.	10/11/2016	\$5,000.00
RUSH UNIVERSITY MEDICAL CENTER	Expert Insights and Key Nursing Considerations: Treating and Caring for Patients with Lung Cancer	10/18/2016	\$5,000.00
GLOBAL EDUCATION GROUP	GOLD COPD: Continuum of Care	10/18/2016	\$75,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™	10/18/2016	\$100,000.00
SOCIETY FOR TRANSLATIONAL ONCOLOGY	2016 Chabner Colloquium: Answering the Big Questions in Cancer Research	10/19/2016	\$10,000.00
HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION	2017 Hematology Oncology Pharmacy Association q	10/26/2016	\$27,500.00
INTERNATIONAL EOSINOPHIL SOCIETY, INC.	10th Biennial Symposium	10/27/2016	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 ASCO-SITC Clinical Immuno-Oncology Symposium Proceedings	11/03/2016	\$13,750.00
MEDSTAR GEORGETOWN UNIVERSITY HOSPITAL	LUNG CANCER 2016: Progress and Future Directions	11/03/2016	\$5,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS INC	18th Annual Intensive Course on Diabetes, Endocrinology, and Metabolic Diseases	11/03/2016	\$15,000.00
GORDON RESEARCH CONFERENCES	Mammalian DNA Repair Gordon Research Conference and Seminar	11/03/2016	\$3,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Fellowships in Lung Cancer Research	11/08/2016	\$73,238.00
PENN STATE UNIVERSITY	Cases from the Community: Investigator Perspectives on Emerging Research & Patients with Advanced Prostate Cancer: A 2017 GU Cancers Symposium ISS	11/08/2016	\$30,000.00
KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY	Genomic Instability and DNA Repair	11/08/2016	\$5,000.00
RENAL PHYSICIANS ASSOCIATION	RPA 2017 Annual Meeting	11/10/2016	\$25,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Fellowships in Immuno-oncology Research	11/13/2016	\$253,000.00
WINGATE UNIVERSITY SCHOOL OF PHARMACY	AmCare Pharmacy Forum of North Carolina	11/21/2016	\$500.00
SOCIETY FOR NEURO-ONCOLOGY	21st Annual Meeting of the Society for Neuro-Oncology	11/28/2016	\$26,000.00
LYMPHOMA RESEARCH FOUNDATION	Lymphoma Research Foundation Postdoctoral Fellowship Grant Program	12/01/2016	\$105,000.00
UNIVERSITY OF NEBRASKA MEDICAL CENTER	PARP INHIBITION IN OVARIAN CANCER: INTEGRATING BASIC SCIENCE, CLINICAL DATA, AND THE PATIENT VOICE TO ENHANCE CARE	12/01/2016	\$45,000.00
KEYSTONE SYMPOSIA	2017 Keystone Symposia Directors' Fund	12/01/2016	\$25,000.00
BOSTON UNIVERSITY SCHOOL OF MEDICINE - OFFICE OF CME	Are You Asking the Question? Strategies for Engaging the Patient in the Diagnosis and Management of Opioid-Induced Constipation	12/04/2016	\$149,275.00
GLOBAL EDUCATION GROUP	Comprehensive Pain Management in Palliative Care: Relieving the Burden of Opioid-Induced Constipation	12/04/2016	\$324,107.00

Organization	Program Title	Date	Amount
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 Conquer Cancer Foundation of the American Society of Clinical Oncology Mission Endowment	12/04/2016	\$500,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH SOCIETY OF GYNECOLOGIC ONCOLOGY	AACR Annual Meeting- 2017 Clinical Management of New Biologics and Immunotherapies in Gynecologic Oncology	12/04/2016 12/04/2016	\$150,000.00 \$50,000.00
SOCIETY OF GYNECOLOGIC ONCOLOGY	Genetic Counseling in Gynecologic Oncology: What Advanced Practitioners Need to Know	12/04/2016	\$210,575.00
JOHNS HOPKINS DIVISION OF NEPHROLOGY	Mid-Atlantic Nephrology Young Investigators Forum	12/04/2016	\$50,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	EGFR Atlas	12/04/2016	\$380,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	2017 IASLC WCLC Association-Satellite Fee	12/04/2016	\$150,000.00
FRIENDS OF CANCER RESERACH	2017 Friends of Cancer Research Programs	12/04/2016	\$100,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	2017 Oncologic Emergency Medicine Conference	12/06/2016	\$5,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 Genitourinary (GU) Cancers Symposium: Translating Research to Value-Based and Patient-Centric Care	12/08/2016	\$50,000.00
ALZHEIMER'S ASSOCIATION	2017 Alzheimer's Association Research Roundtable	12/08/2016	\$50,000.00
ALZHEIMER'S ASSOCIATION	2017 Alzheimer's Association International Conference	12/08/2016	\$45,000.00
CANCER RESEARCH INSTITUTE	Cancer Research Institute's Irvington Postdoctoral Fellowship Program	12/11/2016	\$50,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 ASCO-SITC Clinical Immuno-Oncology Symposium	12/11/2016	\$60,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 11th Annual Congress: Hematologic Malignancies™	12/12/2016	\$15,000.00
INTERNATIONAL SOCIETY OF NEPHROLOGY	ISN World Congress of Nephrology 2017 - WCN 2017	12/12/2016	\$130,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE 26th Annual Scientific & Clinical Congress - Diabetes Session	12/12/2016	\$50,000.00
NATIONAL KIDNEY FOUNDATION INC	National Kidney Foundation s Tenth Annual Mid-Atlantic First Year Renal Fellows Symposium	12/12/2016	\$5,000.00
THE ENDOCRINE SOCIETY	Diabetes Masters Series 2017: Negotiating the Therapeutic Terrain: Steps to Identifying Individualized Treatment Approaches for Patients With T2DM	12/13/2016	\$50,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	Making the Connection between Patients & Providers: A Modern Approach to the Treatment of Type 1 and Type 2 Diabetes	12/14/2016	\$50,000.00
THE NEW YORK ACADEMY OF SCIENCES	Cancer Immunotherapy: Frontiers in Cancer Immunotherapy and Quantitative Approaches in Immuno-Oncology	12/14/2016	\$20,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES	44th Annual Family Medicine Reffresher Course"	12/19/2016	\$2,792.00
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	Rutgers Pharmaceutical Industry Fellowship Program	12/19/2016	\$61,728.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA)	12/21/2016	\$192,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care at the NCCN 22nd Annual Conference	12/21/2016	\$35,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	1st Annual Heart in Diabetes	12/21/2016	\$100,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC 17th World Conference on Lung Cancer	12/21/2016	\$92,500.00

Organization	Program Title	Date	Amount
PRIMARY CARE EDUCATION CONSORTIUM	11th Annual Chief Residents Summit on Intensifying Diabetes Management	12/21/2016	\$50,000.00
AMERICAN NEPHROLOGY NURSES ASSOCIATION	ANNA 2017 National Symposium	12/21/2016	\$20,000.00
NATIONAL ASSOCIATION OF FREE & CHARITABLE CLINICS	2017 Charitable Health Care Symposium	12/21/2016	\$30,000.00
AMERICAN SOCIETY OF NEPHROLOGY	ASN Kidney Week Educational Session Support	12/21/2016	\$37,500.00
AMERICAN SOCIETY OF NEPHROLOGY	ASN Kidney Week Early Program Support	12/21/2016	\$15,000.00
AMERICAN SOCIETY OF NEPHROLOGY	ASN Select Streamed Session Support	12/21/2016	\$20,000.00
AMERICAN UROLOGICAL ASSOCIATION EDUCATION & RESEARCH INC	Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer	12/27/2016	\$100,000.00
AMERICAN SOCIETY OF HEMATOLOGY	2016 American Society of Hematology Annual Meeting	01/04/2017	\$150,000.00
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	Severe Asthma: Clinical Phenotypes and the Emerging Age of Personalized Therapy	01/04/2017	\$225,000.00
TRUSTEES OF BOSTON UNIVERSITY	A Better Life for Your Severe Asthma Patients: Targeted Therapies for Fewer Exacerbations	01/05/2017	\$100,000.00
NATIONAL JEWISH HEALTH	Personalized Medicine in Severe Asthma: Applying Emerging Data and Treatments to Everyday Clinical Practice	01/06/2017	\$345,500.00
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY	Streamlining Toxicity Management Guidelines	01/18/2017	\$60,000.00
FLORIDA ALLERGY, ASTHMA & IMMUNOLOGY SOCIETY	FAAIS 2017 Annual CME Conference	01/25/2017	\$20,000.00
NYU POST-GRADUATE MEDICAL SCHOOL	Asthma, Airways and Environment	01/26/2017	\$20,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Preventing Acute Exacerbations through Novel Insights in Treatment Strategies for COPD	01/29/2017	\$15,000.00
NATIONAL JEWISH HEALTH	39th Annual National Jewish Health Pulmonary and Allergy Update	01/29/2017	\$20,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	Best of World Conference on Lung Cancer	01/29/2017	\$20,000.00
YALE UNIVERSITY	Severe Asthma 2016: A Personalized Approach To Treatment	02/01/2017	\$16,300.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	2017 Multidisciplinary Thoracic Cancers Symposium	02/01/2017	\$50,000.00
NATIONAL MEDICAL ASSOCIATION	Implementing the New GOLD Guidelines: Interdisciplinary Management of Chronic Obstructive Pulmonary Disease as a Chronic Disease	02/01/2017	\$75,000.00
CARDIOVASCULAR INNOVATIONS FOUNDATION	Cardiovascular Innovations 2017	02/01/2017	\$25,000.00
AMERICAN THORACIC SOCIETY INC	ATS 2017 International Conference - Selected Topics in COPD	02/01/2017	\$70,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	23rd Annual Interventional Cardiology Fellows Course	02/01/2017	\$10,000.00
NATIONAL JEWISH HEALTH	13th Annual Respiratory Disease Young Investigators Forum	02/01/2017	\$283,830.79
WASHINGTON HOSPITAL CENTER CORPORATION	Cardiovascular Research Technologies	02/02/2017	\$30,000.00
CONNECTICUT PHARMACISTS ASSOCIATION	Breathe Easy: An Overview of Inhalers for the Management of Asthma and COPD	02/02/2017	\$2,000.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, INC.	AAPA 2017 - Allergy/Immunology and Pulmonology Tracks	02/06/2017	\$7,500.00
NATIONAL COMPREHENSIVE CANCER NETWORK	Immuno-Oncology Therapeutics for Renal Cell Carcinoma and Bladder Cancer: Integrating the Latest Developments Into Clinical Practice	02/07/2017	\$75,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Annual Meeting- 2017	02/09/2017	\$100,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 Conquer Cancer Foundation of ASCO Career Development Award	02/12/2017	\$253,000.00
NYU POST-GRADUATE MEDICAL SCHOOL	NYU Seminar in Advanced Rheumatology	02/13/2017	\$10,000.00

Organization	Program Title	Date	Amount
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	Cardio Renal Connections- 2nd Annual Cardio-Renal Conference 2017	02/14/2017	\$2,500.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	Translational Research Cancer Centers Consortium	02/14/2017	\$2,500.00
AMERICAN HEAD AND NECK SOCIETY	AHNS 2017 Annual Meeting	02/14/2017	\$25,000.00
GORDON RESEARCH CONFERENCES	Gordon Research Conference on Drug Metabolism	02/15/2017	\$2,500.00
NATIONAL JEWISH HEALTH	COPD Now: Applying New Guidelines and Effective Strategies in Diagnosis, Treatment and Management to Everyday Practice	02/15/2017	\$199,618.33
HUMBOLDT-DEL NORTE CONSORTIUM FOR CME	COPD	02/15/2017	\$2,100.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 ASCO Annual Meeting Lung Cancer Track	02/15/2017	\$84,000.00
GORDON RESEARCH CONFERENCES	Model Systems, Emerging Technologies and Precision Medicine in Arrhythmia Research and Therapeutic Development	02/15/2017	\$5,000.00
ST. JOSEPH'S REGIONAL MEDICAL CENTER	Acute Coronary Syndrome	02/15/2017	\$4,200.00
AMERICAN CHEMICAL SOCIETY DIVISION OF MEDICINAL CHEMISTRY	Division of Medicinal Chemistry Program 253rd ACS National Meeting	02/16/2017	\$3,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2017 Advances in Cancer Immunotherapy Series	02/16/2017	\$500,000.00
UNIVERSITY OF FLORIDA	Vascular Biology Working Group US Chapter Meeting	02/16/2017	\$5,000.00
CALIFORNIA ACADEMY OF PHYSICIAN ASSISTANTS	Addressing the Needs of the ACS Patient	02/16/2017	\$3,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	DAPT Dilemmas: A Case-based Roundtable Tutorial	02/19/2017	\$10,000.00
INDIANA ACADEMY OF FAMILY PHYSICIANS	Managing Severe Asthma in the Family Physician's Office	02/19/2017	\$3,921.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	The Emerging Role of Molecular Testing in an Era of Precision Medicine - NSCLC	02/19/2017	\$188,600.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	The Emerging Role of Molecular Testing in an Era of Precision Medicine - Ovarian Cancer	02/19/2017	\$188,600.00
SCRIPPS HEALTH	Scripps 37th Annual Conference: Clinical Hematology and Oncology 2017	02/20/2017	\$5,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	The Great K Debate Continues: Updates and Controversies in Heart Failure Management	2/21/2017	\$100,000.00
GORDON RESEARCH CONFERENCES	2017 Gordon Conference on Medicinal Chemistry	02/22/2017	\$2,500.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	17th Annual Targeted Therapies of lung Cancer Meeting	02/22/2017	\$33,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AHNS Head and Neck Cancer Conference:	02/22/2017	\$25,000.00
ASTHMA & ALLERGY FOUNDATION OF AMERICA, ALASKA CHAPTER	Wheezin', Sneezin' & Itchin' in Alaska	02/22/2017	\$5,000.00
FASEB SCIENCE RESEARCH CONFERENCES	FASEB Autoimmunity	02/22/2017	\$5,000.00
FEDERATION OF CLINICAL IMMUNOLOGY SOCIETIES INC	Federation of Clinical Immunology Societies Annual Meeting	02/23/2017	\$15,000.00
THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	Biennial International Workshop on Chronic Lymphocytic Leukemia (XVII iwCLL 2017)	03/02/2017	\$50,000.00
NATIONAL KIDNEY FOUNDATION, INC.	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease: A Scientific Workshop Sponsored by the National Kidney Foundation, European Medicines Agency and the US Food and Drug Administration	03/02/2017	\$50,000.00



Organization	Program Title	Date	Amount
AMERICAN RESPIRATORY CARE FOUNDATION	56th RESPIRATORY CARE Journal Conference Respiratory Medications for COPD and Adult Asthma: Pharmacologic Actions to Clinical Applications	03/05/2017	\$18,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	ACAAI member publication - AllergyWatch	03/05/2017	\$40,000.00
GORDON RESEARCH CONFERENCE	The Enduring Potential of Heterocycles as Synthetic Targets, Cellular Probes, and Drug Candidates	03/05/2017	\$2,500.00
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	35th Carl M. Pearson Memorial Symposium Frontiers of Rheumatology	03/06/2017	\$10,000.00
GORDON RESEARCH CONFERENCES - STAPHYLOCOCCAL DISEASES	Staphylococcal Gordon Research Conference	03/06/2017	\$5,000.00
COLD SPRING HARBOR LABORATORY	Cell Death	03/07/2017	\$2,500.00
CEDARS-SINAI MEDICAL CENTER	Lupus: What's Next? Examining Mechanisms, Monitoring, and Medication Updates	03/08/2017	\$334,625.00
AMERICAN THORACIC SOCIETY	ATS 2017 Fellows Track Symposium	03/09/2017	\$20,000.00
BOSTON UNIVERSITY SCHOOL OF MEDICINE, CME	EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE: Severity Assessment, Guidelines, and New Therapy Options	03/11/2017	\$100,000.00
PENNSYLVANIA STATE UNIVERSITY	Innovations in Allergy, Asthma and Immunology Management	03/12/2017	\$2,500.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)	IASLC SCLC workshop	03/14/2017	\$25,000.00
TRUSTEES OF BOSTON UNIVERSITY	A Better Life for Your Severe Asthma Patients: Targeted Therapies for Fewer Exacerbations	03/14/2017	\$321,485.44
REGENTS OF THE UNIVERSITY OF MICHIGAN	Clostrpath 10 Support	03/16/2017	\$5,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	Asthma Fellows Conference	03/20/2017	\$5,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	Multidisciplinary Management Of Severe Asthma: It Takes A Village	03/20/2017	\$24,354.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	Asthma Learning Track - CHEST 2017	03/21/2017	\$79,573.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	COPD Learning Track	03/22/2017	\$73,765.00
THOMAS JEFFERSON UNIVERSITY	10th Annual Young Investigators Forum	03/26/2017	\$11,000.00
FLORIDA ACADEMY OF PHYSICIAN ASSISTANTS INC	Diagnoses and treatment for Acute coronary syndrome	03/27/2017	\$8,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC's Toxicity Management Workshop	03/27/2017	\$50,000.00
HOUSTON METHODIST HOSPITAL	Cardiology for the Non-Cardiologist	03/27/2017	\$8,000.00
WEST PENN ALLEGHENY HEALTH SYSTEM INC	Cardiovascular Medicine Update	03/28/2017	\$3,000.00
AMERICAN COLLEGE OF CARDIOLOGY PUERTO RICO CHAPTER	28th Annual Meeting of the ACC Puerto Rico Chapter	03/29/2017	\$5,000.00
HOWARD UNIVERSITY	The Kenneth Austin 12th Annual Rheumatology Symposium at Howard University Hospital	03/30/2017	\$2,500.00
AMERICAN RADIUM SOCIETY	99th Annual Meeting of the American Radium Society	04/02/2017	\$10,000.00
TENNESSEE ACADEMY OF PHYSICIAN ASSISTANTS	Spring Fling 2017: Optimizing Outcomes in Patients with Opioid Induced Constipation	04/03/2017	\$2,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Navigating a Complex Treatment Landscape in Advanced Non-Small Cell Lung Cancer (NSCLC): Individualizing Therapy for Improved Patient Outcomes	04/04/2017	\$35,000.00

Organization	Program Title	Date	Amount
MEDICAL LEARNING INSTITUTE INC	Improving the Physical and Mental Well-Being of Patients With COPD: Integrating Pharmacotherapy With Pulmonary Rehabilitation and Self-Management	04/06/2017	\$149,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS INC	UPDATES ABOUT! Latest and Greatest in Practical Application of Cardiovascular Outcomes for Diabetes Drugs	04/06/2017	\$374,606.00
GLOBAL EDUCATION GROUP	Overcoming Challenges in Cancer Pain Management: Engaging With Patients About Opioid-Induced Constipation	04/06/2017	\$289,267.50
AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS	AAPS Sustaining Sponsorship	04/09/2017	\$50,000.00
THE UNIVERSITY OF CHICAGO CENTER FOR CONTINUING MEDICAL EDUCATION	14th International Ultmann Chicago Lymphoma Symposium	04/10/2017	\$10,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Hematologic Malignancies:	04/10/2017	\$25,000.00
THE HOPE FOUNDATION	2017 SWOG Group Meetings	04/11/2017	\$10,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	2017 PCNA FALL Regional Education Programs: Cardiometabolics: Focus on New Medications and Risk Reduction Benefits and Protection	04/11/2017	\$25,000.00
EMORY UNIVERSITY SCHOOL OF MEDICINE	Updates in the Management of Head and Neck Cancer	04/12/2017	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK INC	NCCN 2017 Congress Series : Lung Cancer	04/16/2017	\$50,000.00
ONCOLOGY NURSING SOCIETY	42nd Annual ONS Congress and Oncology Updates Regional Meetings	04/16/2017	\$50,000.00
SWEDISH MEDICAL CENTER FOUNDATION	Annual Oncology Symposium: Innovations in Gynecologic Cancer Care - Prevention to Survivorship	04/16/2017	\$5,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Master Class for Oncologists - Breast Cancer Track	04/18/2017	\$10,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Master Class for Oncologist - Genitourinary Cancers Track	04/18/2017	\$10,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Oral Oncolytics Adherence Resource Center: An Educational Platform for Advanced Practitioners in Oncology	04/18/2017	\$50,000.00
BLADDER CANCER ADVOCACY NETWORK	2017 Bladder Cancer Think Tank	04/18/2017	\$35,000.00
SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS	SCAI 2017 Scientific Sessions	04/23/2017	\$50,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	BRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer	04/23/2017	\$20,000.00
CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION	Molecular Therapeutics of Cancer Research Conference 2017	04/24/2017	\$2,000.00
YALE UNIVERSITY	2017 Lung SPORE Workshop	04/24/2017	\$30,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	ECOG-ACRIN Spring 2017 Group Meeting	04/24/2017	\$5,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Hormone Receptor-Positive Advanced Breast Cancer: Challenges & New Treatment Options	04/25/2017	\$20,111.61
INTERNATIONAL THYROID ONCOLOGY GROUP	2017 ITOG Annual Meeting	04/25/2017	\$5,000.00
COLUMBIA UNIVERSITY DEPARTMENT OF SURGERY	Breast Cancer Management 2017	04/25/2017	\$3,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	2017 Cleveland Breast Cancer Summit: Collaborating For A Cure	04/26/2017	\$5,000.00
DUKE UNIVERSITY	16th Annual Southeastern Fellows Research Skills & Training Workshop	04/27/2017	\$10,000.00
YALE UNIVERSITY	Yale ASCO Review 2017	05/01/2017	\$5,000.00
MEDICAL LEARNING INSTITUTE INC	Acute Management of Immune-Related Adverse Events in Cancer Patients Receiving Immunotherapies: Essential Guidance for Emergency Medicine Specialists	05/02/2017	\$573,560.00

Organization	Program Title	Date	Amount
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	EAC 2017 Update in Allergy, Asthma & Immunology	05/04/2017	\$10,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	The Real Deal: Translating Cardiovascular Outcomes Data into Best Practices in Type 2 Diabetes Management	05/07/2017	\$162,855.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	EACR-AACR-SIC Special Conference 2017: The Challenges of Optimizing Immuno- and Targeted Therapies	05/08/2017	\$50,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2017 Best of ASCO Meetings	05/09/2017	\$120,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	Making the Connection Between Patients and Providers - A Modern Approach to the Treatment of Type 1 and Type 2 Dia	05/10/2017	\$200,000.00
GORDON RESEARCH CONFERENCE	Gordon Research Conference: Hormone-Dependent Cancer: Functional Insight and Clinical Application	05/11/2017	\$1,500.00
CARDIOVASCULAR RESEARCH FOUNDATION	29th Annual Transcatheter Cardiovascular Therapeutics	05/14/2017	\$25,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	DAPT and Triple Therapy: A Case-based Guide to Optimal Antiplatelet Therapies	05/14/2017	\$10,000.00
MINNESOTA PHARMACISTS ASSOCIATION	Treating Acute Coronary Syndrome (ACS)	05/15/2017	\$3,500.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	Live Symposium of Complex Coronary, Valvular and Vascular Cases	05/15/2017	\$5,000.00
AMERICAN ASSOCIATION OF CRITICAL CARE NURSES SEPA CHAPTER	Acute Coronary Syndrome New Guidelines and Therapeutic Options	05/17/2017	\$5,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Integration of Immunotherapy into the Treatment of Solid Tumors and Hematologic Malignancies: Considerations for Advanced Practitioners in Oncology	05/18/2017	\$50,000.00
ST. FRANCIS HOSPITAL	Contemporary Dilemmas in Anti Platelet Therapy	05/18/2017	\$3,300.00
MEMORIAL SLOAN KETTERING CANCER CENTER	2017 MSK Cardio-Oncology Symposium: Cardiovascular Health and Disease During and After Cancer Therapy - A Case Based Curriculum	05/18/2017	\$5,000.00
GORDON RESEARCH CONFERENCE	Gordon Research Seminar and Conference on Lung Development, Injury and Repair	05/18/2017	\$8,000.00
GORDON RESEARCH CONFERENCES	Next Generation Computer-Aided Medicine Design: Going Beyond Traditional Targets, Pathways, Modalities, Agents and Techniques	05/18/2017	\$2,000.00
Regents of the University of California	13th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Symposium	05/19/2017	\$5,000.00
LUNGEVITY FOUNDATION	LUNGeVity Foundation Science and Clinical Research Roundtable	05/22/2017	\$40,000.00
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	Breast Cancer: New Horizons, Current Controversies	05/22/2017	\$20,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	2017-2018 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	05/25/2017	\$50,000.00
AMERICAN LUNG ASSOCIATION IN MISSOURI	LungForce Expo	05/28/2017	\$1,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	Cardiovascular Risk in Diabetes	06/03/2017	\$150,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	ASTRO 2017 59th Annual Meeting	06/04/2017	\$25,000.00
THE GOG FOUNDATION, INC	8th Semi Annual Meeting of NRG Oncology	06/04/2017	\$20,000.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	AAFP FMX 60-minute Interactive Lecture and 60-Minute Problem-Based Learning Workshop titled Acute Coronary Syndromes.	06/04/2017	\$33,000.00
NORTHWESTERN UNIVERSITY	6th Annual Chicago Cardiovascular Symposium	06/04/2017	\$10,000.00
MERCY HOSPITAL FOUNDATION	Catholic Health 8th Annual Cardiovascular Symposium	06/04/2017	\$5,000.00

Organization	Program Title	Date	Amount
AMERICAN COLLEGE OF CHEST PHYSICIANS	Lung Cancer Learning Track	06/06/2017	\$50,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2017 Primer on Tumor Immunology and Cancer Immunotherapy	06/06/2017	\$50,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2017 Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy	06/07/2017	\$150,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2018 SITC-AstraZeneca Postdoctoral Cancer Immunotherapy in Combination Therapies Clinical Fellowship Award	06/07/2017	\$120,000.00
TRANSLATIONAL RESEARCH IN ONCOLOGY-US, INC.	TRIO-US & UCLA Annual Research Conference	06/08/2017	\$5,000.00
ACS DIVISION OF MEDICINAL CHEMISTRY	Division of Medicinal Chemistry Program 254th ACS National Meeting	06/08/2017	\$2,000.00
SAINT FRANCIS HOSPITAL AND MEDICAL CENTER	53rd Annual Robert M. Jeresaty, M.D., Cardiovascular Symposium	06/11/2017	\$3,000.00
NYU POST-GRADUATE MEDICAL SCHOOL	Women and Cancer: From Screening to Survivorship	06/12/2017	\$5,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	Antiplatelet Therapy Post-ACS: Choosing the Right Therapy for the Right Duration	06/12/2017	\$10,000.00
PERSONALIZED MEDICINE COALITION	Turning the Tide Against Cancer Through Sustained Medical Innovation 2017 National Conference	06/13/2017	\$10,000.00
MEDICAL LEARNING INSTITUTE	The Present and the Future of Cancer Immunotherapy Biomarkers: Assessing Challenges, Opportunities, and Implications for Pathologists (150204581)	06/13/2017	\$177,230.00
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	ACEP17 Cardiovascular Track	06/13/2017	\$15,000.00
BINAYTARA FOUNDATION	5th International Conference on Advances in Hematology and Oncology (ICAO 2017)	06/14/2017	\$5,000.00
NORTHWESTERN UNIVERSITY	19th Annual Lynn Sage Breast Cancer Symposium	06/14/2017	\$15,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Special Conference on Tumor Immunology and Immunotherapy	06/14/2017	\$35,000.00
COPD FOUNDATION INC	COPD10USA	06/14/2017	\$6,800.00
DUKE UNIVERSITY	Duke Heart Center General Cardiology Update - A Case-Based Review	06/15/2017	\$5,000.00
AMERICAN HEART ASSOCIATION	2017 TN M:L STEMI Conference	06/19/2017	\$10,000.00
THE TRANSVERSE MYELITIS ASSOCIATION	2017 Rare Neuro-immune Disorders Symposium	06/19/2017	\$5,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC - Lung Cancer Education	06/19/2017	\$1,605,600.00
MEDICAL LEARNING INSTITUTE INC	Acute Coronary Syndrome: Getting to the Heart of the Matter for Pharmacists	06/20/2017	\$125,000.00
USF HEALTH PROFESSIONS CONFERENCING CORPORATION	inPractice Oncology 2017-2018: Breast and Gynecologic Cancers Tracks	06/21/2017	\$30,000.00
USF HEALTH PROFESSIONS CONFERENCING CORPORATION	inPractice Oncology 2017-2018: Lung Cancer Track	06/21/2017	\$20,000.00
GLOBAL EDUCATION GROUP, LTD.	The Role of Antiplatelet Therapy in the Short- and Long-term Management of High-risk Patients with ACS	06/22/2017	\$10,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	FASEB Autoimmunity- Additional Funding for Grant #73697	06/22/2017	\$5,000.00
THE LEUKEMIA & LYMPHOMA SOCIETY, INC.	Precision and emerging Medicine for Hematological Diseases	06/27/2017	\$25,000.00
ASSOCIATION OF ASTHMA EDUCATORS	Unraveling Current Asthma Challenges	06/27/2017	\$10,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	NCCN 2017 Oncology Case Manager and Medical Director Program	06/27/2017	\$40,000.00
COPD FOUNDATION	PRAXIS and the COPD Readmissions Institute	06/27/2017	\$120,000.00
NATIONAL KIDNEY FOUNDATION, INC.	New Paradigms in the Treatment of Hyperkalemia	06/28/2017	\$158,250.00

Organization	Program Title	Date	Amount
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS IN ALLERGY, ASTHMA & IMMUNOLOGY	9th Allergy, Asthma & ENT CME	06/28/2017	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	NCCN 2017 Congress Series : Biomarkers 101 (4 Live Webinars & 4 Enduring Webinars)	06/29/2017	\$25,000.00
ASSOCIATION OF PHYSICIAN ASSISTANTS IN ONCOLOGY INC	Association of Physician Assistants in Oncology 20th Annual Conference	06/29/2017	\$10,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY	TSAAI 2017 Annual Meeting	07/02/2017	\$3,000.00
FLORIDA ACADEMY OF PHYSICIAN ASSISTANTS	Rashes, joints and ANA: 2017 Lupus update	07/02/2017	\$3,000.00
WEILL CORNELL MEDICINE	Emerging Immunological Themes in Oncology, Metabolism and Inflammation	08/01/2017	\$20,000.00
THE DIATRIBE FOUNDATION	Glycemic Outcomes Beyond A1c Consensus Conference	08/01/2017	\$25,000.00
THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA MEDICAL CENTER DBA UNMC CENTER FOR CONTINUING EDU	PARP Inhibitors: Their Role in the Treatment of Ovarian Cancer	08/02/2017	\$90,000.00
LUNGEVITY FOUNDATION	HCP Attitudes toward Re-biopsy of Lung Cancer Patients Project	08/03/2017	\$91,800.00
HEART FAILURE SOCIETY OF AMERICA INC	Clinical Care Crossroads: Navigating the Intersection of Heart Failure and Diabetes	08/03/2017	\$150,000.00
AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY	35th Annual Aspen Allergy Conference	08/03/2017	\$10,000.00
BIOCONDUCTOR FOUNDATION OF NA INC	Bioconductor Conference 2017	08/03/2017	\$2,000.00
MEDICAL LEARNING INSTITUTE, INC.	Orienteering on the Complex Treatment Landscape for EGFR-Mutant NSCLC: Latest Evidence to Guide Clinical Decisions in Everyday Community Practice	08/09/2017	\$795,250.00
THE ANGIOGENESIS FOUNDATION	xME: Targeted Therapy, Immunotherapy, and the Chronic Lymphocytic Leukemia Microenvironment	08/10/2017	\$15,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 12th Annual Congress: Hematologic Malignancies™	08/21/2017	\$75,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Fellowships in Hematology-Oncology Research (Lymphoma)	08/21/2017	\$253,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Master Class and Practicum Live at IASLC 2017 CMSTO: New Options and Evolving Strategies for Hitting the Target in EGFR-Mutant NSCLC	08/21/2017	\$340,120.00
AMERICAN SOCIETY OF HEMATOLOGY	ASH Meeting on Hematologic Malignancies	08/22/2017	\$60,000.00
MEDICAL LEARNING INSTITUTE, INC.	Addressing Unmet Needs in Lung Cancer With Rational Immunotherapy-Based Approaches: Evidence and Practicalities (150204646)	08/22/2017	\$270,630.00
MEDICAL LEARNING INSTITUTE, INC.	Integrating Immunotherapy into a Multimodal Treatment Approach (150204726)	08/22/2017	\$304,174.00
ENDOCRINE FELLOWS FOUNDATION	Fourth Annual Endocrine Fellows Research Forum	08/23/2017	\$250,000.00
AMERICAN SOCIETY OF HEMATOLOGY	59th ASH Annual Meeting	08/24/2017	\$250,000.00
MAYO CLINIC ARIZONA	Acute and Chronic Leukemias 2017	08/31/2017	\$5,000.00
COLUMBIA UNIVERSITY DEPARTMENT OF SURGERY	Innovations in the Management of Lung Cancer: Immunotherapy, targeted therapies and minimally invasive techniques	08/31/2017	\$1,500.00
ANNEBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	JADPRO Live at APSHO 2017: Managing Side Effects of Cancer Patients Treated With Immunotherapy	08/31/2017	\$25,000.00

Organization	Program Title	Date	Amount
UNIVERSITY OF MARYLAND, SCHOOL OF MEDICINE	UPDATE: Thoracic Oncology 2017	08/31/2017	\$5,000.00
BAYLOR COLLEGE OF MEDICINE. BREAST CENTER	Breast Cancer Research and Education Program	09/03/2017	\$3,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	Grant Writing Workshop	09/03/2017	\$10,000.00
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS, DEPT. OF SURGERY	2017 Gigi Shaw Arledge Conference on Pancreatic Disease	09/07/2017	\$3,500.00
LUPUS RESEARCH ALLIANCE, INC.	Lupus Research Alliance 2017 Annual Scientific Conference - Forum for Discovery	09/11/2017	\$25,000.00
DANA FARBER CANCER INSTITUTE	Dana-Farber Cancer Institute's 13th Annual Postdoctoral and Graduate Student Retreat	09/13/2017	\$2,500.00
ASSOCIATION OF COMMUNITY CANCER CENTERS	The Evolving Role of the Oncology Pharmacist in the Management of Non-small Cell Lung Cancer	09/13/2017	\$20,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	Pharmacy Updates: A Webinar Series	09/14/2017	\$50,000.00
CINCINNATI CHILDREN'S	4th CURED EGID Research Conference and Patient Education Program	09/18/2017	\$5,000.00
JOHNS HOPKINS UNIVERSITY	OncologyConsults.com Integrating Immunotherapy into SCCHN Care: Implications for the Multidisciplinary Oncology Care Team	09/19/2017	\$10,000.00
PROSTATE CANCER FOUNDATION	24th Annual Scientific Retreat	09/19/2017	\$20,000.00
AMERICAN PANCREATIC ASSOCIATION, INC.	48th Annual Meeting of the American Pancreatic Association	09/19/2017	\$25,000.00
MAYO CLINIC ARIZONA	Mayo Clinic Cancer Center Thoracic Oncology Update State of the Art Evaluation and Management of Thoracic Cancers	09/20/2017	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK FOUNDATION (NCCN)	Behind the Guidelines: Insights into the Standard of Care in Oncology 2018	09/24/2017	\$25,000.00
FOUNDATION FOR HEART FAILURE INC.	21st Annual Heart Failure 2017-An Update on Therapy	09/25/2017	\$10,000.00
UNIVERSITY OF COLORADO/ CENTER FOR WOMEN'S HEALTH RESEARCH	Sex Differences across the Lifespan: A Focus on Metabolism	10/02/2017	\$30,000.00
LYMPHOMA RESEARCH FOUNDATION	Adherence and Oral Therapies in Lymphoma and CLL Workshop	10/02/2017	\$20,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	ECOG-ACRIN 2017 Fall Group Meeting	10/02/2017	\$15,000.00
SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS FOUNDATION	SCAI 2017 Interventional Cardiology Fellows Course	10/02/2017	\$35,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	Emerging Therapies in Oncology From Phase I and Beyond	10/04/2017	\$5,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	Best of 18th World Conference on Lung Cancer (WCLC)	10/05/2017	\$20,000.00
AMERICAN UROLOGICAL ASSOCIATION	Assessing the Educational Needs of Urologic Care Team in the area of Bladder Cancer and Immunotherapy	10/09/2017	\$75,000.00
COLORADO ALLERGY AND ASTHMA SOCIETY	CAAS October 2017 "State of the Art Approaches to Asthma Diagnosis and Treatment"	10/09/2017	\$3,343.10
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	Top Ten Advances in Clinical Cardiology	10/12/2017	\$5,000.00
THE MASSACHUSETTS GENERAL HOSPITAL	Boston Angiogenesis Meeting	10/12/2017	\$4,000.00
AMERICAN SOCIETY OF NEPHROLOGY	Anemia in Kidney Diseases: Beyond the Usual Suspects	10/16/2017	\$155,550.00
Regents of the University of California, UCSD OFFICE OF CME	Updates in Rheumatology 2017: Highlights from the ACR and EULAR Meetings	10/16/2017	\$5,000.00
FLORIDA ACADEMY OF PHYSICIAN ASSISTANTS	Acute Coronary Syndrome	10/16/2017	\$7,500.00

Organization	Program Title	Date	Amount
NEBRASKA ACADEMY OF PHYSICIAN ASSISTANTS	Acute Coronary Syndrome: A Review of Diagnostic Criteria, & Treatment Options	10/16/2017	\$7,500.00
PEPTIDE THERAPEUTICS FOUNDATION	12th Annual Peptide Therapeutics Symposium	10/18/2017	\$15,000.00
KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY	Cancer Immunotherapy: Combinations	10/18/2017	\$15,000.00
THE PENNSYLVANIA STATE UNIVERSITY	Beyond the Guidelines: Investigator Perspectives on Current Clinical Issues and Ongoing Research in the Management of Advanced Prostate Cancer -- An ISS Held as a Premium Ancillary Educational Event During the 2018 Genitourinary Cancers Symposium	10/24/2017	\$30,000.00
TRUSTEES OF TUFTS COLLEGE	2017 Tufts Cancer Symposium, Transforming Therapeutic Outcomes: Innovations in Cancer Modeling	10/26/2017	\$2,500.00
MEDSTAR GEORGETOWN MEDICAL CENTER INC	Lung Cancer 2017: Progress and Future Directions	10/26/2017	\$7,500.00
AMERICAN COLLEGE OF TOXICOLOGY	American College of Toxicology 38th Annual Meeting, Symposium 6: Early Career Professionals' Forum: Current Topics in Toxicology	10/29/2017	\$5,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC's connectED	11/01/2017	\$500,000.00
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY	Stanford Review of the 59th Annual American Society of Hematology Meeting 2018	11/06/2017	\$5,000.00
UNIVERSITY OF CINCINNATI	Rheumatology Winter Clinical Symposium 2018 (RWCS 2018)	11/07/2017	\$15,000.00
UT HEALTH SAN ANTONIO (UTHSCSA)	40TH Annual San Antonio Breast Cancer Symposium	11/07/2017	\$75,000.00
THE GOG FOUNDATION INC	9th Semi Annual Meeting of NRG Oncology	11/08/2017	\$20,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN AACR ASCO Stage III NSCLC Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy	11/08/2017	\$710,115.00
CANCER RESEARCH INSTITUTE	CRI Irvington Postdoctoral Fellowship Program	11/08/2017	\$50,000.00
MID-ATLANTIC SECTION OF THE AMERICAN UROLOGICAL ASSOCIATION	2017 Society for Basic Urologic Research (SBUR) and European Society for Urological Research (ESUR) joint Fall Symposium	11/09/2017	\$10,000.00
WEST PENN ALLEGHENY HEALTH SYSTEM DBA ALLEGHENY GENERAL HOSPITAL	Twelfth Annual Nemaclin International Asthma Conference An Interactive Forum on Patient Care, Therapy, and Research	11/09/2017	\$8,000.00
UNIVERSITY OF CALIFORNIA BERKELEY FOUNDATION	Request for 2017 Funding for the Forum for Collaborative Research's Program on HBV	11/14/2017	\$5,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO)	2018 Multidisciplinary Head and Neck Cancer Symposium: Expanding Treatment Horizons	11/14/2017	\$35,000.00
AMERICAN SOCIETY OF HEMATOLOGY	Hematology 2017: the ASH Education Program	11/15/2017	\$75,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	Leukemia Research Meeting	11/15/2017	\$5,000.00
AMERICAN SOCIETY OF HEMATOLOGY	2018 Highlights of ASH® in North America	11/15/2017	\$100,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 Conquer Cancer Foundation of ASCO Merit Awards	11/16/2017	\$40,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 ASCO-SITC Clinical Immuno-Oncology Symposium	11/21/2017	\$60,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	New York Cardiovascular Symposium	11/21/2017	\$5,000.00
NATIONAL KIDNEY FOUNDATION INC	Scientific Workshop on Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease	11/22/2017	\$160,000.00

Organization	Program Title	Date	Amount
MEDICAL LEARNIGN INSTITUTE, INC.	PeerView MasterClass_Practicum Live at ASCO GI The Quest to Win Through Science in Pancreatic Cancer From Sequencing Current Options to Testing Novel Approaches	11/27/2017	\$50,000.00
THE GUTHY JACKSON CHARITABLE FOUNDATION	ECTRIMS 2017 NMO Symposium	11/29/2017	\$6,000.00
AALAS FOUNDATION	Student and Teacher Public Educational Outreach	11/30/2017	\$5,000.00
GORDON RESEARCH CONFERENCE	Biology of Acute Respiratory Infection Gordon Research Conference	12/01/2017	\$5,000.00
LEUKEMIA RESEARCH FOUNDATION	Hollis Brownstein Research Grants Program	12/03/2017	\$100,000.00
AMERICAN COLLEGE OF RHEUMATOLOGY	2017 ACR/ARHP Annual Meeting Lupus Educational Track	12/03/2017	\$75,000.00
NATIONAL JEWISH HEALTH	40th Annual National Jewish Health Pulmonary and Allergy Update	12/04/2017	\$20,000.00
KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY	2018 Keystone Symposia Directors' Fund	12/04/2017	\$25,000.00
AMERICAN DIABETES ASSOCIATION	Diabetes Is Primary Digital Program on Cardiovascular Risk	12/04/2017	\$40,568.50
AMERICAN COLLEGE OF LABORATORY ANIMAL MEDICINE	2017 ACLAM Grants	12/04/2017	\$4,000.00
SOUTHERN MEDICAL ASSOCIATION	Medical Dilemmas in Patient Care Conference	12/05/2017	\$2,500.00
THE NORTH AMERICAN 3RS COLLABORATIVE	Virtual Education Community Support	12/06/2017	\$8,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 Conquer Cancer Foundation of ASCO Mission Endowment	12/10/2017	\$500,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 Genitourinary (GU) Cancers Symposium: Translating Evidence to Multidisciplinary Care	12/10/2017	\$60,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA)	12/10/2017	\$256,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	15th Annual Nephrology Young Investigators Forum	12/10/2017	\$40,000.00
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	Mid Atlantic Nephrology Young Investigators Forum	12/10/2017	\$50,000.00
ILLINOIS ACADEMY OF FAMILY PHYSICIANS	The 12th Annual Chief Residents Summit on Intensifying Diabetes Management	12/11/2017	\$54,771.32
AMERICAN COLLEGE OF RHEUMATOLOGY	2018 ACR Rheumatology Courses	12/11/2017	\$50,000.00
JOHNS HOPKINS UNIVERSITY	FastForward Corporate Sponsorship	12/12/2017	\$25,000.00
THE DEUEL CONFERENCE ON LIPIDS	The 2018 Deuel Conference on Lipids	12/13/2017	\$5,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY (FASEB)	FASEB SRC Immunoreceptors and Immunotrophy	12/13/2017	\$5,000.00
UNIVERSITY OF CALIFORNIA BERKELEY FOUNDATION	Request for 2018 Funding for the Forum for Collaborative Research's	12/13/2017	\$10,000.00
GORDON RESEARCH CONFERENCE	Gordon Conference on Drug Resistance 2018	12/14/2017	\$5,000.00
ASSOCIATION FOR WOMEN IN SCIENCE	Innovation and Inclusion: Women at the Forefront of STEM	12/17/2017	\$25,000.00
VIRGINIA BIOTECHNOLOGY ASSOCIATION	MedImmune Chairman's Circle Membership	12/17/2017	\$25,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY SRC	The Lung Epithelium in Health and Disease	12/20/2017	\$5,000.00
ENGINEERING CONFERENCES INTERNATIONAL	Cell Culture Engineering XVI Conference	12/21/2017	\$10,000.00
PENNSYLVANIA SOCIETY FOR BIOMEDICAL RESEARCH	2018 PSBR Membership	12/24/2017	\$2,000.00
NATIONAL ACADEMY OF SCIENCES	Roundtable in Science and Welfare of Laboratory Animal Use	12/24/2017	\$4,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 Gastrointestinal (GI) Cancers Symposium: Multidisciplinary Care: Local Practice, Global Outcomes	01/02/2018	\$30,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer	01/02/2018	\$25,000.00



Organization	Program Title	Date	Amount
NATIONAL JEWISH HEALTH	14th Annual Respiratory Disease Young Investigators' Forum	01/02/2018	\$299,608.49
THE CHEST FOUNDATION	CHEST Foundation Research Award in COPD	01/02/2018	\$55,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	Implementation of diagnostic and molecular guidelines in low-middle income regions for targeted therapies in NSCLC	01/04/2018	\$300,000.00
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	9th International Symposia for the CGRP Family Peptides Conference	01/09/2018	\$2,500.00
UNIVERSITY OF CINCINNATI	The Intersection Between COPD and Cardiometabolic Comorbidities	01/14/2018	\$95,000.00
NATIONAL KIDNEY FOUNDATION INC	13th Annual National Young Investigator Forum	01/14/2018	\$50,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY (ACAAI)	WSAAI 2018: 56th Annual Scientific Session	01/17/2018	\$15,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy	01/18/2018	\$10,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	2018 Oncologic Emergency Medicine Conference	01/23/2018	\$10,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	Exploring the Challenges of Severe Asthma: Understanding Appropriate Treatment Strategies for Improved Patient Outcomes	01/25/2018	\$35,000.00
CANCER RESEARCH INSTITUTE	Cancer Immunotherapy Consortium Workshop	02/05/2018	\$10,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Advancing Knowledge to Practice Optimizing Severe Asthma Care in the Age of Biologics	02/11/2018	\$200,000.00
PENNSYLVANIA STATE UNIVERSITY	PeerView Live at the 2018 ASCO Annual Meeting, The Arrival of Novel Agent Classes in B-Cell Non-Hodgkin Lymphoma: A Personal Guide to Integrating New Therapy into Patient Care (150204877)	02/12/2018	\$104,507.00
ANNENBERG CENTER FOR HEALTH SCIENCES	Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology	02/13/2018	\$75,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2018 Oncology Fellows Program: New Horizons in Quality Cancer Care™ at the NCCN 23rd Annual Conference	02/14/2018	\$35,000.00
INDY HEMATOLOGY EDUCATION, INC.	2018 Indy Hematology Review	02/14/2018	\$10,000.00
JOHNS HOPKINS UNIVERSITY	14th International Symposium on Sjogrens Syndrome	02/14/2018	\$20,000.00
SCRIPPS HEALTH	Scripps 38th Annual Clinical Hematology and Oncology Conference	02/14/2018	\$25,000.00
THE CHEST FOUNDATION	CHEST Foundation Research Award in Severe Asthma	02/14/2018	\$35,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES	Clinical Management of Novel Therapies for Hematological Malignancies (5 Regional lectures by APSHO/JADPRO)	02/14/2018	\$100,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView inVision, "Targeted Treatment in Severe Asthma: Moving Toward Precision Medicine"	02/14/2018	\$64,125.00
COLLEGIUM INTERNATIONALE ALLERGOLOGICUM	32nd Symposium of the Collegium Internationale Allergologicum	02/14/2018	\$10,000.00
AMERICAN SOCIETY FOR CLINICAL PATHOLOGY	Immuno-Oncology: Scientific Updates	02/14/2018	\$60,490.00
NATIONAL JEWISH HEALTH	COPD Basics: An Integrated Approach to Best Practices in Five Healthcare Networks	02/14/2018	\$100,000.00
MAYO CLINIC ARIZONA	Clinical Multidisciplinary Hematology & Oncology: The 15th Annual Review	02/14/2018	\$15,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	18th Targeted Therapy meeting	02/14/2018	\$55,100.00

Organization	Program Title	Date	Amount
MEDICAL LEARNING INSTITUTE, INC.	PeerView Master Class and Practicum Live at CHEST 2018, "New Avenues in Asthma Management: Finding the Right Patients for Targeted Therapies" (150205033)	02/14/2018	\$299,330.00
NATIONAL KIDNEY FOUNDATION INC	Chronic Hyperkalemia Management and Outcomes in CKD	02/15/2018	\$232,979.00
ALZHEIMER'S ASSOCIATION	Alzheimer's Association International Conference, AAIC 2018	02/15/2018	\$45,000.00
ASTHMA AND ALLERGY FOUNDATION OF AMERICA - ALASKA CHAPTER	Wheezin', Sneezin' & Itchin' in Alaska	02/16/2018	\$10,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS	New Agents and Emerging Strategies in Advanced Breast Cancer: Patient-Centric Navigation in the Age of Personalized Care	02/18/2018	\$35,000.00
THE PENNSYLVANIA STATE UNIVERSITY	PeerView inPlay, "The Role of the Eosinophil in COPD: Implications for Personalized Care and Novel Treatments" (150205058)	02/18/2018	\$145,730.00
DUKE UNIVERSITY	3rd Annual Duke Heart Center/DCRI Fellows' Presentation Skills Course	02/19/2018	\$2,500.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Novel Treatment Strategies in the Management of Ovarian Cancer: A Closer Look at the Role of PARP Inhibitors	02/19/2018	\$35,000.00
AMERICAN THORACIC SOCIETY INC	ATS 2018 Fellows Track Symposium	02/19/2018	\$10,000.00
MEDSTAR WASHINGTON HOSPITAL CENTER	Cardiovascular Research Technologies (CRT) Annual Meeting	02/20/2018	\$30,000.00
DUKE UNIVERSITY	The Southeastern Fellows Research Skills & Training Workshop	02/21/2018	\$2,500.00
AMERICAN THORACIC SOCIETY INC	ATS 2018 International Conference - Selected Sessions in COPD	02/21/2018	\$30,000.00
SCRIPPS HEALTH	15th Annual Fundamentals of Diabetes Management	02/22/2018	\$25,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	FDA-AACR-ASTRO: Clinical Development of Drug-Radiotherapy Combinations Workshop	02/22/2018	\$25,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	Advances in Malignant Lymphoma (AACR/ICML "off year" conference in US)	02/25/2018	\$25,000.00
BLADDER CANCER ADVOCACY NETWORK	2018 Bladder Cancer Think Tank	02/25/2018	\$35,000.00
Gordon Research Conference	2018 Gordon Research Council on New Antibiotic Discovery and Development	02/27/2018	\$5,000.00
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	Treat-to-Target and Targeted Therapy: The Evolving State of Systemic Lupus Erythematosus Patient Care	02/28/2018	\$124,857.00
AMERICAN DIABETES ASSOCIATION	Diabetes Is Primary Core Programs	03/01/2018	\$300,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Annual Meeting- 2018	03/01/2018	\$225,000.00
NATIONAL JEWISH HEALTH	A Severe Asthma Roadmap for Improved Diagnosis and Personalized Treatment – A Guided Workflow	03/01/2018	\$322,170.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	California Chapter of the American Association of Clinical Endocrinologists Presents Hot Topics in Diabetes and Endocrinology for Primary Care 2018 Series	03/01/2018	\$10,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™	03/02/2018	\$100,000.00
EASTERN VIRGINIA MEDICAL SCHOOL	Turning the Tide on Diabetes 2018	03/04/2018	\$5,000.00
THE UNIVERSITY OF CHICAGO	15th International Ultmann Chicago Lymphoma Symposium	03/05/2018	\$25,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	Innovating Diabetes Care—Use of Real-Time Data to Transform Clinical Practice and Optimize Patient Glucose Management	03/05/2018	\$300,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	24th Annual Interventional Cardiology Fellows Course	03/05/2018	\$10,000.00

Organization	Program Title	Date	Amount
AMERICAN PHARMACISTS ASSOC	APhA2018 Your Annual Diabetes Update	03/05/2018	\$5,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	DAPT Dilemmas: A Case-Based Roundtable at Fellows 2018	03/05/2018	\$20,000.00
AMERICAN UROLOGICAL ASSOCIATION	Japanese Urological Association (JUA) Meeting	03/05/2018	\$40,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN Foundation Young Investigator Awards	03/06/2018	\$171,801.00
PURDUE UNIVERSITY OFFICE OF CONTINUING PROFESSIONAL EDUCATION	Can You Do It Better? -- A Unique Approach to Enabling Improved Asthma Management	03/06/2018	\$377,342.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC Workshop on Neopadjvant Therapy in Lung Cancer	03/06/2018	\$25,000.00
UNT HEALTH SCIENCE CENTER	Filling the Gaps in Asthma Care - Lessons Learned from Asthma411	03/07/2018	\$4,750.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Updates in Precision Medicine Elevating the Treatment of Severe, Eosinophilic Asthma	03/07/2018	\$155,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	27th Annual Scientific & Clinical Congress - Diabetes Sessions	03/07/2018	\$63,052.00
NATIONAL COMPREHENSIVE CANCER NETWORK	Support for NCCN Distribution of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Management of Immunotherapy-Related Toxicities Pocket Guides	03/08/2018	\$60,000.00
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	2018 Pan Pacific Lymphoma Conference	03/11/2018	\$125,000.00
SCRIPPS HEALTH	Fifth Annual Clinical Advances in Heart Failure and Arrhythmias	03/11/2018	\$5,000.00
NORTHEAST GEORGIA MEDICAL CENTER	10th Annual Northeast Georgia STEMI Summit	03/12/2018	\$2,500.00
HEMATOLOGY/ONCOLOGY PHARMACY ASSOCIATION	HOPA 14th Annual Conference	03/12/2018	\$30,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 ASCO Annual Meeting Breast Cancer Track	03/12/2018	\$20,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 ASCO Annual Meeting Genitourinary Cancer Tracks Bundle: Prostate and Nonprostate	03/12/2018	\$30,000.00
THE GUTHY JACKSON CHARITABLE FOUNDATION	The Guthy-Jackson Industry Council	03/12/2018	\$25,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	Making the Connection Between Patients & Providers: A Comprehensive Overview of the Modern Treatment Strategies For People With Type 1 and Type 2 Diabetes	03/13/2018	\$200,000.00
NATIONAL KIDNEY FOUNDATION	Cardiovascular Risk in Patients with Chronic Kidney Disease (CKD): The Impact of Anemia	03/13/2018	\$232,979.00
ACADEMY OF MANAGED CARE PHARMACY	The Immuno-Oncology Pipeline and the Managed Care Considerations	03/13/2018	\$35,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC Immunotherapy Meeting	03/13/2018	\$25,000.00
ACS DIVISION OF BIOCHEMICAL TECHNOLOGY	255th ACS National Meeting and Exposition (BIOT Division)	03/13/2018	\$5,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	12th Biennial Ovarian Cancer Research Symposium	03/14/2018	\$15,000.00
AMERICAN HEART ASSOCIATION	Arteriosclerosis, Thrombosis and Vascular Biology   Peripheral Vascular Disease 2018 Scientific Sessions, Vascular Discovery: From Genes to Medicine	03/18/2018	\$2,000.00
RILITE FOUNDATION	Lupus 21st Century 2018 Conference	03/18/2018	\$25,000.00
RHEUMATOLOGIC DERMATOLOGY SOCIETY INC.	4th International Conference on Cutaneous Lupus Erythematosus	03/19/2018	\$10,000.00
HOWARD UNIVERSITY	13th Annual Kenneth Austin Rheumatology Symposium	03/19/2018	\$2,500.00
SOCIETY OF GYNECOLOGIC ONCOLOGY	SGO Lunch and Learn Contemporary Ovarian Cancer: Keys to Therapies and Integrated Learning	03/20/2018	\$125,000.00

Organization	Program Title	Date	Amount
LYMPHOMA RESEARCH FOUNDATION	Mantle Cell Lymphoma Scientific Workshop	03/20/2018	\$20,000.00
CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION	Molecular Therapeutics of Cancer Research Conference 2018	03/21/2018	\$5,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	PCNA's 24th Annual Symposium	03/22/2018	\$10,000.00
ASPEN LUNG CONFERENCE	Thomas Petty Aspen Lung Conference/Translating Resilience and Pathogenesis to Personalized Therapy for COPD	03/22/2018	\$25,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES	Master Class for Oncologists - Hematology Track	03/22/2018	\$24,246.27
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Clinical Advances in the Diagnosis, Treatment and Management of COPD	03/25/2018	\$15,000.00
FOUNDATION FOR SURGICAL FELLOWSHIPS	American Head and Neck Society Annual Meeting - Evaluating Head and Neck Cancer Care Through Evidence Based Medicine	03/25/2018	\$15,000.00
DUKE UNIVERSITY	Duke Debates: Controversies in the Management of Patients with Hematologic Malignancies	03/25/2018	\$15,000.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	Mount Sinai Division of Occupational Medicine Seminar Series	03/29/2018	\$7,500.00
GORDON RESEARCH CONFERENCE	Gordon Research Conference: Mutagenesis - Mechanisms of Intrinsic and Induced Genome Instability	04/01/2018	\$2,500.00
THE UNIVERSITY OF CHICAGO	Frontiers in Precision Medicine for Inherited Cancers: From Risk Assessment to Targeted Therapies	04/02/2018	\$25,000.00
THE PENNSYLVANIA STATE UNIVERSITY	PeerView Live: "Unraveling the Complex Treatment Landscape for Prostate Cancer: Guidance for Delivering Evidence-Based, Patient-Centered Care" (150204517)	04/02/2018	\$73,575.00
GORDON RESEARCH CONFERENCES	2018 Gordon Research Conference on Medicinal Chemistry	04/03/2018	\$2,500.00
CLEVELAND CLINIC EDUCATION FOUNDATION	2018 Cleveland Breast Cancer Summit: Collaborating for a Cure	04/03/2018	\$5,000.00
THE PENNSYLVANIA STATE UNIVERSITY	New Directions in the Management of Recurrent Ovarian Cancer: Focus on PARP Inhibitors	04/04/2018	\$124,611.00
ASSOCIATION FOR MOLECULAR PATHOLOGY	Advancing Patient Care in NSCLC: Breaking Down Barriers	04/04/2018	\$416,900.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	2018 Diabetes Day 23rd Annual Symposium New Frontiers in Diabetes	04/04/2018	\$5,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Master Class & Practicum Live at ASH 2018: "Exploring the Present and Future of BTK Inhibition in B-cell malignancies: Expert Insights on Practical Implications for Patient Management" (150205092)	04/04/2018	\$370,100.00
AMERICAN UROLOGICAL ASSOCIATION	AUA2018 Highlights: Immunotherapy in GU Cancer	04/04/2018	\$150,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES	Master Class for Oncologists - Women's Cancer Track	04/05/2018	\$19,391.02
FRIENDS OF CANCER RESEARCH	2018 Friends of Cancer Research Programs	04/08/2018	\$100,000.00
THE HOPE FOUNDATION	2018 SWOG Group Meetings	04/08/2018	\$10,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 ASCO Annual Meeting Gynecologic Cancer Track	04/09/2018	\$45,000.00
LAHEY CLINIC HOSPITAL, INC.	Cardiovascular Disease State of the Art 2018	04/09/2018	\$5,000.00
BOARD OF REGENTS FOR UNIVERSITY OF NEBRASKA	Dissecting the Decision: Documenting and Discussing the Clinical Practice Patterns of Hematologic Oncology Investigators in the Management of Chronic Lymphocytic Leukemia - — An ISS Held in Conjunction with the 2018 Pan Pacific Lymphoma Conference	04/11/2018	\$75,000.00

Organization	Program Title	Date	Amount
TRUSTEES OF BOSTON UNIVERSITY	CVD AND RENAL DISEASE IN T2DM: Pivotal Role of Physician Assistants in Patient Management	04/11/2018	\$109,420.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 Conquer Cancer Foundation of ASCO Career Development Award (CDA)	04/12/2018	\$253,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	CHEST 2018 Post Graduate Program on Difficult to Treat Asthma	04/12/2018	\$25,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	ECOG-ACRIN 2018 Spring Group Meeting	04/12/2018	\$5,000.00
LUPUS FOUNDATION OF NEW ENGLAND	Lupus Medical and Educational Symposim	04/15/2018	\$5,000.00
HEART FAILURE SOCIETY OF AMERICA INC	Future Leaders in Heart Failure Symposium	04/16/2018	\$10,000.00
AMERICAN ACADEMY OF CME INC	Applying the Latest Evidence to Improve Care for Patients with HR+/HER2- Metastatic Breast Cancer	04/17/2018	\$313,595.00
PRESIDENT AND FELLOWS OF HARVARD COLLEGE ACTING THROUGH THE DEPARTMENT OF GCE	Practical Considerations and Rationale for Immunotherapy 2018	04/17/2018	\$5,000.00
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS	AACE 27th Annual Scientific & Clinical Congress - Cardiovascular Track	04/17/2018	\$30,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	2nd Annual Heart in Diabetes	04/18/2018	\$50,000.00
SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS FOUNDATION	SCAI 2018 Scientific Sessions featuring Controversies in Interventional Pharmacology	04/18/2018	\$40,000.00
AMERICAN HEART ASSOCIATION	STEMI Protocol Stakeholder Education	04/18/2018	\$3,730.00
ALZHEIMER'S ASSOCIATION	2018 Research Roundtable	04/19/2018	\$50,000.00
PURDUE UNIVERSITY	Critical Conversations on Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies (CCO GR Pgm)	04/23/2018	\$575,210.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	Severe Asthma Shared Decision Making Tool Instructional Video	04/23/2018	\$60,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	Symposium - A Personalized Approach to Managing Patients with Uncontrolled Asthma / Shifting Paradigms in Management of Severe Asthma: Pathogenesis, Phenotypes & Personalized Medicine	04/23/2018	\$80,375.00
MEDSTAR HEALTH, INC.	2018 MedStar Health System Prostate Cancer Annual Meeting	04/24/2018	\$15,000.00
UT HEALTH SAN ANTONIO	3rd Annual Cardio Renal Connections	04/24/2018	\$5,000.00
MEDSTAR HEALTH, INC.	Enhancing Health System Initiatives Utilizing Clinical Advances to Optimize the Diagnosis and Treatment of Prostate Cancer	04/24/2018	\$10,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Best Practices in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Individualizing Therapy for Optimized Patient Outcomes	04/25/2018	\$35,000.00
TRUSTEES OF BOSTON UNIVERSITY	CVD AND RENAL DISEASE IN T2DM: Individualizing Therapeutic Options to Reduce Comorbid Risk	04/25/2018	\$49,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 Best of ASCO® Meetings	04/25/2018	\$120,000.00
AMERICAN CHEMICAL SOCIETY, DIVISION OF BIOCHEMICAL TECHNOLOGY, RECOVERY OF BIOLOGICAL PRODUCTS	Recovery of Biological Products XVIII Conference	04/26/2018	\$10,000.00
AMERICAN RADIUM SOCIETY	American Radium Society 100th Annual Meeting	04/26/2018	\$10,000.00
VANDERBILT UNIVERSITY	Midwest Islet Club Meeting	04/26/2018	\$2,500.00
WEST PENN ALLEGHENY HEALTH SYSTEM, INC. DBA ALLEGHENY GENERAL HOSPITAL	2018 Cardiovascular Medicine Update Conference	04/29/2018	\$5,000.00

Organization	Program Title	Date	Amount
PRESIDENT AND FELLOWS OF HARVARD COLLEGE ACTING THROUGH THE DEPARTMENT OF GCE	Diabetes Update 2018	04/30/2018	\$5,000.00
ASPEN CANCER CONFERENCE	33rd Aspen Cancer Conference	04/30/2018	\$10,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA/PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PA	6th Annual Scientific Symposium: BRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer	04/30/2018	\$20,000.00
ASSOCIATION OF AMERICAN CANCER INSTITUTES	2018 AACI/CCAF Annual Meeting	05/01/2018	\$15,000.00
ONCOLOGY NURSING SOCIETY	2018 ONS Annual Congress and two Regional Conferences	05/01/2018	\$50,000.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA/PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PA	2018 New Advances in Lung Cancer: Stretching the Envelope	05/03/2018	\$10,000.00
HEMATOLOGY ONCOLOGY PHARMACY ASSOCIATION	Immuno oncology Educational Modules for Oncology Pharmacists	05/06/2018	\$35,000.00
CANCER RESEARCH INSTITUTE	2018 International Cancer Immunotherapy Conference	05/06/2018	\$50,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Pancreatic Cancer: Advances in Science and Clinical Care	05/06/2018	\$25,000.00
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY FOUNDATION	2018 Group Meetings	05/07/2018	\$40,000.00
AMERICAN THORACIC SOCIETY INC	ATS 2018 International Conference - Selected Sessions in Lung Cancer	05/07/2018	\$40,000.00
AMERICAN SOCIETY OF HEMATOLOGY	2018 ASH Meeting on Lymphoma Biology	05/08/2018	\$50,000.00
LUNGEVITY FOUNDATION	LUNgevity Foundation Scientific and Clinical Roundtable--Streamlining Clinical Trials 2018	05/08/2018	\$50,000.00
HEMATOLOGY/ONCOLOGY PHARMACY ASSOCIATION	HOPA Early Career Research Grant	05/08/2018	\$60,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Live at ASTRO 2018 - The Era of Immunotherapy in Stage III NSCLC (150205115)	05/09/2018	\$323,020.00
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA/PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PA	2018 Breast Cancer Clinical Case Series: The Year in Review	05/09/2018	\$5,000.00
HEART FAILURE SOCIETY OF AMERICA INC	2018 HFSA Board Certification Review Course in Advanced Heart Failure and Transplant Cardiology	05/09/2018	\$15,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	Immuno-Oncology Biomarkers State of the Art	05/10/2018	\$25,000.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS	AAPA 2018 Annual Conference	05/10/2018	\$10,000.00
HDL WORKSHOP	HDL Workshop 2018	05/10/2018	\$5,000.00
LUPUS RESEARCH ALLIANCE, INC.	Lupus Research Alliance 2018 Annual Scientific Conference - Forum for Discovery	05/10/2018	\$25,000.00
BOARD OF REGENTS FOR UNIVERSITY OF NEBRASKA	Dissecting the Decision: Documenting and Discussing the Clinical Practice Patterns of Hematologic Oncology	05/13/2018	\$200,000.00
Regents of the University of California	24th Annual San Diego Heart Failure Symposium	05/13/2018	\$10,000.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Intensive Review of Cardiology	05/15/2018	\$10,000.00
GORDON RESEARCH CONFERENCE	2018 Heterocyclic Gordon Research Conference	05/15/2018	\$2,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	30th Annual Transcatheter Cardiovascular Therapeutics	05/16/2018	\$40,000.00
AMERICAN ACADEMY OF FAMILY PHYSICIANS	2018 Family Medicine Experience Interactive Lecture titled Acute Coronary Syndrome	05/16/2018	\$19,000.00
HUNTSVILLE HOSPITAL FOUNDATION	RSS Breast Cancer Conference	05/16/2018	\$2,000.00
SOCIETY OF INTERVENTIONAL ONCOLOGY (SIO)	2018 WCIO	05/20/2018	\$15,000.00

Organization	Program Title	Date	Amount
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE	University of Washington Topics in Allergy and Immunology Teaching Series	05/20/2018	\$24,300.00
THE GOG FOUNDATION	10th Semi Annual Meeting of NRG Oncology (formerly NCI cooperatives groups, GOG, NSABP, RTOG)	05/21/2018	\$20,000.00
NORTHWESTERN UNIVERSITY	20th Annual Lynn Sage Breast Cancer Symposium	05/21/2018	\$15,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	Molecular Biology in Clinical Oncology Workshop	05/22/2018	\$15,000.00
UNIVERSITY OF COLORADO	Precision Medicine in Autoimmunity	05/23/2018	\$20,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Live at CAP18: Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines (150205165)	05/23/2018	\$313,240.00
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	2018 Lung Cancer SPORE Workshop	05/23/2018	\$15,000.00
AMERICAN COLLEGE OF EMERGENCY PHYSICIANS	ACEP18, ACEP National Scientific Assembly - Cardiovascular Track	05/23/2018	\$20,000.00
HOSPITAL QUALITY FOUNDATION, LLC	Advances in the Management of Acute and Chronic Hyperkalemia: An Update for Emergency Medicine, Hospitalists and Healthcare Providers (MD, PA and CRNP)	05/23/2018	\$222,127.50
GORDON RESEARCH CONFERENCE	2018 Cardiac Regulatory Mechanisms Gordon Research Conference	05/23/2018	\$5,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 ASCO Annual Meeting Head and Neck Cancer Track	05/24/2018	\$30,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 ASCO Pre-Annual Meeting Seminar: New Drugs in Oncology	05/24/2018	\$10,000.00
FEDERATION OF CLINICAL IMMUNOLOGY SOCIETIES	18th Annual Meeting of the Federation of Clinical Immunology Societies	05/24/2018	\$10,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	2018-2019 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	05/24/2018	\$75,000.00
WINTHROP UNIVERSITY HOSPITAL	3rd Annual NYU Winthrop Breast Health Symposium	05/24/2018	\$3,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2018 ASCO Annual Meeting Lung Cancer Track	05/27/2018	\$25,000.00
MISSOURI ACADEMY OF PHYSICIANS ASSISTANTS	Updates in Treating Chronic Obstructive Pulmonary Disorder	05/30/2018	\$3,000.00
MEDICAL LEARNING INSTITUTE, INC.	Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Immune-Related Adverse Effects in the Emergency Department (150205075)	06/03/2018	\$568,470.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2018 Oncology Case Manager and Medical Director Program	06/03/2018	\$40,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	ASTRO 2018 60th Annual Meeting	06/03/2018	\$50,000.00
UNIVERSITY OF PITTSBURGH	2018 Pittsburgh International Lung Conference - Pulmonary Medicine: Basic Biology and Novel Therapies	06/04/2018	\$10,000.00
AEGEAN CONFERENCES, INC.	2nd International Conference on Tissue Repair, Regeneration, and Fibrosis	06/05/2018	\$5,000.00
SYNAPTIV, INC.	Atlanta Lung Cancer Symposium 2018	06/05/2018	\$20,000.00
SOCIETY FOR TRANSLATIONAL ONCOLOGY	NSCLC Treatment in the Era of Precision Medicine: Case-Based Insights from ASCO 2018	06/05/2018	\$38,885.00

Organization	Program Title	Date	Amount
MEDICAL LEARNING INSTITUTE, INC.	Traveling Master Class for Emergency Medicine Specialists: Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED	06/06/2018	\$390,030.00
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	33rd Annual Critical Issues In Tumor Microenvironment: Angiogenesis, Metastasis and Immunology	06/06/2018	\$15,000.00
KERN ASPEN LIPID CONFERENCE	Metabolic Regulation of Immunity, Cardiometabolic Diseases and Cancer: New Therapeutic Approaches	06/06/2018	\$10,000.00
SOCIETY OF TOXICOLOGIC PATHOLOGY	STP 37th Annual Symposium: KEEPING IT RENAL	06/06/2018	\$3,000.00
WEILL CORNELL MEDICAL COLLEGE	2nd Annual International Conference Immunotherapy Radiotherapy Combinations	06/10/2018	\$15,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	2018 COPD Learning Track	06/10/2018	\$5,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	2018 Interdisciplinary Program- Lung Cancer: 2018 Update in Staging and Management	06/10/2018	\$27,000.00
AMERICAN COLLEGE OF OSTEOPATHIC INTERNISTS	Breathing New Air into the Treatment of COPD and Asthma	06/10/2018	\$20,400.00
THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA	PREP2018 Symposium	06/10/2018	\$5,000.00
SOCIETY FOR NEURO-ONCOLOGY	3rd CNS Anticancer Drug Discovery and Development Conference	06/11/2018	\$15,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	2018 JADPRO Live: The Annual APSHO Meeting - Sequencing Therapies in Indolent Lymphomas	06/12/2018	\$50,000.00
AMERICAN COLLEGE OF OSTEOPATHIC INTERNISTS	ACOI 2018 Annual Convention and Scientific Sessions: Addressing Unmet Needs in Type 2	06/12/2018	\$33,782.00
UNIVERSITY OF CINCINNATI	Moving Toward A New Standard of Care: Checkpoint Inhibitors in Advanced Urothelial Cancer	06/13/2018	\$59,912.00
AMERICAN ASSOCIATION OF DIABETES EDUCATORS	Reducing Cardiovascular Risk in T2DM with SGLT2 Inhibitors and GLP1-Receptor Antagonists: Translating Evidence into Patient Outcomes	06/13/2018	\$178,188.13
SOCIETY FOR NEURO-ONCOLOGY	23rd Annual Scientific Meeting of the Society for Neuro-Oncology	06/13/2018	\$75,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	2018 Lung Cancer Learning Track	06/13/2018	\$70,000.00
UNIVERSITY OF CALIFORNIA BERKELEY FOUNDATION	Request for 2018 Funding for the Forum for Collaborative Research's Program on HBV	06/14/2018	\$5,000.00
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	OncologyConsults.com Improving Outcomes in Stage III NSCLC The Emerging Role of Immunotherapy in Curbing Disease Progression	06/15/2018	\$89,885.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	Advances in Cancer Immunotherapy™ 2018-19 Educational Program Series	06/17/2018	\$500,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	Medications' Class Effects in DM & CVD - All you need to know- and never asked.	06/19/2018	\$100,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Live at ASCP 2018: Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Selection of EGFR-Targeted Therapy for Patients With Lung Cancer (150205135)	06/21/2018	\$262,040.00
NORTHWESTERN UNIVERSITY	Lurie Cancer Center Multidisciplinary Head and Neck Symposium	06/21/2018	\$10,000.00
CHARLOTTE AHEC	30th Annual Fall Foliage Cancer Conference	06/25/2018	\$5,000.00
KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY	Integrated Pathways of Disease in NASH and NAFLD	06/25/2018	\$6,000.00
AMERICAN SOCIETY OF NEPHROLOGY	ASN Kidney Week Educational Session Support	06/25/2018	\$20,000.00



Organization	Program Title	Date	Amount
GORDON RESEARCH CONFERENCE	DNA Topoisomerases in Biology and Medicine	06/25/2018	\$10,000.00
INDUSTRY NETWORKING GROUP	BioHealth Capital Region Workforce Community Engagement	06/25/2018	\$10,000.00
AMERICAN COLLEGE OF OSTEOPATHIC INTERNISTS	Unraveling the Effects of Antihyperglycemic Agents on Cardiovascular Risk	07/01/2018	\$33,782.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Live at ASCP 2018: Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing (150205136)	07/02/2018	\$262,040.00
ENDOCRINE FELLOWS FOUNDATION	Fifth Annual Research Forum	07/02/2018	\$250,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC 2018 Workshop on Nutrition, Metabolism and the Microbiome in Cancer Therapy	07/02/2018	\$100,000.00
AMERICAN SOCIETY OF NEPHROLOGY	The Role of Hypoxia-Inducible Factors and Inflammation in the Anemia of Kidney Disease	07/02/2018	\$167,500.00
AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS	Managing Cardiovascular Risk Factors in Patients with Type 2 Diabetes: Emerging Concepts	07/04/2018	\$160,000.00
AMERICAN SOCIETY OF HEMATOLOGY	ASH Meeting on Hematologic Malignancies	07/04/2018	\$60,000.00
AMERICAN HEART ASSOCIATION	Scientific Sessions 2018 Dedicated Programming on Acute Coronary Syndrome	07/05/2018	\$20,000.00
BREATHE CALIFORNIA OF LOS ANGELES COUNTY	2018 BREATHE California of Los Angeles County 10th Annual COPD Conference	07/08/2018	\$3,000.00
SOCIETY FOR INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY	SIMB Annual Meeting	07/08/2018	\$3,000.00
JOSLIN DIABETES CENTER, INC.	2018 AANHPI Diabetes Coalition Conference The Future of Population Diabetes Research and Advocacy: Asian American Native Hawaiian Pacific Islanders	07/08/2018	\$5,000.00
ACS DIVISION OF MEDICINAL CHEMISTRY	Division of Medicinal Chemistry Program 256th ACS national meeting	07/09/2018	\$2,500.00
GORDON RESEARCH CONFERENCES, INC.	Gordon Research Conference Tissue Niches & Resident Stem Cells in Adult Epithelia	07/10/2018	\$10,000.00
NORTH AMERICAN THROMBOSIS FORUM	Reducing Cardiovascular Risk in Patients with Diabetes: A Comprehensive Yet Concise Patient Focused Action Plan	07/11/2018	\$60,000.00
AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY	36th Annual Aspen Allergy Conference	07/11/2018	\$3,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC 33rd Annual Meeting	07/16/2018	\$400,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC Cancer Immunotherapy Sparkathon 2018--Emerging Leaders Igniting Innovation	07/16/2018	\$67,500.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	Respiratory Syncytial Virus (RSV) Education Program	07/16/2018	\$35,000.00
BINAYTARA FOUNDATION	6th International Conference on Advances in Hematology and Oncology	07/16/2018	\$5,000.00
SOCIETY FOR MUCOSAL IMMUNOLOGY	Mucosal Immunology Course and Symposium	07/16/2018	\$10,000.00
BAYLOR COLLEGE OF MEDICINE	Breast Cancer Research and Education program	07/17/2018	\$3,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Conference on The Science of Cancer Health Disparities	07/17/2018	\$25,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Live at CAP18: The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle in the Era of Precision Medicine (150205123)	07/18/2018	\$164,230.00

Organization	Program Title	Date	Amount
PENNSYLVANIA STATE UNIVERSITY	PeerView inClinic, Building Innovative Treatment Options for Patients with B-cell Malignancies: Practical Insights on Clinical Evidence and Integration Strategies 150205182	07/18/2018	\$32,330.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	2018 JADPRO Live: The Annual APSHO Meeting - Sequencing of Treatments for Patients with Ovarian Cancer	07/19/2018	\$50,000.00
AMERICAN SOCIETY OF HEMATOLOGY	ASH Scholar Awards	07/20/2018	\$100,000.00
AMERICAN SOCIETY OF HEMATOLOGY	60th ASH Annual Meeting	07/20/2018	\$150,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Cancer Health Disparities Think Tank	07/22/2018	\$25,000.00
ASSOCIATION OF PHYSICIAN ASSISTANTS IN ONCOLOGY	Association of Physician Assistants in Oncology 21st Annual Conference	07/23/2018	\$10,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	2018 JADPRO Live: The Annual APSHO Meeting - Management of Side Effects for Patients with Multi-Modality Therapy in Thoracic Oncology	07/24/2018	\$50,000.00
AMERICAN SOCIETY OF NEPHROLOGY	Kidney Health Initiative	07/24/2018	\$30,000.00
GORDON RESEARCH CONFERENCES	2018 Gordon Research Conference & Seminar on Cell Death	07/26/2018	\$2,500.00
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	Fifth Annual Metastatic Breast Cancer Conference	07/29/2018	\$10,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Translational Cancer Research for Basic Scientists Workshop	07/31/2018	\$25,000.00
BOARD OF REGENTS FOR UNIVERSITY OF NEBRASKA	Virtual Challenging Case Clinic: B-Cell Lymphomas	08/01/2018	\$75,000.00
MASSACHUSETTS GENERAL HOSPITAL	Gene Panel Testing: Decision Aid	08/01/2018	\$100,000.00
LUNG CANCER ALLIANCE,	Florida and Georgia Lung Cancer Screening Demonstration Project	08/01/2018	\$199,200.00
YALE SCHOOL OF MEDICINE	Severe Asthma 2018 Advances in Pathogenesis and Treatment	08/01/2018	\$15,000.00
UTAH CHAPTER OF THE AMERICAN COLLEGE OF CARDIOLOGY	Rockies Chapter Meeting	08/02/2018	\$3,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	Immune Escape: Current Understanding of Mechanisms and Advances in Therapeutics Approaches	08/02/2018	\$25,000.00
LUNG CANCER ALLIANCE	Florida and Georgia Lung Cancer Screening Demonstration Project	08/02/2018	\$147,972.00
NATIONAL JEWISH HEALTH	23rd Annual Regional Allied Health Conference: Current Perspectives in Asthma, Allergy, and Pulmonary Practice	08/02/2018	\$5,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	FDA-AACR Workshop on Non-clinical Models for Safety Assessment of Immunology Products	08/02/2018	\$25,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Novel Treatment Advances and Approaches in the Management of Advanced Breast Cancer: Expert Strategies for Individualized Treatment	08/06/2018	\$35,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	New Frontiers in the Management of Ovarian Cancer: Exploring the Role of PARP Inhibitors in the Evolving Treatment Paradigm	08/06/2018	\$45,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2018 SITC Primer on Tumor Immunology and Cancer Immunotherapy™	08/07/2018	\$50,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC 2018 Grant Writing Workshop: Grant Writing: From Start to Finish, and Then Starting Again	08/07/2018	\$10,000.00
AMERICAS HEALTH FOUNDATION	The Diagnosis and Treatment of Hereditary Breast and Ovarian Cancer Syndrome in Brazil	08/07/2018	\$85,240.00
ADMINISTRATORS OF THE TULANE EDUCATION FUND	18th Annual SSCI Nephrology Young Investigators Forum	08/10/2018	\$55,000.00
NATIONAL KIDNEY FOUNDATION	Joint Analyses of GFR slope and Change in Albuminuria by AstraZeneca and the CKD-EPI Collaboration	08/10/2018	\$105,895.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	JADPRO Live 2018: New Drug Updates	08/12/2018	\$25,000.00

Organization	Program Title	Date	Amount
UNIVERSITY OF FLORIDA	Vascular Biology Working Group Global Chapter Meeting	08/12/2018	\$7,500.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas	08/12/2018	\$50,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Improving Clinical and Economic Outcomes with Emerging Therapies in the Management of Chronic Lymphocytic Leukemia (CLL)	08/12/2018	\$35,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Optimizing Treatment Strategies in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Individualized Therapy for Improved Patient Outcomes	08/13/2018	\$35,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 13th Annual Congress: Hematologic Malignancies™	08/13/2018	\$75,000.00
AMERICAN PANCREATIC ASSOCIATION, INC.	49th Annual Meeting of the American Pancreatic Association	08/13/2018	\$25,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	16th Annual Nephrology Young Investigators Forum	08/14/2018	\$50,000.00
PENNSYLVANIA STATE UNIVERSITY COLLEGE OF MEDICINE	PeerView MasterClass: Innovative Therapy in B-Cell Malignancies: An Expert Tumor Board on Novel Agent Classes in CLL, FL, and MCL (150205208)	08/15/2018	\$115,000.00
ASSOCIATION OF UNIVERSITY TECHNOLOGY MANAGERS INC.	Series of AUTM 2019 Annual Meetings	08/15/2018	\$25,287.50
TRANSLATIONAL RESEARCH IN ONCOLOGY-US, INC.	TRIO-US & UCLA Annual Research Conference	08/16/2018	\$5,000.00
DANA-FARBER CANCER INSTITUTE	IWWM10- International Workshop on Waldenstroms macroglobulinemia	08/17/2018	\$100,000.00
MEDICAL LEARNING INSTITUTE, INC.	Integrating BTK Inhibitors into the Management of B cell Malignancies: How is Evidence Driving Patient Care	08/20/2018	\$245,090.00
MEDICAL LEARNING INSTITUTE, INC.	CRI-AACR ISS - Improving Patient Outcomes With Cancer Immunotherapies & Combinations Throughout the Continuum of Lung Cancer (150205201)	08/20/2018	\$324,460.00
AMERICAN NEPHROLOGY NURSES ASSOCIATION (ANNA)	ANNA Fall Meeting CE Symposium	08/20/2018	\$42,500.00
AMERICAN SOCIETY OF NEPHROLOGY	Risk and Treatment of Hyperkalemia	08/20/2018	\$125,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Lymphoma Research Fellowships	08/20/2018	\$276,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	2019 SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship	08/20/2018	\$120,000.00
GBMC HEALTHCARE	Advances in Treatment and Management of Ovarian Cancer	08/21/2018	\$2,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing	08/21/2018	\$240,000.00
UT HEALTH SCIENCE CENTER AT SAN ANTONIO SCHOOL OF MEDICINE OFFICE OF CME	41st Annual San Antonio Breast Cancer Symposium	08/21/2018	\$75,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Live -The Evolving Role of Immunotherapy as a Component of Multi-Modal Therapy in Earlier Stages of Lung Cancer: Rationale, Current Evidence, Key Trials, and Implications for Multidisciplinary Care (150205392)	08/22/2018	\$269,660.00
TEMPLE UNIVERSITY LUNG CENTER- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	Severe Uncontrolled Asthma: Definition, Management, and Advance Therapies	08/26/2018	\$65,000.00
OHIO CHAPTER OF THE AMERICAN COLLEGE OF CARDIOLOGY	28th Annual Meeting of the Ohio Chapter of the American College of Cardiology	08/26/2018	\$4,500.00
PROSTATE CANCER FOUNDATION	25th Annual Scientific Retreat	08/27/2018	\$20,000.00

Organization	Program Title	Date	Amount
AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.	Advancing the Treatment of Genitourinary Cancer	08/27/2018	\$25,000.00
THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	The Lancet Women and Cardiovascular Disease Commission	08/30/2018	\$50,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	Behind the Guidelines: Insights into the Standard of Care in Oncology 2019	08/30/2018	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK	Behind the Guidelines: Insights into the Standard of Care in Oncology 2019	08/30/2018	\$25,000.00
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ON BEHALF OF ITS SCHOOL OF MEDICINE	Stanford Review of the 60th Annual American Society of Hematology Meeting 2019	09/05/2018	\$5,000.00
INTERNATIONAL CYTOKINE AND INTERFERON SOCIETY INC.	6th Annual Meeting of the International Cytokine and Interferon Society	09/11/2018	\$20,000.00
CEDARS-SINAI	7th Annual New Therapeutics in Oncology: The Road to Personalized Medicine	09/11/2018	\$10,000.00
MERCY HEALTH FOUNDATION	2019 Tri-State ASH Update	09/11/2018	\$5,000.00
DUKE UNIVERSITY	Duke Stanford CEC Summit: Scientific, Regulatory and Operational Best Practices	09/18/2018	\$20,000.00
KENTUCKY ACADEMY OF PHYSICIAN ASSISTANTS	Breast Cancer - Diagnosis and Patient Treatment Options	09/18/2018	\$3,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	13th Update on the Management of Genitourinary Malignancies	09/20/2018	\$5,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2019 Congress Series™: Breast Cancer with Updates from the 2018 San Antonio Breast Cancer Symposium	09/20/2018	\$50,000.00
AMERICAN SOCIETY OF HEMATOLOGY	Hematology 2018: the ASH Education Program Book	09/21/2018	\$100,000.00
PENN STATE COLLEGE OF MEDICINE	Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Prostate Cancer— An ISS Held as a Premium Ancillary Educational Event During the 2019 Genitourinary Cancers Symposium	09/23/2018	\$75,000.00
HARTFORD HOSPITAL	34th Annual Cardiovascular Symposium presented by Hartford HealthCare	09/23/2018	\$5,000.00
JOHN HOPKINS UNIVERSITY	Novel Therapeutic Approaches to Allergic Diseases	09/24/2018	\$5,000.00
INTERNATIONAL SOCIETY FOR MAGNETIC RESONANCE IN MEDICINE	Advances in Multiscale Cancer Detection: From Micro to Macro	09/24/2018	\$2,500.00
PARENTERAL DRUG ASSOCIATION (PDA)	PDA Universe of Pre-filled Syringes and Injection Devices	10/01/2018	\$24,000.00
KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY	2019 Keystone Symposia Directors' Fund	10/01/2018	\$25,000.00
MEMORIAL SLOAN KETTERING CANCER CENTER	State-of-the-Art Gynecologic Surgery & Ovarian Cancer Management Conference 2018	10/01/2018	\$5,000.00
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO	Official Best of San Antonio Breast Cancer Symposium	10/02/2018	\$60,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Immuno-Oncology Research Fellowships	10/03/2018	\$276,000.00
MEDCHI, THE MARYLAND STATE MEDICAL SOCIETY	OPTIMAL DURATION OF ANTIPLATELET THERAPY AFTER PCI: The Case for Longer-term Dual Antiplatelet Therapy in Patients with History of MI	10/8/2018	\$387,213.13
AMERICAN COLLEGE OF TOXICOLOGY	Symposium 4: Update on RNA Therapies: Challenges and Opportunities, American College of Toxicology 39th Annual Meeting	10/08/2018	\$5,000.00

Organization	Program Title	Date	Amount
PEPTIDE THERAPEUTICS FOUNDATION	13th Annual Peptide Therapeutics Symposium	10/08/2018	\$15,000.00
UNIVERSITY OF NEBRASKA MEDICAL CENTER	7th International Conference on Gram-Positive Pathogens	10/09/2018	\$5,000.00
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE OFFICE OF CONTINUING MEDICAL EDUCATION	2019 Atlanta Breast Cancer Symposium	10/09/2018	\$10,000.00
LYMPHOMA RESEARCH FOUNDATION	LRF Postdoctoral Fellowship	10/10/2018	\$105,000.00
THE GOG FOUNDATION INC	11th Semi Annual Meeting of NRG Oncology (formerly GOG, NSABP, RTOG) cooperative groups	10/10/2018	\$20,000.00
THE UNIVERSITY OF CHICAGO	Chicago Lung Cancer Updates 2018	10/10/2018	\$10,000.00
AMERICAN ASSOCIATION OF THE STUDY OF LIVER DISEASES	The Liver Meeting 2018 Park Benches Support	10/11/2018	\$15,000.00
NATIONAL ANIMAL INTEREST ALLIANCE	The Continued Importance of Animal Research	10/14/2018	\$2,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Lung Cancer Research Fellowships (Driver Mutations)	10/17/2018	\$276,000.00
THE COOPER HEALTH SYSTEM	Contemporary Practices in Cardiology	10/22/2018	\$2,500.00
AMERICAN SOCIETY OF HEMATOLOGY	2019 Highlights of ASH in North America	10/22/2018	\$100,000.00
EMORY UNIVERSITY SCHOOL OF MEDICINE	3rd National Congress on the Prevention of Diabetes and Its Complications	10/24/2018	\$5,000.00
MEMORIAL SLOAN KETTERING CANCER CENTER	2018 Annual Cancer Treatment-Related Adverse Events Symposium	10/24/2018	\$5,000.00
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	2018 ECOG-ACRIN Fall Group Meeting	10/24/2018	\$5,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Special Conference on Tumor Immunology and Immunotherapy	10/28/2018	\$25,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	Best of 19th World Conference on Lung Cancer (WCLC)	10/28/2018	\$20,000.00
WASHINGTON UNIVERSITY	45th Annual Washington University Kilo Diabetes Symposium	10/29/2018	\$3,000.00
VIRGINIA BIOTECHNOLOGY ASSOCIATION	Medimmune Chariman's Circle Membership	11/01/2018	\$25,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	16th Annual World congress on Insulin Resistance Diabetes and Cardiovascular Disease (WCIRDC)	11/01/2018	\$100,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Live - ISS at the Thoracic Cancers Symposium, "The Present and Future of Immunotherapy as a Key Component of the Treatment Arsenal for Locally Advanced & Earlier Stages of Lung Cancer: State of the Science, Practicalities, & Implications for Mult	11/01/2018	\$286,060.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	CHF, the Next Frontier in Diabetes: Do SGLT2 Inhibitors Have a Role in Management and Prevention?	11/01/2018	\$150,705.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	ASCO and NCCN 2019 ISS CCO: PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing	11/01/2018	\$60,000.00
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	Grand Rounds series Bioascend: 2019 Ovarian Community Grand Rounds: Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer	11/01/2018	\$250,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Webinars: PARP Inhibition and its Evolving Use in the Treatment of Cancers: What Managed Care Needs to Know for Improved Clinical and Economic Outcomes	11/01/2018	\$150,000.00
JOHNS HOPKINS UNIVERSITY	FastForward Silver Sponsorship	11/05/2018	\$25,000.00
ASSOCIATION FOR WOMEN IN SCIENCE	Innovation and Inclusion Summit	11/05/2018	\$25,000.00

Organization	Program Title	Date	Amount
FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH	2018 Biomarkers Consortium Cancer Steering Committee Annual Scientific Symposium	11/05/2018	\$10,000.00
MEDICAL LEARNING INSTITUTE, INC.	PeerView Oncology - ISS at ASCO-SITC, Seminars in Immuno-Oncology, "III, II, I: Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy" (150205292)	11/06/2018	\$324,340.00
MEDICAL LEARNING INSTITUTE, INC.	ISS at 2019 Multidisciplinary Thoracic Cancers Symposium- Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC (150205322)	11/06/2018	\$286,060.00
AMERICAN COLLEGE OF VETERINARY PATHOLOGISTS	Comparative Pathologists in Translational Medicine reception at the 2018 ACVP/ASVCP Concurrent Annual Meeting	11/06/2018	\$2,000.00
AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS	AAPS PharmSci 360	11/06/2018	\$50,000.00
MAYO CLINIC ARIZONA	Mayo Clinic Cancer Center Thoracic Oncology Update State of the Art Evaluation and Management of Thoracic Cancers	11/07/2018	\$5,000.00
SOCIETY FOR CARDIOVASCULAR ANGIOGRAPHY AND INTERVENTIONS FOUNDATION	Case-based Forum: Individualizing Antithrombotic Therapies for PCI Patients	11/07/2018	\$20,000.00
UT HEALTH SAN ANTONIO	2019 Practical Application of New Agents in Oncology	11/07/2018	\$5,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	2018 Best of ASTRO	11/07/2018	\$10,000.00
PERSONALIZED MEDICINE COALITION	14th Annual Personalized Medicine Conference	11/11/2018	\$25,000.00
ACLAM FOUNDATION	2018 ACLAM Grants	11/11/2018	\$4,000.00
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	LIVE Conference: 3rd International Prostate Cancer and Urologic Oncology Symposium	11/11/2018	\$5,000.00
AMERICAN SOCIETY FOR RADIATION ONCOLOGY	2019 Multidisciplinary Thoracic Cancers Symposium	11/11/2018	\$50,000.00
CENTER FOR MEDICAL TECHNOLOGY POLICY	Core Outcomes in Non-Alcoholic Steatohepatitis	11/11/2018	\$75,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	Medical Oncology and Hematology 2019: Multidisciplinary Approaches that Improve Coordination of Care	11/11/2018	\$10,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2019 Nursing Program: Advancing Oncology Nursing™ at the NCCN Annual Conference	11/11/2018	\$30,000.00
NORTH AMERICAN 3R'S COLLABORATIVE	Virtual Education Community (VEC) Support	11/11/2018	\$4,000.00
COLLEGIUM INTERNATIONALE ALLERGOLOGICUM	32nd Biennial Symposium of the Collegium Internationale Allergologicum	11/12/2018	\$40,000.00
PENN STATE COLLEGE OF MEDICINE	ISS at AACR BTK Inhibition as an Anti-Cancer Strategy: Exploring a Model for Modern Targeted Therapy in Hematologic Malignancies and Beyond (150205409)	11/12/2018	\$370,330.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Cleveland Clinic Florida's 2nd Annual San Antonio Breast Cancer Symposium SABCS Official Review Course	11/12/2018	\$5,000.00
MAYO CLINIC JACKSONVILLE	Mayo Clinic Advances in Breast Cancer Management 2019	11/12/2018	\$15,000.00
LEUKEMIA RESEARCH FOUNDATION INC	Hollis Brownstein Research Grants Program	11/13/2018	\$100,000.00
MEDICAL LEARNING INSTITUTE, INC.	ISS at ONS- Taking Aim at B-Cell Malignancies with BTK Inhibitors: Hematology/Oncology Nurse Perspectives and Insights on Clinical Care (150205361)	11/13/2018	\$317,050.00
MEDSTAR HEALTH, INC.	Lung Cancer 2018: Progress and Future Directions	11/15/2018	\$5,000.00

Organization	Program Title	Date	Amount
NATIONAL KIDNEY FOUNDATION	Research initiative to extend the analytical work related to evaluation of clinical endpoints suitable for early phase trials in CKD using the CKD-Epidemiology Consortium (CKD-EPI)	11/18/2018	\$28,800.00
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	2019 Lymphoma Study Group Hematology Highlights A Post ASH Review	11/20/2018	\$7,500.00
SCRIPPS HEALTH	39th Annual Clinical Hematology and Oncology Conference	11/20/2018	\$25,000.00
AMERICAN ACADEMY OF CME, INC	Pharmacists' Role in the Comprehensive Care of Acute Coronary Syndrome	11/25/2018	\$49,800.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	Connecting Heart Disease and Diabetes-HCP Live and On-Demand Education	11/26/2018	\$40,000.00
UHS PROFESSIONAL EDUCATION PROGRAMS INC (DBA VCU HEALTH CONTINUING MEDICAL EDUCATION)	Women's Health 2019	11/26/2018	\$5,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	25th Annual Interventional Cardiology Fellows Course	11/26/2018	\$15,000.00
CEDARS-SINAI MEDICAL CENTER	13th Annual Women and Ischemic Heart Disease Symposium	11/28/2018	\$5,000.00
SCRIPPS HEALTH	Dr. Richard Schatz Interventional Cardiology Summit	11/28/2018	\$5,000.00
KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY	2019 DNA Replication and Genome Instability: From Mechanism to Disease A1	11/29/2018	\$10,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	11th ANNUAL HEMATOLOGIC MALIGNANCIES DEMYSTIFIED: A CRITICAL APPRAISAL OF DATA FROM 2018	11/29/2018	\$50,000.00
MEDSTAR WASHINGTON HOSPITAL CENTER	Cardiovascular Research Technologies, (CRT) 2019	11/29/2018	\$25,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2019 Conquer Cancer Foundation of ASCO Merit Awards	12/02/2018	\$40,000.00
NORTHWELL HEALTH	New York City - Debates in Interventional Cardiology	12/02/2018	\$20,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	New York Cardiovascular Symposium	12/02/2018	\$10,000.00
INTERNATIONAL EOSINOPHIL SOCIETY, INC.	11th Biennial Symposium	12/02/2018	\$25,000.00
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	Grand Rounds series MCM:15 visting faculty series: Novel Targeted Agents in the Management of Recurrent Advanced Ovarian Cancer	12/03/2018	\$150,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2019 Conquer Cancer Foundation of ASCO Mission Endowment	12/03/2018	\$500,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Breast Cancer Research Fellowships	12/03/2018	\$276,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR-AstraZeneca Ovarian Cancer Research Fellowships (DNA Damage Response)	12/03/2018	\$276,000.00
AMERICAN SOCIETY OF HEMATOLOGY	ASH Bridge Grant Program	12/03/2018	\$150,000.00
GORDON RESEARCH CONFERENCE	Gordon Research Conference: Biotherapeutics and Vaccines Development	12/03/2018	\$4,000.00
INDIANA UNIVERSITY	Breast Cancer Year in Review	12/03/2018	\$5,000.00
AMERICAN ASSOCIATION FOR CANCER RESEARCH	AACR Annual Meeting 2019	12/03/2018	\$225,000.00
TEXAS HEART INSTITUTE	9th Annual Women's Heart and Vascular Symposium: A New Era in Prevention, Diagnosis and Treatment	12/03/2018	\$3,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	2018 Managing Cardiovascular Risk in Diabetes Roundtable	12/03/2018	\$150,000.00
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER	IASLC 19th Targeted Therapies for Lung Cancer Meeting	12/03/2018	\$100,000.00
NORTH CAROLINA THORACIC SOCIETY	North Carolina Thoracic Society Annual Meeting	12/04/2018	\$14,500.00

Organization	Program Title	Date	Amount
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2019 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA)	12/05/2018	\$287,500.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2019 Conquer Cancer Foundation of ASCO Career Development Award (CDA)	12/05/2018	\$230,000.00
FRIENDS OF CANCER RESEARCH	2019 Friends of Cancer Research Programs	12/05/2018	\$200,000.00
COLEGIO DE MÉDICOS CIRUJANOS DE PUERTO RICO	Innovations in Medicine 2018	12/06/2018	\$10,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC's Cancer Immunotherapy Winter School	12/06/2018	\$150,000.00
USF HEALTH PROFESSIONS CONFERENCING CORPORATION	15th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies	12/06/2018	\$7,500.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC's Cancer Immunotherapy Guidelines Project	12/09/2018	\$100,000.00
AMERICAN UROLOGICAL ASSOCIATION	Next Frontiers in Urology 2019: a Biennial AUA/JUA Symposium	12/09/2018	\$10,000.00
HOSPITAL QUALITY FOUNDATION	Update on NSTEMI Management for Hospitalists	12/10/2018	\$185,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	DAPT Dilemmas: A Case-Based Roundtable Tutorial	12/12/2018	\$25,000.00
ST. DOMINIC-JACKSON MEMORIAL HOSPITAL	Neuroscience Cardiovascular Symposium	12/12/2018	\$5,000.00
HEART FAILURE SOCIETY OF AMERICA INC	2019 Future Leaders in Heart Failure Symposium	12/12/2018	\$25,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2019 Gastrointestinal (GI) Cancers Symposium: Multidisciplinary Treatment, Personalized Care, Optimal Outcomes	12/13/2018	\$40,000.00
UNIVERSITY OF NEBRASKA MEDICAL CENTER	ONS 2019 ISS Bioascend: Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes	12/13/2018	\$150,000.00
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	2019 Oncologic Emergency Medicine Conference	12/13/2018	\$20,000.00
DUKE UNIVERSITY	4th Annual Duke Heart Center/DCRI Fellows' Presentation Skills Course	12/13/2018	\$3,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	Acute Kidney Injury: from bedside to bench (and back again)	12/16/2018	\$5,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2019 ASCO-SITC Clinical Immuno-Oncology Symposium	12/16/2018	\$70,000.00
PENNSYLVANIA SOCIETY FOR BIOMEDICAL RESEARCH	2018 Educational Programming Support	12/16/2018	\$2,000.00
AMERICAN DIABETES ASSOCIATION	Pathway to Stop Diabetes	12/16/2018	\$500,000.00
MEDICAL LEARNING INSTITUTE, INC.	ISS at ASCO GI - Breaking the Paradox: Expanding Options & New Questions in HCC Management (150205289)	12/17/2018	\$37,500.00
C DAVIS & S THOMPSON DVM FOUNDATION	Corporate Membership	12/17/2018	\$2,000.00
MIDWINTER CONFERENCE OF IMMUNOLOGISTS	58th Midwinter Conference of Immunologists	12/18/2018	\$5,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC General Society	12/19/2018	\$3,000.00
NATIONAL ACADEMY OF SCIENCES	Roundtable in Science and Welfare of Laboratory Animal Use	12/20/2018	\$4,000.00
MIT	Koch Institute 2019 Immune Engineering Symposium	12/23/2018	\$5,000.00
NATIONAL KIDNEY FOUNDATION	The Role of the Kidney and SGLT2 in Glucose Homeostasis and Kidney Disease: A Scientific Workshop Sponsored by the National Kidney Foundation	01/03/2019	\$100,000.00
AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY FOUNDATION, INC.	AAAAI Foundation 2019 Lectureship Series	01/03/2019	\$150,000.00
NATIONAL JEWISH HEALTH	15th Annual Respiratory Disease Young Investigators' Forum	01/03/2019	\$299,856.00



Organization	Program Title	Date	Amount
MEDICAL LEARNING INSTITUTE INC	ONS 2019 ISS Peerview:, "Realizing the Promise of PARP Inhibitors in Solid Tumor Therapy Guiding Oncology Nurses on the Advances and Challenges" (150205359)	01/07/2019	\$250,000.00
AMERICAN SOCIETY OF NEPHROLOGY	Kidney Health Initiative	01/14/2019	\$30,000.00
MELANOMA RESEARCH ALLIANCE	Melanoma Research Alliance 11th Annual Scientific Retreat	01/14/2019	\$10,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	3rd Annual Heart in Diabetes (HiD)	01/15/2019	\$100,000.00
COLD SPRING HARBOR LABORATORY	Integrated control of feeding and energy balance by hypothalamic and hindbrain circuits	01/16/2019	\$10,000.00
NEW YORK UNIVERSITY	XXIV Conference on the Chemistry of the Organic Solid State	01/16/2019	\$5,000.00
NATIONAL JEWISH HEALTH	41st Annual National Jewish Health Pulmonary and Allergy Update	01/22/2019	\$10,000.00
MEDICAL LEARNING INSTITUTE INC	ISS at AATS 2019 Broadening Horizons:The Expanding Role of Immunotherapy in Locally Advanced and Earlier Stages of Lung Cancer (150205422)	01/22/2019	\$302,760.00
MEDICAL LEARNING INSTITUTE, INC.	CAP Chapter Meetings: Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines What Do Pathologists Need to Know and Do? (150205307)	01/24/2019	\$414,050.00
LUNGEVITY FOUNDATION	LUNGeVity Foundation Nursing and Nurse Navigator Roundtable	02/03/2019	\$10,000.00
REGENTS OF UC SAN DIEGO	2nd Annual Multi-Disciplinary Head & Neck Cancer Conference–Maximizing Speech and Swallowing Outcomes in Patients Undergoing Radiation Therapy: We're in This Together	02/04/2019	\$25,000.00
UNIVERSITY OF KANSAS MEDICAL CENTER	2018 San Antonio Breast Cancer Symposium Review	02/06/2019	\$5,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Individualizing Treatment in the Management of Advanced Breast Cancer: How Novel Therapies Are Changing the Treatment Paradigm	02/06/2019	\$22,500.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Integrating New and Emerging Targeted Therapies into the Treatment Paradigm in Ovarian Cancer: Expert Strategies for Improved Patient Outcomes	02/06/2019	\$22,500.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	Mitochondrial Biogenesis and Dynamics in Health & Disease	02/07/2019	\$10,000.00
NATIONAL JEWISH HEALTH	Impact of Educational Program on the Career Development of Physician Scientists; Outcomes from 14 years of the Annual Respiratory Disease Young Investigators' Forum -- An Article for Publication	02/07/2019	\$64,925.00
NYU SCHOOL OF MEDICINE	Asthma Airways and the Environment	02/10/2019	\$20,000.00
MEDSTAR HEALTH	Mid-Atlantic Nephrology Young Investigators Forum	02/10/2019	\$50,000.00
SOCIETY OF GYNECOLOGIC ONCOLOGY	SGO 2019 Annual Meeting on Women's Cancer	02/10/2019	\$62,500.00
COLUMBIA UNIVERSITY DEPARTMENT OF SURGERY	Heart Disease and Women	02/11/2019	\$7,500.00
AMERICAN DIABETES ASSOCIATION	66th Advanced Postgraduate Course	02/11/2019	\$40,000.00
NATIONAL KIDNEY FOUNDATION	Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD Related Anemia A Scientific Workshop Sponsored by the National Kidney Foundation	02/11/2019	\$100,000.00

Organization	Program Title	Date	Amount
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	2019-2020 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	02/13/2019	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	2019-2020 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	02/13/2019	\$25,000.00
THE SOCIETY OF SURGICAL ONCOLOGY	SSO 2019 Annual Cancer Symposium	02/14/2019	\$5,000.00
ONCOLOGY NURSING SOCIETY	ONS EVIDENCE-BASED PRACTICE IMPROVEMENT PROJECT: CONSTIPATION	02/17/2019	\$293,500.00
THE UNIVERSITY OF CHICAGO	16th Annual International Ultmann Chicago Lymphoma Symposium	02/17/2019	\$50,000.00
HOUSTON METHODIST HOSPITAL	Heart of a Woman	02/17/2019	\$3,000.00
HEMATOLOGY/ONCOLOGY PHARMACY ASSOCIATION	HOPA 15th Annual Conference	02/18/2019	\$35,000.00
BAYLOR SCOTT & WHITE HEALTH	8th Annual Symposium on Current Strategies in the Treatment of Multiple Myeloma, Leukemia, Hodgkin's Lymphoma and B-cell Non-Hodgkin's Lymphoma	02/18/2019	\$10,000.00
USF HEALTH PROFESSIONS CONFERENCING CORPORATION	CARDIOVASCULAR AND RENAL COMPLICATIONS IN T2DM: Roles of Physician Assistants and Nurse Practitioners in Patient Management	02/18/2019	\$247,330.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	New Horizons in the Treatment and Management of B-Cell Non-Hodgkin Lymphoma: A Closer Look at the Role of Emerging Targeted Therapies	02/18/2019	\$35,000.00
ONCOLOGY NURSING SOCIETY	ONS 44th Annual Congress and Regional Workshops	02/18/2019	\$50,000.00
MEDICAL LEARNING INSTITUTE INC	PeerView inVision: "New Frontiers in Managing Heart Failure: Are SGLT2 Inhibitors the Next Leap Forward in Optimizing Patient Care?" (150205455)	02/19/2019	\$122,250.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2019 Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™	02/19/2019	\$75,000.00
ACS DIVISION OF MEDICINAL CHEMISTRY	257th ACS National Meeting	02/19/2019	\$2,000.00
ASSOCIATION FOR MOLECULAR PATHOLOGY	TARC Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors	02/19/2019	\$125,000.00
COLUMBIA UNIVERSITY DEPARTMENT OF SURGERY	Pancreas Symposium 2019: Current Controversies in Benign and Malignant Pancreatic Disease	02/20/2019	\$3,000.00
CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY	2019 ASCO Annual Meeting Breast Cancer Track	02/20/2019	\$30,000.00
ST. JOSEPH REGIONAL HEALTH NETWORK	Annual Cardiovascular Symposium	02/21/2019	\$1,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Master Class for Oncologists 2019 - Women's Cancer Track	02/21/2019	\$25,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	Master Class for Oncologists 2019 - Hematologic Malignancies Track	02/21/2019	\$25,000.00
AMERICAN COLLEGE OF PHYSICIANS; PUERTO RICO CHAPTER	Achieving Excellence in Patient Care American College of Physician Annual Meeting and Internal Medicine Update & Board Review	02/24/2019	\$1,500.00
MEDICAL LEARNING INSTITUTE INC	PeerView Video inExchange Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies (150204478)	02/25/2019	\$95,975.00
COLUMBIA UNIVERSITY DEPARTMENT OF SURGERY	Breast Cancer Management 2019	02/26/2019	\$2,000.00
HOLY CROSS HOSPITAL INC.	Updates in the Treatment of Common Cancers: Lung, Gastrointestinal, GYN, and Breast	02/28/2019	\$2,000.00
HOLY CROSS HOSPITAL INC.	Updates in the Treatment of Common Cancers: Lung, Gastrointestinal, GYN, and Breast	02/28/2019	\$2,000.00

Organization	Program Title	Date	Amount
NATIONAL KIDNEY FOUNDATION	Chronic Hyperkalemia Management and Outcomes in CKD	03/01/2019	\$257,085.00
AMERICAN ACADEMY OF CME, INC	Crucial Conversations in Nephrology: PHD Inhibition as an Emerging Approach to Treating CKD Anemia	03/03/2019	\$99,990.00
UNIVERSITY OF ROCHESTER	20th Annual Diabetes Conference: Current Treatments for Diabetes Complications	03/03/2019	\$6,500.00
CLEVELAND CLINIC EDUCATIONAL FOUNDATION	Advanced Diagnostic Bronchoscopy Workshop	03/03/2019	\$10,000.00
PREVENTIVE CARDIOVASCULAR NURSES ASSOCIATION	Cardiovascular Risk Reduction: 25th Cardiovascular Nursing Symposium Opening Session	03/03/2019	\$50,000.00
PENN STATE COLLEGE OF MEDICINE	An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients with Type 2 Diabetes (150205286)	03/03/2019	\$142,430.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO	Making the Connection: A Comprehensive Strategy on the Modern Management of Type 1 and Type 2 Diabetes 2019	03/03/2019	\$200,000.00
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER	From Inquiry to Investigation to Insight (I3): Clinical Clarity in Non-Small Cell Lung Cancer - The 2019 JADPRO Lung Cancer Conference	03/03/2019	\$50,000.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Advances in the Management of Acute Coronary Syndrome (ACS): Updated Guideline Recommendations for Dual Antiplatelet Therapy	03/03/2019	\$30,000.00
EASTERN VIRGINIA MEDICAL SCHOOL	Turning the Tide on Diabetes 2019	03/03/2019	\$5,000.00
AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY	Foundations of Asthma Management	03/04/2019	\$200,000.00
KEYSTONE SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY	2019 Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit	03/04/2019	\$5,000.00
METABOLIC ENDOCRINE EDUCATION FOUNDATION	The Primary Prevention of CHF and CKD in Diabetes Satellite Symposium	03/04/2019	\$154,110.00
THE CHEST FOUNDATION	2019 CHEST Foundation Research Award in Severe Asthma	03/04/2019	\$35,000.00
MEDICAL LEARNING INSTITUTE INC	PeerView Live at USCAP 2019, Clinical Advances in Cancer Immunotherapies, Biomarkers, and Testing: Implications for Pathologists at the Forefront of the Emerging Precision Oncology Era (150205529)	03/04/2019	\$90,000.00
AMERICAN NEPHROLOGY NURSES ASSOCIATION (ANNA)	The CKD Patient with Hyperkalemia: Nephrology Nurses Evidence Based Care	03/05/2019	\$61,500.00
NATIONAL ASSOCIATION OF MANAGED CARE PHYSICIANS, INC.	Improving Clinical and Economic Outcomes with Personalized Treatment in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC)	03/05/2019	\$35,000.00
DUKE UNIVERSITY	The Southeastern Fellows Research Skills & Training Workshop	03/06/2019	\$2,500.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	NCCN 2019 Oncology Fellows Program: New Horizons in Quality Cancer Care™ at the NCCN Annual Conference	03/06/2019	\$10,000.00
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE	Allergy Fellowship	03/06/2019	\$40,000.00
DREXEL MEDICINE	Updates In Women's Health 2109	03/06/2019	\$2,000.00
MEDICAL LEARNING INSTITUTE INC	Addressing Unmet Needs in Managing Anemia in Chronic Kidney Disease: A Closer Look at the Clinical Potential of HIF-PH Inhibitors (150205556)	03/06/2019	\$122,250.00
SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY	7th Annual Lung Cancer Symposium	03/06/2019	\$2,500.00

Organization	Program Title	Date	Amount
MEDICAL LEARNING INSTITUTE INC	ASCO 2019 peer view Stories from the Pancreatic Cancer CaseBook: Taking the Road to Improved Outcomes with Modern Therapeutic Concepts and Innovative Treatments (150205416)	03/10/2019	\$30,000.00
AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY	GKCAS 2019 Annual Meeting	03/10/2019	\$3,000.00
REGENTS OF THE UNIVERSITY OF CALIFORNIA	13th International Congress on Systemic Lupus Erythematosus (LUPUS 2019)	03/10/2019	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	Support for NCCN Distribution of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Management of Immunotherapy-Related Toxicities Pocket Guides	03/11/2019	\$60,000.00
AMERICAN UROLOGICAL ASSOCIATION	Bladder Cancer in Women: Identifying Research Needs to Improve Diagnosis and Treatment A Johns Hopkins Greenberg Bladder Cancer Institute/ American Urological Association Translational Research Collaboration	03/11/2019	\$15,000.00
GORDON RESEARCH CONFERENCES	2019 Multidrug Efflux Systems Gordon Research Conference	03/11/2019	\$2,500.00
NATIONAL KIDNEY FOUNDATION	14th Annual Young Investigator's Forum	03/12/2019	\$50,000.00
AMERICAN COLLEGE OF CHEST PHYSICIANS	Lung Cancer Screening Decision Counselor and Navigator Training	03/12/2019	\$25,000.00
SOCIETY OF INTERVENTIONAL RADIOLOGY	SIR Annual Scientific Meeting	03/13/2019	\$12,500.00
ECOG RESEARCH AND EDUCATION FOUNDATION, INC.	ECOG-ACRIN Spring 2019 Group Meeting	03/13/2019	\$5,000.00
MEDSTAR HEALTH, INC.	Kidney and Bladder Cancers 2019	03/14/2019	\$10,000.00
AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION	ACC Annual Scientific Session	03/14/2019	\$50,000.00
SAINT FRANCIS HOSPITAL AND MEDICAL CENTER	55th Annual Robert M. Jeresaty, MD Cardiovascular Symposium	03/14/2019	\$5,000.00
CARDIOVASCULAR RESEARCH FOUNDATION	A New Beat: Improving Cardiovascular Care in Women and Minorities	03/14/2019	\$25,000.00
GORDON RESEARCH CONFENCE	Therapeutically Targeted Small Molecules and Enabling Technologies in Drug Discovery	03/14/2019	\$2,500.00
NATIONAL COMPREHENSIVE CANCER NETWORK	Support for NCCN Distribution of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Pocket Guides	03/14/2019	\$25,000.00
NORTHWELL HEALTH	1st Annual Heart of Prevention Symposium: Updates on Cardiovascular Disease Prevention With a Focus on Women's Heart Health	03/17/2019	\$15,000.00
AMERICAN THORACIC SOCIETY INC	ATS 2019 Fellows Track Symposium	03/17/2019	\$10,000.00
SOCIETY FOR IMMUNOTHERAPY OF CANCER	SITC's PD-L1 Resistance Definition Project	03/17/2019	\$35,000.00
CITY OF HOPE	8th Annual Clinical Cancer Genetics & Genomics Conference; From Exceptionalism to Exceptional Care: Mainstreaming Genomic Medicine in Clinical Practice	03/17/2019	\$10,000.00
FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY	2019 FASEB SRC on Intracellular RNA localization and local translation	03/18/2019	\$5,000.00
FOUNDATION FOR HEART FAILURE EDUCATION, INC.	23rd Annual Heart Failure-An Update on Therapy	03/18/2019	\$10,000.00
PURDUE UNIVERSITY	Type 2 Diabetes Mellitus and Heart Failure: Screening, Diagnosis, and Management	03/19/2019	\$75,000.00
ASTHMA AND ALLERGY FOUNDATION OF AMERICA - ALASKA CHAPTER	Wheezin", Sneezin" & Itchin' in Alaska	03/19/2019	\$10,000.00
AMERICAN RADIUM SOCIETY	101st Annual Meeting	03/19/2019	\$25,000.00

<b>Organization</b>	<b>Program Title</b>	<b>Date</b>	<b>Amount</b>
NATIONAL KIDNEY FOUNDATION	Anemia in Chronic Kidney Disease: Arming Clinicians with Meaningful Solutions	03/19/2019	\$257,085.00
AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.	The Evolving Role of the Urologist in Advanced Castration Dependent Prostate Cancer: a Guidelines and Case-based Discussion	03/19/2019	\$25,000.00
NATIONAL COMPREHENSIVE CANCER NETWORK, INC.	Emerging Issues in Oncology – Ensuring Access to, and Delivery of, Innovative Therapies and Patient Centered Care in Oncology	03/20/2019	\$25,000.00
ACS DIVISION OF BIOCHEMICAL TECHNOLOGY	257th ACS National Meeting and Exposition (BIOT Division)	03/20/2019	\$5,000.00

<u>Product</u>	<u>Q114</u>	<u>Q214</u>	<u>Q314</u>	<u>Q414</u>	<u>Q115</u>	<u>Q215</u>	<u>Q315</u>	<u>Q415</u>	<u>Q116</u>	<u>Q216</u>	<u>Q316</u>	<u>Q416</u>	<u>Q117</u>	<u>Q217</u>	<u>Q317</u>	<u>Q417</u>	<u>Q118</u>	<u>Q218</u>	<u>Q318</u>	<u>Q418</u>
FARXIGA													X	X	X	X	X	X	X	X
ONGLYZA					X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
KOMBIGLYZE								X	X	X	X	X	X	X	X	X	X	X	X	X
SYMBICORT									X	X	X	X	X	X	X	X	X	X	X	X
PULMICORT FLEXHALER													X	X	X	X	X	X	X	X
NEXIUM OS	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
NEXIUM XSULE	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X	X		
CRESTOR	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
BYETTA					X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
BYDUREON																	X	X	X	X
SYMLIN	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
TUDORZA																	X	X	X	X

X URA Capped at AMP

Product	MPD Plan	Effective Dates
Byetta	Abarca	1/1/18 – 12/31/19
	Envision	1/1/18 – 12/31/18
	Express Scripts	4/1/18 – 12/31/19
	Health Delegates	1/1/18 – 12/31/18
	MedImpact	1/1/19 – 12/31/19
	SIS	1/1/18 – 12/31/19
Crestor	Abarca	1/1/16 – 12/31/16
	Blue Shield of CA	7/1/15 – 12/31/16; 5/2/16 – 12/31/16
	Emblem Health	1/1/15 – 12/31/15; 1/1/16 – 12/31/16
	Envision	1/1/17 – 12/31/17
	Express Scripts	5/2/16 – 12/31/19
	Florida Health	1/1/14 – 12/31/16
	Health Alliance Medical Plan	1/1/15 – 12/31/16
	Health Partners Plans	1/1/15 – 12/31/16
	Healthspring	4/1/15 – 12/31/15
	Highmark	7/1/14 – 12/31/16
	Humana	1/1/15 – 12/31/16; 5/1/16-7/30/16; 8/1/2016 – 12/31/16
	IHA	1/1/15 – 12/31/16
	MedImpact	1/1/15 – 5/1/16
	Navitus	1/1/15 – 12/31/16
	OptumRx	7/1/16 – 12/31/17
	Perform Rx	10/1/15 – 12/31/16
	Pharm. Tech	1/1/15 – 12/31/16
	Prime Therapeutics	5/2/16 – 12/31/16
	SelectHealth	1/1/15 – 12/31/16
	SilverScript	7/1/14 – 12/31/16
SIS	1/1/15 – 12/31/16	
Ventegra	1/1/15 – 12/31/16	
WellCare	1/1/15 – 12/31/16	
Nexium	Envision	1/1/17 – 12/31/17; 1/1/18 – 12/31/18
	Express Scripts	1/1/16 – 12/31/19
	Harvard Pilgrim	1/1/14 – 12/31/14
	Health Alliance Medical Plan	1/1/14 – 12/31/14
	Healthspring	4/1/15 – 12/31/15
	Highmark	7/1/14 – 12/31/16
	Humana	1/1/14 – 12/31/14; 1/1/15 – 12/31/16
	Navitus	1/1/14 – 1/31/14; 1/1/15 – 12/31/16
	Optum Rx	1/1/14 – 12/31/18
	Prime Therapeutics	1/1/14 – 12/31/14
	Scott & White	1/1/14 – 12/31/14
	SilverScript	7/1/14 – 12/31/16
WellCare	1/1/15 – 12/31/16	

Product	MPD Plan	Effective Dates
Seroquel	Abarca	1/1/16 – 12/31/16
	Blue Shield of CA	1/1/15 – 12/31/16
	Emblem Health	1/1/15 – 12/31/15; 1/1/16 – 12/31/16
	Envision	1/1/17 – 12/31/17; 1/1/18 – 12/31/18
	Health Partners Plans	1/1/15 – 12/31/16
	Healthspring	4/1/15 – 12/31/15
	Highmark	7/1/14 – 12/31/16
	Humana	1/1/15 – 12/31/16
	IHA	1/1/15 – 12/31/16
	Navitus	1/1/15 – 12/31/16; 1/1/17 – 12/31/19
	Perform Rx	10/1/15 – 12/31/16
	Pharm. Tech	1/1/15 – 12/31/16; 1/1/18 – 12/31/18
	SelectHealth	1/1/17 – 12/31/18
	SIS	1/1/15 – 12/31/16
Seroquel XR	Health Alliance Medical Plan	1/1/15 – 12/31/16
	SilverScript	7/1/14 – 12/31/16
	Ventegra	1/1/15 – 12/31/16
	WellCare	1/1/15 – 12/31/16